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ANALYSIS OF FREE SOLUTE FRACTIONS AND SOLUTE-PROTEIN 
INTERACTIONS USING ULTRAFAST AFFINITY EXTRACTION AND AFFINITY 
MICROCOLUMNS 
Xiwei Zheng, Ph.D. 
University of Nebraska, 2015 
Advisor: David S. Hage 
This dissertation describes the use of a high-performance affinity chromatography 
method based on ultrafast affinity extraction and microcolumns to study biological 
interactions.  
In the first project, a new method was created and based on ultrafast affinity 
extraction to determine both the dissociation rate constants (kd) and association 
equilibrium constants (Ka) for drug−protein interactions in solution. Various conditions to 
optimize the use of ultrafast affinity extraction for equilibrium and kinetic studies were 
considered. 
The objective of the next portion of this dissertation was to develop a 
chromatographic approach to measure free drug fractions in more complex samples.  This 
was accomplished by combining ultrafast affinity extraction with a multi-dimensional 
HPAC system. In the first project in this section, the target of interest was R- and S-
warfarin, which have slightly different binding strengths for the serum transport protein 
human serum albumin (HSA).  A multi-dimensional HPAC system was developed to 
study the binding of each enantiomer with HSA. This system was used to simultaneously 
 
 
measure the free fraction of each enantiomer and its Ka value with HSA. The second 
project used ultrafast affinity extraction and a multi-dimensional affinity system to 
measure the free fractions and global affinity constants of several sulfonylurea drugs in 
the presence of normal HSA or glycated HSA. A third project used a similar approach to 
measure the free fractions and Ka value of various drugs in serum  
The next project used ultrafast affinity extraction to study the interactions of a 
steroid hormone (i.e., testosterone) with its serum transport proteins, HSA and sex 
hormone binding globulin (SHBG). Both the kd and Ka values for these systems were 
determined. The free fractions of testosterone in samples containing HSA or SHBG at 
physiological concentration were also estimated. 
The last project sought to develop a method to increase the binding capacity and 
activity of proteins in small affinity columns. This was accomplished by combining a 
traditional covalent immobilization method with protein cross-linking/modification. It 
was found that up to a 75-113% increase in total protein content could be obtained by this 
method when compared with more traditionally prepared supports.  
iv 
 
ACKNOWLEDGEMENTS 
 
I would like to thank many people who have provided me with great help 
throughout my graduate studies. First of all, I would like to express my most gratitude to 
Dr. David S. Hage for his mentorship and support in my research over the past five years. 
Your generous guidance and brilliant advice throughout my graduate studies exposed me 
to fantastic academic areas and helped me to become a good researcher. I appreciate all 
of your help in my paper writing and editing. I also want to specially thank you for your 
understanding and offering me time to return to China to reunite with my family. I would 
also like to thank my committee members, Dr. Lai, Dr. Dussault, Dr. Guo and Dr. 
Subramanian. I really appreciate all the valuable suggestions and guidance you gave me 
during my Ph.D. studies. Many thanks also go to Dr. Lai for providing me with the 
opportunity to start my journey at UNL. 
I also would like to thank the members of the Hage lab in the past and at present. 
Ryan Matsuda, Penny and Zhao, I am very grateful and fortunate to have met all of you. 
You gave me countless help, support and happiness over the past years. Thank you for 
accompanying with me all the time. I know my graduate life would have been very 
helpless, lonely and pale without any of you. I also would like to say many thanks to 
Maria for your great assistance in my research and paper writing. It was so amazing to 
work with you during the past three years. I also would like to thank my friends outside 
of the Hage group whom I met before or after I came to Lincoln. Thank you, Weiwei, 
Yunyun, Xi, Tong, and Haotong for bringing me many wonderful moments and happy 
memories. Every Chinese New Year Festival we celebrated together made me feel like I 
v 
 
was back at our home country.  I also would like to thank Yunan and Jiahan for always 
being there for me in every possible way. Your support and trust made me believe that I 
can be strong and brave enough to overcome all the challenges in my life and studies.  
Most of all, I owe my deepest gratitude to my family. Baba and Mama, thanks for 
your understanding and allowing me to leave home for five years to some place that is 
super far away from you. I am so sorry that, as your only kid, I missed five years in your 
life and could not accompany with and take care of both of you. Instead, I made you two 
worry and miss me all the time. You are the most awesome parents I could ever have. 
Your wisdom and sincerity lead me to know how to be a good person. Your love has 
always overcome the time difference and geographical distance between us and gave me 
the encouragement and support to cross any difficulties I encountered. At last, many 
thanks to my fiancé, Lei, for everything! You are the biggest treasure I have here. I 
cannot describe to you how you have brightened my life and how happy you make me. 
You make me believe that everything is possible and we can make it through no matter 
how hard it is. Thank you for being with me. 
vi 
 
TABLE OF CONTENTS 
 
CHAPTER 1 
General Introduction 
Basic Principles of Affinity Chromatography and HPAC ............................................. 1 
Types of Affinity Microcolumns ....................................................................................... 3 
Zonal Elution and Affinity Microcolumns .................................................................... 10 
Principles of zonal elution ......................................................................................... 10 
Estimating binding strength and retention using affinity microcolumns ................... 14 
Competition and displacement studies using affinity microcolumns ......................... 17 
Ultrafast affinity extraction method .......................................................................... 25 
Other applications of zonal elution with affinity microcolumns ............................... 29 
Frontal Analysis and Affinity Microcolumns ............................................................... 34 
Principles of frontal analysis ..................................................................................... 34 
Estimating binding strength and number of sites using affinity microcolumns ......... 37 
Competition and displacement studies using affinity microcolumns ......................... 39 
Other applications of frontal analysis with affinity microcolumns ........................... 43 
Overall Goal and Summary of Work ............................................................................ 45 
References ........................................................................................................................ 48 
vii 
 
 
CHAPTER 2 
Analytical Methods for Kinetic Studies of Biological Interactions 
Introduction ..................................................................................................................... 61 
Stopped-Flow Analysis ................................................................................................... 62 
General principles ..................................................................................................... 62 
Applications involving single-molecule reactions ..................................................... 66 
Applications involving bimolecular reactions ........................................................... 70 
Applications involving competition studies ............................................................... 74 
Applications involving multistep reactions................................................................ 77 
Advantages and potential limitations ........................................................................ 80 
Surface Plasmon Resonance........................................................................................... 81 
General principles ..................................................................................................... 81 
Data analysis methods ............................................................................................... 84 
Applications in kinetic studies ................................................................................... 86 
Advantages and potential limitations ........................................................................ 90 
Affinity Chromatography .............................................................................................. 92 
General principles ..................................................................................................... 92 
Band broadening methods ......................................................................................... 95 
viii 
 
Peak fitting methods ................................................................................................ 100 
Split-peak method .................................................................................................... 103 
Peak decay method .................................................................................................. 105 
Advantages and potential limitations ...................................................................... 109 
Capillary Electrophoresis ............................................................................................. 111 
General principles ................................................................................................... 111 
Analysis of slow biological reactions ...................................................................... 111 
Kinetic capillary electrophoresis............................................................................. 115 
Advantages and potential limitations ...................................................................... 122 
Conclusions .................................................................................................................... 123 
References ...................................................................................................................... 125 
 
CHAPTER 3 
Improvement of Ultrafast Affinity Extraction for Determination of both the Kinetics 
and Thermodynamics of Drug-Protein Interactions 
Introduction ................................................................................................................... 140 
Experimental ................................................................................................................. 144 
Materials and reagents ............................................................................................ 144 
Apparatus................................................................................................................. 145 
ix 
 
Column preparation ................................................................................................ 145 
Chromatographic studies ........................................................................................ 146 
Results and Discussion .................................................................................................. 147 
Optimization of free drug fraction measurements ................................................... 147 
Determination of dissociation rate constants .......................................................... 153 
Measurement of association equilibrium constants ................................................ 158 
Estimation of association rate constants ................................................................. 162 
Conclusions .................................................................................................................... 163 
References ...................................................................................................................... 165 
 
CHAPTER 4 
Combination of Ultrafast Affinity Extraction and Multi-Dimensional HPAC for the 
Analysis of Free Fractions for Chiral Drugs 
Introduction ................................................................................................................... 169 
Experimental ................................................................................................................. 171 
Materials and reagents ............................................................................................ 171 
Apparatus................................................................................................................. 171 
Column preparation ................................................................................................ 172 
Chromatographic studies ........................................................................................ 172 
x 
 
Ultrafiltration studies .............................................................................................. 178 
Results and Discussion .................................................................................................. 179 
Optimization of conditions for multi-dimensional affinity system ........................... 179 
Measurement of free drug fractions for warfarin enantiomers ............................... 185 
Simultaneous estimation of association equilibrium constants for R- and S-warfarin 
with soluble HSA ..................................................................................................... 188 
Conclusions .................................................................................................................... 191 
References ...................................................................................................................... 193 
 
CHAPTER 5 
The Use of Ultrafast Affinity Extraction and Multi-Dimensional HPAC to Study the 
Interactions of Sulfonylurea Drugs with Normal or Glycated Human Serum 
Albumin 
Introduction ................................................................................................................... 195 
Experimental ................................................................................................................. 200 
Marterials and reagents .......................................................................................... 200 
Apparatus................................................................................................................. 200 
Column preparation and protein glycation ............................................................. 201 
Chromatographic studies ........................................................................................ 202 
Results and Discussion .................................................................................................. 206 
xi 
 
Optimization of conditions for ultrafast affinity extraction ..................................... 206 
Optimization of conditions for multi-dimensional affinity system ........................... 211 
Measurement of free fractions for sulfonylurea drugs ............................................ 217 
Estimation of affinity for sulfonylurea drugs with normal HSA or glycated HSA .. 220 
Conclusions .................................................................................................................... 223 
References ...................................................................................................................... 225 
 
CHAPTER 6 
The Use of Ultrafast Affinity Extraction for Free Fraction Measurements of Various 
Drugs in Clinical Samples 
Introduction ................................................................................................................... 229 
Experimental ................................................................................................................. 231 
Materials and reagents ............................................................................................ 231 
Apparatus................................................................................................................. 232 
Column preparation ................................................................................................ 233 
Chromatographic studies ........................................................................................ 234 
Ultrafiltration studies .............................................................................................. 238 
Results and Discussion .................................................................................................. 239 
Optimization of conditions for ultrafast affinity extraction ..................................... 239 
xii 
 
Optimization of conditions for multi-dimensional affinity system ........................... 244 
Measurement of free fractions and binding of drugs to HSA in serum ................... 251 
Conclusions .................................................................................................................... 254 
References ...................................................................................................................... 257 
 
CHAPTER 7 
The Use of Ultrafast Affinity Extraction to Study the Interactions of Steroid 
Hormone with Human Serum Albumin and Sex Hormone Binding Globulin 
Introduction ................................................................................................................... 260 
Experimental ................................................................................................................. 263 
Materials and reagents ............................................................................................ 263 
Apparatus................................................................................................................. 263 
Column preparation ................................................................................................ 264 
Preparation of Testosterone Solutions .................................................................... 265 
Chromatographic studies ........................................................................................ 266 
Results and Discussion .................................................................................................. 271 
Optimization of ultrafast affinity extraction for testosterone-protein binding studies
 ................................................................................................................................. 271 
Determination of binding strength for testosterone with HSA ................................ 280 
Determination of rate constants for interactions of testosterone with HSA ............ 283 
xiii 
 
Determination of the binding strength for testosterone with SHBG ....................... 284 
Determination of rate constants for the interactions of testosterone with SHBG ... 287 
Conclusions .................................................................................................................... 290 
References ...................................................................................................................... 292 
 
CHAPTER 8 
Development of High Capacity Affinity Microcolumns Based on Hybrid Cross-
Linking and Protein Immobilization Methods 
Introduction ................................................................................................................... 295 
Experimental ................................................................................................................. 299 
Materials and reagents ............................................................................................ 299 
Apparatus................................................................................................................. 300 
Preparation of affinity supports .............................................................................. 301 
Chromatographic studies ........................................................................................ 302 
Results and Discussion .................................................................................................. 305 
Optimization of HSA modification ........................................................................... 305 
Effects of protein modification on retention ............................................................ 307 
Use of BMH-treated HSA microcolumns with a sulfhydryl-reactive drug .............. 313 
Use of BMH-treated HSA microcolumns in ultrafast affinity extraction ................ 317 
xiv 
 
Conclusions .................................................................................................................... 323 
References ...................................................................................................................... 325 
 
CHAPTER 9 
Summary and Future Work 
Summary of Work ......................................................................................................... 328 
Future Work .................................................................................................................. 332 
 
 1 
CHAPTER 1 
General Introduction 
Portion of this chapter have previously appeared in X. Zheng, Z. Li, S. Beeram, M. Podariu, R. Matsuda, 
E.L. Pfaunmiller, C.J. White II, N. Carter, D.S. Hage “Analysis of Biomolecular Interactions Using Affinity 
Microcolumn: A Review” Journal of Chromatography B 2014, 968, 49-63. 
 
Basic Principles of Affinity Chromatography and HPAC 
Affinity chromatography is a liquid chromatographic technique that uses a 
biologically-related binding agent, or “affinity ligand”, as the stationary phase to separate 
or analyze sample components.1-8  This stationary phase can be created by covalently 
attaching, entrapping, absorbing or in some other way immobilizing the affinity ligand to 
a chromatographic support.3-5 This solid support and the stationary phase are placed 
within a column or capillary that can then be used for the purification, separation or 
analysis of targets capable of binding to the affinity ligand. 5-14 The retention and 
separation of a target from other sample components is based on the specific and 
reversible interactions that characterize many biological interactions, such as the binding 
of an antibody with an antigen or a hormone with a receptor.1-3,5-8  If the interaction is 
strong (i.e., with an association equilibrium constant greater than 105-106 M-1), an elution 
buffer and a change in the pH, temperature, or mobile phase composition may be required 
to remove the target from the column.15-17 If weaker binding is present (i.e., an 
association equilibrium constant of 105-106 M-1 or less), it may be possible to elute the 
target under isocratic conditions.  This latter method is sometimes referred to as weak 
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affinity chromatography (WAC).18-19 The variety of elution formats, immobilized ligands, 
and columns that can be used in affinity chromatography has made this method a 
valuable tool for the study of biomolecular interactions,1-3,20-29 as will be discussed in this 
chapter.  
In any type of affinity chromatography, the support that is used for the 
immobilized affinity ligand should have low non-specific binding to sample components 
and yet be easy to modify for ligand attachment.4-8,30-33 Traditional affinity 
chromatography typically employs relatively inexpensive supports and non-rigid 
materials with low-to-moderate efficiencies, such as agarose gels or other carbohydrate-
based materials.3,6,7,30 In the method of HPAC, which is the type of affinity 
chromatography utilized with most affinity microcolumns, the support is a material that 
has sufficient mechanical stability and efficiency for use in HPLC. 3,5,8,30-31  This type of 
support, in turn, tends to provide HPAC with better speed and precision than traditional 
affinity chromatography, along with greater ease of automation through the use of HPLC 
systems. 1,5,30,33 Possible supports for HPAC include particulate materials based on 
modified silica or glass, azalactone beads, and hydroxylated polystyrene media. 1,3,5,30,31  
Various types of monolithic supports have also been considered for use in HPAC and 
affinity chromatography, such as those based on organic polymers, silica monoliths, 
cryogels and modified forms of agarose. 30,75-39  The recent interest in monoliths for these 
affinity-based separations is due to several useful features of these supports, including 
their rapid mass transfer properties, low back pressures, and ability to be made in a 
variety of shapes and sizes. 30,32,33,36,39 
The use of affinity chromatography and HPAC for the study of biomolecular 
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interactions is sometimes referred to as analytical affinity chromatography, quantitative 
affinity chromatography, or biointeraction chromatography. 2,3,20-29,40-41  This type of 
approach either examines the interaction of an applied target with the immobilized 
affinity ligand or uses the affinity ligand to examine interactions of the target with 
another binding agent in the mobile phase (see Figure 1.1). 2,5,20 A great deal of 
information can be obtained through such experiments,  including data on the number of 
interaction sites for the target with a binding agent, the equilibrium constants for this 
process, and the rate of the interaction. 2,5,20,21,25,27,40-42  Data can also be obtained on the 
types of competition the target may have with other compounds for interactions with the 
binding agent, and the structure and location of the sites that are involved in these 
interactions.20,27,42  
 
Types of Affinity Microcolumns 
A reduction in column size has been of interest in the fields of HPLC and 
chromatographic separations for many years.  This interest initially appeared due to some 
common limitations with traditional 10-25 cm × 4.6 mm i.d. HPLC columns, such as 
issues related to high backpressure, solvent consumption, and difficulties in working with 
small sample volumes. 43 To overcome these limitations, work began in the 1970s to 
reduce the size of columns in chromatographic systems and to produce various types of 
small-volume columns. 44-46 Examples of approaches that have been used specifically in 
HPAC and affinity chromatography to produce affinity microcolumns are shown in 
Figure 1.2. 15,47-51   
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Figure 1.1   Two general schemes for the use of HPAC and affinity chromatography to 
study biomolecular interactions based on (a) the binding of an applied 
target with the immobilized affinity ligand or (b) use of the affinity ligand 
to examine interactions of the target with another binding agent in 
solution. Reproduced with permission from X. Zheng, Z. Li, S. Beeram, 
M. Podariu, R. Matsuda, E.L. Pfaunmiller, C.J. White II, N. Carter, D.S. 
Hage, J. Chromatogr. B 968 (2014) 49-63. 
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The first approach for reducing the size of a chromatographic column is to 
decrease the column's inner diameter, as is illustrated in Figure 1.2(a). This change is 
usually accompanied by an increase in column length to maintain or provide high 
efficiency for the system while still giving an overall decrease in volume versus 
traditional columns. This approach may involve the use of either open-tubular capillary 
columns or packed capillary columns.43 Open-tubular capillaries that have been used with 
affinity ligands for binding studies have generally had an inner diameter of 100 μm and 
lengths of 30-40 cm, giving total volumes of approximately 2-4 µL.47-49 Packed 
capillaries that have been used with affinity ligands and binding studies have had an inner 
diameter of up to 0.5 mm and a length that ranges from 5-15 cm (volumes,10-30 µL).47-60 
There are several advantages to using the open-tubular or packed capillary 
columns in affinity-based binding studies.  For instance, the flow rates applied to such 
columns are usually quite low (i.e., in the nL/min to µL/min range) and the efficiencies 
can be high, resulting in a significant reduction in mobile phase consumption and sample 
size requirements. 43,61 One potential disadvantage is that these capillary columns often 
require specialized equipment designed for work at low flow rates and high efficiencies 
(e.g., microbore or nano-HPLC systems). 43,52,61  However, these columns are attractive 
for use with on-line detection by mass spectrometry, which can provide high sensitivity in 
detecting small amounts of targets and can be used to confirm the identity of a target in a 
mixture of applied compounds.62-64 
Another approach to decreasing the column size is to reduce the length of the 
column, as shown in Figure 1.2(b).  This type of design can be employed in separations 
that do not require high efficiencies, such as those based on simple adsorption/desorption 
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Figure 1.2 Examples of affinity microcolumns that have been used for studying 
biomolecular interactions including designs based on (a) open-tubular or 
packed capillaries and (b) short microcolumns or sandwich microcolumns. 
Reproduced with permission from X. Zheng, Z. Li, S. Beeram, M. 
Podariu, R. Matsuda, E.L. Pfaunmiller, C.J. White II, N. Carter, D.S. 
Hage, J. Chromatogr. B 968 (2014) 49-63. 
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mechanisms and selective binding for affinity separations involving moderate-to-high 
strength interactions.3-5,28,65 Various types of short microcolumns based on particulate 
supports or monolithic materials have been developed for affinity separations and binding 
studies.  These columns often have an inner diameter of 2.1 mm or smaller and lengths of 
1-5 cm (i.e., volumes less than 35-175 µL).   Other possible formats include affinity 
disks, with an inner diameter of 4.6 mm and lengths of 1-2 mm,37,66-68 or sandwich 
affinity microcolumns, with effective lengths as small as 60-250 µm and volumes of only 
0.2-0.9 µL.69  A few advantages of using these columns in binding studies is that they are 
easy to employ with traditional HPLC systems, and they require only a small amount of 
support and binding agent.  This type of column is often capable of withstanding high 
flow rates, because of its low backpressure, and can provide sample residence times in 
the second to millisecond range. 50,70,71 
One advantage to utilizing either type of affinity microcolumn is that they are 
compatible with a variety of detection approaches.  These detection forms include 
absorbance, fluorescence and near-infrared fluorescence, chemiluminescence, matrix-
assisted laser desorption/ionization mass spectrometry, and electrospray ionization mass 
spectrometry.47-58,70,71 The small volumes of affinity microcolumns53,72 also leads to a 
significant decrease in the amount of support and affinity ligand that are needed for 
binding studies when compared to more traditional affinity columns.37,65,69-73 In many 
cases it is possible to reuse the same binding agent for many experiments, which further 
helps to improve the precision and to decrease the cost of this method.74-76  
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Zonal Elution and Affinity Microcolumns 
Principles of zonal elution 
Zonal elution is one of the most common formats applied in HPAC and affinity 
chromatography for studying biomolecular interactions.  This method was first used with 
affinity columns in 1974 and is based on the measurement of peak retention times, 
retention factors or peak profiles.77  This approach can be used to provide information on 
the strength of binding by a target with an affinity ligand and on the competition of the 
target with other compounds for the binding agent.1-3,20, 27,78,79 In this type of experiment, 
a narrow plug of the target is injected onto the affinity column under isocratic conditions 
as a detector is used to monitor the elution time or profile for the injected analyte.  If 
relatively fast association and dissociation kinetics are present on the time scale of the 
experiment, the retention time of the target should be directly related to the target’s 
strength of binding to the immobilized agent and the amount of active binding agent that 
is present in the column.2,40,79 Factors that can be altered during zonal elution experiments 
include the mobile phase pH, ionic strength and polarity, as well as the temperature, type 
of target, type of affinity ligand in the column, and the presence of competing or 
displacing agents in the mobile phase.  By monitoring the changes in the retention for the 
target as these conditions are varied, detailed data can be obtained on the nature of the 
interactions between the target and the immobilized binding agent. 2,10,14,19,40, 79-81  
The Figure 1.3(a) shows a typical zonal elution experiment in which competition 
by a mobile phase additive causes a shift in the retention of an injected target as these two 
compounds compete for binding sites on an immobilized affinity ligand. 80 This example 
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shows the chromatograms generated during injections of the site-selective probe R-
warfarin onto a 2 cm × 2.1 mm i.d. column (volume, 69 µL) that contained the 
immobilized protein human serum albumin (HSA), with the drug tolbutamide being 
placed into the mobile phase as a competing agent.  In this specific experiment, a 
decrease was observed in the retention of R-warfarin as the concentration of tolbutamide 
was increased, indicating that either direct competition or a negative allosteric effect was 
occurring between these two compounds on HSA. 80 
Another format in which zonal elution has been employed with microcolumns is 
shown in Figure 1.3(b).  In this case, the immobilized binding agent is utilized to examine 
the binding of a retained target with a second binding agent that is applied in the mobile 
phase.82  The column in this particular example was 275 μL in volume and contained an 
immobilized form of cellular retinoic acid binding protein (CRABP) that was initially 
loaded with the target retinoic acid. A sample of a second possible binding agent for 
retinoic acid (i.e., retinoic acid receptor isoform γ, or RARγ) was then applied to the 
column and examined for its elution profile.  The presence of a shift in the elution profile 
for this applied binding agent versus a control was used to detect an interaction between 
RARγ and CRABP during the transfer of retinoic acid between these binding agents.82  
One advantage of zonal elution is it requires only a small amount of target for 
injection.  This method can also examine more than one compound in a sample provided 
there is adequate resolution between the peaks for these compounds or a detection format 
is employed that can distinguish between these eluting solutes.27 As is illustrated in 
Figure 1.3(a-b), it is also possible with zonal elution to obtain information on site-specific 
interactions, on the competition of two targets for the same binding agent 79,83,84 or on the 
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Figure 1.3 Examples of the use of zonal elution with affinity microcolumns in 
examining biomolecular interactions.  In (a) competition studies based on 
zonal elution were carried out using the injection of R-warfarin as a site-
specific probe onto a microcolumn containing immobilized human serum 
albumin (HSA) in the presence of various concentrations of tolbutamide in 
the mobile phase.  The results in (b) show the elution profiles for retinoic 
acid receptor γ (RARγ) that was applied to columns containing apo-
cellular retinoic acid binding protein II (CRABP II) (open circles) or holo-
CRABP II (black circles) and in the presence of retinoic acid; the gray-
shaded circles represent an elution profile of carbonic anhydrase II (CA II) 
applied to an apo-CRABP II column.  Adapted with permission from 
Refs.80,82. 
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competition of two binding agents to the same target.85  As will be described in the next 
few sections, this format can also provide information on the strength of binding and the 
effects that changes in the structure of a target or binding agent may have on an 
interaction. 
 
Estimating binding strength and retention using affinity microcolumns  
Zonal elution can be used in a variety of ways to obtain information on 
biomolecular interactions.  An important parameter to measure when describing these 
interactions is the degree or strength of binding that occurs in the system. 27,40,86-96 This 
information can be obtained from the retention time or retention factor (k) for a target that 
is injected onto an affinity column.  This retention factor can be calculated from the 
observed elution times through the following relationship, 
                      𝑘 =
𝑡R−𝑡M
𝑡M
                          (1.1) 
where tR is the observed retention time for the injected target, and tM is the column void 
time.   
If relatively fast association/dissociation kinetics and linear elution conditions are 
present during the measurement of the retention factor (i.e., the apparent value of k is not 
affected by the amount of injected sample or the flow rate), Equation 1.2 can be used to 
relate this retention factor to the number of binding sites for the target in the affinity 
column and to the association equilibrium constants for the target at these sites.81,101 
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   𝑘 =
(𝐾a1𝑛1+𝐾a2𝑛2…+𝐾an𝑛n)𝑚L
𝑉M
                           (1.2) 
In this equation, the terms Ka1 through Kan represent the association equilibrium constants 
for the target at each of its binding sites in the column, n1 through nn are the fractions for 
each type of site in the column, mL is the total moles of all binding sites in the column, 
and VM is the void volume of the column.   
The global association equilibrium constant (nKa’) for the interaction of a target 
with the immobilized binding agent can be obtained from the numerator of Equation 1.2, 
where nKa’ is the summation of the terms Ka1n1 through Kannn.  This term is directly 
proportional to k if all of the binding sites have independent interactions with the target. 
If the target binds to only one type of site on the affinity ligand and in the column, the 
multisite equation in Equation 1. 2 can be rearranged to the simpler form that is provided 
in Equation 1.3, 
                                                          𝑘 =
𝐾a𝑚L
𝑉M
                             (1.3) 
where Ka is the association equilibrium constant for the interaction, mL/VM represents the 
molar concentration of the binding sites for this interaction, and other terms are as 
defined previously. 81,101 
A few recent studies have examined the ability of short affinity microcolumns to 
be used with zonal elution for estimates of retention factors and binding strength.  One set 
of experiments were carried out at various flow rates for the drugs carbamazepine and 
warfarin when applied to HSA affinity microcolumns.86 These columns contained 4.6 mm 
i.d. silica monoliths with lengths of 1-5 mm or 4.6 mm i.d. columns that were 3 mm in 
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length and that contained HSA immobilized to silica particles.  It was found that similar 
retention factors were obtained for warfarin on 3 to 5 mm long microcolumns, and for 
carbamazepine when the column length ranged from 1 to 5 mm. These results indicated 
microcolumns as short as 1-3 mm could be used to provide reproducible retention factors 
for drug-protein binding studies that involve systems with binding constants in the range 
of 103 to 106 M-1.86 Additional work was carried out with racemic warfarin and L-
tryptophan on 2.1 mm i.d. HSA microcolumns that contained silica particles and that 
ranged in length from 1 mm to 2 cm.  This report also indicated that columns as small as 
only a few millimeters in length could be used for zonal elution studies of drug-protein 
binding for systems with affinities of 104 to 106 M-1.72  Some loss of precision in retention 
measurements did occur with the use of these small columns and there was a greater 
chance of column overloading.72, 86 However, it was noted that the latter effect could be 
dealt with by decreasing the sample load or by using reference compounds and retention 
ratios to adjust for shifts in the retention factors. 72   
The fact that the retention factor is related both to the association equilibrium 
constants and number of binding sites for an interaction can be used in a variety of ways.  
For instance, retention factor measurements of R- and S-propranolol, as model drugs, 
have been used in examining the long-term stability of affinity microcolumns that 
contained high-density lipoprotein (HDL) and low-density lipoprotein (LDL).87-89 If an 
independent estimate is available for the binding capacity (mL), it is possible to use this 
information with measured retention factors and Equations 1.2 or 1.3 to estimate the 
value of nKa’ for a multi-site system, or Ka for a single-site interaction.  This method has 
been used to screen and compare the binding of several site-selective probes and 
 17 
sulfonylurea drugs on microcolumns containing entrapped samples of HSA or glycated 
HSA.90 Zonal elution data with detection based on mass spectrometry has been combined 
with binding capacities obtained by frontal analysis on a packed capillary containing 
cyclin G-associated kinase for drug discovery; the results were then used to estimate and 
rank the affinity of the kinase for a series of drug fragments. 93 A similar method was 
used to rank the binding constants for various drug fragments with the chaperone protein 
HSP90 (see Figure 1.4) 74 and for various carbohydrates in their binding to hen egg-white 
lysozyme.24 It is also possible to use the ratio of the retention factor to the known amount 
of binding agent to provide an index that is related to nKa’ or Ka. 
96 This technique has 
been used to compare the activities and properties for proteins attached within organic-
based monoliths that were prepared under various polymerization conditions.68  
 
Competition and displacement studies using affinity microcolumns 
Zonal elution and traditional HPAC or affinity columns have often been employed 
in studying the competition and displacement between drugs and other solutes during 
solute-protein interactions. 20,27,40,42,105 In this type of experiment, a competing agent is 
placed at a fixed concentration in the mobile phase.  A small pulse of a target or site-
selective probe is then injected onto the column and allowed to interact with the 
immobilized binding agent, as illustrated earlier in Figure 1.3(a).  As the target passes 
through the column, the competing agent may influence binding by the target to the 
affinity ligand through direct competition or allosteric effects.  When these data are fit to 
the response that is predicted by various models, the types of interactions that are 
occurring between the target, competing agent and immobilized binding agent can be 
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Figure 1.4 Use of zonal elution and mass spectrometry with a 0.5 mm i.d. × 10 cm 
packed capillary containing the N-terminal domain of the protein HSP90 
to compare the relative retention of four drug fragments (four upper plots), 
using adenosine (bottom plot) as a reference.  Adapted with permission 
from Ref. 74. 
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determined.  This, in turn, can provide information on the number of interaction sites, the 
location of these sites (i.e., through the use of site-selective probes), and the binding 
strength at particular sites. 20,97,103  
To illustrate this process, Equation 1.4 shows the response that would be expected 
between the retention factor for an injected solute and the concentration of a competing 
agent in the mobile phase if these two solutes have direct competition at a single type of 
site on an affinity column. 20,27,40 
                                          
1
𝑘
=
𝐾a,IL𝑉M[I]
𝐾a,AL𝑚L
+
𝑉M
𝐾a,AL𝑚L
                             (1.4) 
In this equation, Ka,AL and Ka,IL are the association equilibrium constants for the 
interactions of the immobilized binding agent (or affinity ligand, L) with the 
target/analyte (A) and the competing agent (I) at their site of competition.  This 
relationship predicts that a linear response with a positive slope should be obtained for a 
plot of 1/k versus [I] if A and I have a single site of competition.  This relationship, in 
turn, can be used to provide the value of Ka,IL for I at its site of competition with A.  If no 
competition is present between A and I, this type of plot will show only random 
variations in 1/k as [I] is increased.  If negative allosteric effects or multisite interactions 
are present, deviations from a linear response at low concentrations of I should be 
obtained.  If positive allosteric effects are present, the value of 1/k should decrease as the 
concentration of I is increased. 20,27  
  Plots made according to Equation 1.4 have been used in many recent studies 
involving affinity microcolumns.  An example of a plot from a study that used a 
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microcolumn containing HSA is shown in Figure 1.5(a).80 In this case, a linear response 
was obtained in a plot of 1/k for L-tryptophan as the concentration of tolbutamide was 
varied in the mobile phase.  This result indicated that tolbutamide had direct competition 
with L-tryptophan at Sudlow site II, the known binding site for the latter compound with 
HSA.  The same approach has been employed with affinity microcolumns to investigate 
the competition of various probes with a number of other drugs during their interactions 
with the proteins HSA, glycated HSA, and α1-acid glycoprotein (AGP).
79,80,83100-105  
Alternative forms of Equations 1.3-1.4 have been used with other systems.21,23,42,106 One 
example was the use of competitive zonal elution studies to examine the binding of L-
fucose, as a mobile phase additive, to immobilized Aleuria aurantia lectin as injections of 
the oligosaccharide LNF III were made as a probe. 21 
Another type of graph that can be used to analyze both direct competition and 
allosteric effect using zonal elution data is given in Figure 1.5(b).  In this case, a plot of 
k0/(k - k0) versus 1/[I] is made according to Equation 1.5, where k0 and k are the retention 
factors for injected target A in the absence and presence of the competing agent, 
respectively.107   
                                        
𝑘0
  𝑘−𝑘0
=
1
βI→A−1
∙ (
1
𝐾a,IL[I]
+ 1)        (1.5) 
This equation is based on a model where A and I may have direct competition at a single 
site or allosteric interactions through two different sites.  If an allosteric effect is present, 
the ability of A to bind to L is influenced by the binding of I on L, which causes the 
association equilibrium constant for A to change from Ka,AL to Ka,AL’.  This change can 
also be described by the coupling constant βI→A, which is equal to the ratio K’a,AL/Ka,AL.  
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Figure 1.5 Results of zonal elution competition studies on HSA microcolumns 
examining the change in retention of (a) L-tryptophan as a probe for 
Sudlow site II and (b) R-warfarin as a probe for Sudlow site I in the 
presence of tolbutamide as a competing agent.  The solid lines show the 
best-fit responses that were obtained when fitting (a) Equation 1.4 or (b) 
Equation 1.5 to the data.  These results were obtained under similar or 
identical conditions to those used in Figure 1.3(a).  Reproduced with 
permission from Ref. 80. 
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A linear relationship obtained from this plot can be used to determine the association 
equilibrium constant for I with L (Ka,IL) and the coupling constant, βI→A.  A value of βI→A 
between 0 and 1 indicates that a negative allosteric effect is present between A and I, 
while a positive allosteric effect is indicated if βI→A is larger than 1.  A unique advantage 
of this method is that it can be used to look independently at both directions of an 
allosteric effect by changing which compound is used as A or I in the experiment. 107-109  
Plots made according to Equation 1.5 have been used in various studies of 
biomolecular interactions based on affinity microcolumns.  Figure 1.5(b) is one example, 
which was used to determine how binding by R-warfarin to HSA was affected by 
tolbutamide as a competing agent.  This plot was used to help differentiate between 
allosteric effects and multi-site binding during the interaction of these two solutes on an 
HSA microcolumn.80 Equation 1.5 and similar plots have been utilized with 
microcolumns to study the interactions between various fatty acids and sulfonylureas 
with HSA or glycated HSA 110 and allosteric effects that may occur on AGP as it binds to 
S-propranolol and warfarin.83   
 Experiments based on competition studies and zonal elution can further be used 
to determine the location and structure of binding regions on proteins or other 
biomolecules.  This is done by using an injected probe compound that is known to bind to 
a specific site on the protein or affinity ligand, with the competing agent in the mobile 
phase being the compound for which possible interactions at this site are being 
examined.20 Such an experiment is illustrated by the examples provided in Figure 1.5.  
With this technique it is possible to develop a model of both the number of binding 
regions a solute may have with a protein, or other type of affinity ligand, and the 
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association equilibrium constants for the solute at each of these sites.  This technique has 
been used with microcolumns containing HSA or modified forms of this protein to study 
the interactions of drugs such as acetohexamide, tolbutamide, gliclazide, glibenclamide 
and imipramine at Sudlow sites I and II or the digitoxin site of this protein. 80,100,103, 
104,105,111 The same method has been employed to look for common binding regions of 
drugs and drug enantiomers on microcolumns that contained AGP. 83  
 
Ultrafast affinity extraction method 
Ultrafast affinity extraction is one of the methods developed based on zonal 
elution and used for examining biomolecular interactions. 37,69,71,73,50,51 This approach 
examines the interaction of a target and a binding agent that is in solution but uses an 
affinity microcolumn to probe the non-bound, or free, fraction of the target that remains.  
In this technique, the target is injected in the presence or absence of the soluble binding 
agent onto a microcolumn that contains an affinity ligand that can selectively retain the 
target in its free form.  This affinity ligand may be a specific agent, such as an antibody 
for a given target. 37,69  Alternatively, the affinity ligand may be a more general binding 
agent, such as a serum transport protein like HSA for the retention of various drugs. 
50,51,71,73  If the flow rate and column conditions are selected correctly, the residence time 
for the sample in the column can be made small enough that no significant dissociation 
will occur of the target from the soluble binding agent as the sample passes through the 
column.  For instance, affinity microcolumns have been used to produce sample 
residence times down to the low-to-mid millisecond range for this method.50,70,73 
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This type of study is carried out by using the general scheme shown in Figure 1.6, 
in which an affinity microcolumn containing HSA is used to separate the free and 
protein-bound fractions of drug or small target in a sample.50 In this example, the protein-
bound fraction of the target and the protein in the sample will elute first in the non-
retained fraction.  This is followed later by elution of the retained free fraction of the 
target, which can then be determined by comparing the measuring retained peaks for the 
target in the presence or absence of the soluble binding agent.  This information, in turn, 
can be used to determine the association equilibrium constant for the interaction of the 
target with the binding agent in the sample if the binding agent’s total concentration is 
also known.  For instance, Equations 1.6-1.7 describe the relationship between the 
observed free fraction (f) and the association equilibrium constant (Ka) for a target (A) 
and soluble binding agent (P) that have a single-site interaction. 
𝑓 =
𝐶A − [A−P]     
𝐶A 
                             (1.6)  
                                              𝐾𝑎 =
[A−P]     
(𝐶A − [A−P])(𝐶P − [A−P])
                                   (1.7)  
In these equations, CA is the total concentration of the target in the original sample, CP is 
the total concentration of soluble binding agent, and [A-P] is the concentration of the 
target-binding agent complex in the original sample. 50,70  
One advantage of free fraction analysis is its ability for rapid analysis.  This is 
partly due to the fact that sample residence times in the range of only a few hundred 
milliseconds or less are used to minimize the possibility that the target may dissociate 
from soluble binding agent during the analysis.50,70,73  It has been shown that the results 
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Figure 1.6  General scheme for the use of ultrafast affinity extraction with an HSA 
microcolumn to separate the free and bound fractions of a drug or solute in 
an injected sample.  Reproduced with permission from Ref. 50. 
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obtained by this technique are comparable to those found with the reference methods 
such as ultrafiltration and equilibrium dialysis, among others. 27,50,70 Furthermore, 
because this method directly examines the interactions between a target and a soluble 
binding agent, it is not subject to the immobilization effects that can occur with other 
affinity methods if improper conditions are used to couple the binding agent to the 
support. 37,50,51, 69,71,73 
Several recent studies have used ultrafast affinity extraction to examine 
biomolecular interactions.  For instance, this method has been used with immobilized 
antibodies and fluorescence detection to measure the free drug fraction in mixtures of 
warfarin and HSA.73 This technique has also been combined with a displacement 
immunoassay to measure the free fraction of thyroxine and phenytoin in clinical samples 
by using chemiluminescence or near-infrared fluorescence detection. 51,71, Use of this 
scheme to estimate association equilibrium constants has been shown with HSA and 
drugs such as R- or S-warfarin, S-ibuprofen and imipramine to give good agreement with 
the values obtained by other methods. 50  
 
Other applications of zonal elution with affinity microcolumns 
Another application of zonal elution is its use in examining the effects of various 
conditions on binding of the target with the affinity ligand.  Conditions that can be altered 
during such studies include the temperature, pH, ionic strength and content of the mobile 
phase.10,14,20,81,113,115 For instance, varying the polarity of the mobile phase can be used to 
alter non-polar interactions between a target and a protein, and/or change the 
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conformation of the protein or the target.  This is a common tactic used with chiral 
stationary phases based on proteins to alter their retention and stereoselectivity.70, 113, 
114,116 Some examples are provided in Figure 1.7, in which an organic modifier was used 
to increase the speed of chiral separations for R/S-warfarin and D/L-tryptophan on a 4.6 
mm i.d. × 10 mm microcolumn that contained HSA immobilized to an organic 
monolith.68 
It is also possible to use zonal elution to examine the effects of changes in the 
structure of a target on its interactions with a given biding agent.  This general approach 
can involve creating a quantitative structure-retention relationship (QSRR), in which the 
retention factors for a set of structurally-related molecules are measured on an affinity 
column under otherwise similar temperature and mobile phase conditions.  These data are 
then compared to various factors that describe the structural components of the applied 
targets to see which of these factors most affected the retention.47,117-120 This technique 
has been used with traditional HPAC columns to investigate a number of questions: the 
skin permeation of several organic molecules through the use of a column containing 
immobilized keratin; 117 the binding of HSA to benzodiazepine; 118-120 and the interactions 
of AGP with antihistamines, beta-adrenolytic drugs, and other agents.121-127 In work with 
affinity microcolumns, the same general method has been used to compare the binding of 
various sulfonylurea drugs at both Sudlow sites I and II of HSA.128   
A related approach is to use affinity microcolumns to see how biomolecular 
interactions change as variations are made in the structure of the immobilized binding 
agent. 129-131 This tactic has been used to see how the non-enzymatic glycation of HSA, as 
occurs during diabetes, 99,132 may alter the binding of this protein to various drugs and  
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Figure 1.7 Chiral separations for (a) R- and S-warfarin and (b) D- and L-tryptophan 
on a 4.6 mm i.d. × 10 mm microcolumn containing HSA immobilized to a 
monolith based on a co-polymer of glycidyl methacrylate and ethylene 
glycol dimethacrylate.  The mobile phase was pH 7.4, 0.067 M phosphate 
buffer that contained 0.5% 1-propanol and the flow rate was (a) 2.0 
mL/min or (b) 3.0 mL/min.  Reproduced with permission from Ref. 68. 
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solutes.  These studies have used R-warfarin, L-tryptophan and digitoxin as probes (i.e., 
for Sudlow sites I and II and the digitoxin site of HSA, respectively), along with samples 
of glycated HSA that had various known levels of modification.  The results for in vitro 
glycated samples indicated that changes in the affinities for sulfonylurea drugs and L-
tryptophan did occur as the level of glycation for HSA was increased and that these 
changes differed between solutes and the binding site that was examined.105,80,100,103  
Similar effects were seen in affinity microcolumns that contained in vivo glycated HSA 
that was obtained from several patients with diabetes. 104  
Affinity microcolumns and zonal elution have also been used in the high-
throughput screening of compound fragment mixtures based on WAC and mass 
spectrometry (WAC-MS).  This method has been utilized to screen the binding of drugs 
to albumin 133 and binding of compound fragments to protease 22,134 or kinase targets. 93 
As an example, one recent study showed that 111 fragments could be screened on 
capillary column containing the protein HSP90, as illustrated earlier in Figure 1.4.  The 
results of WAC were found to show good agreement with data obtained by NMR, SPR, 
and isothermal titration calorimetry, as well as crystallographic data.74 
Zonal elution has also been applied for the study of biomolecular interactions and 
the kinetic process involved in these interactions. These techniques include peak decay 
analysis, split-peak analysis, band-broadening measurements and peak fitting methods. 
The principles behind each of these methods will be described in Chapter 2.  The 
advantages and possible limitations of these methods will be discussed in that chapter, 
and various examples will be provided to illustrate the use of these techniques with 
affinity chromatography.  
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Frontal Analysis and Affinity Microcolumns 
Principles of frontal analysis 
Frontal analysis, or frontal affinity chromatography (FAC), is another common 
technique that is used in HPAC and affinity chromatography to study biomolecular 
interactions.  In this method, a target solution is continuously applied to a column while 
the amount of target that elutes from the end of the column is monitored.27,79,135 As the 
target binds to the immobilized affinity ligand, the column begins to become saturated 
and the amount of the target that elutes from the column increases with time or with the 
volume of applied target. 20 The result is the formation of a breakthrough curve, as is 
illustrated in Figure 1.8(a) for R-propranolol that was applied to an affinity microcolumn 
containing HDL as the binding agent.87  
Frontal analysis was first used with traditional affinity columns in the mid-to-late 
1970s.136-138 In the early 1990s this technique was used with HPAC to study drug-protein 
binding.139 Over the last 10-15 years, this method has been utilized with various types of 
affinity microcolumns and capillary columns for binding studies; this includes the 
combination of this method with mass spectrometry, giving a method known as frontal 
affinity chromatography-mass spectrometry (or FAC-MS).54,58,60,87,140  
There are several advantages, and potential disadvantages, to using frontal 
analysis versus zonal elution to examine a biomolecular interaction.  For instance, frontal 
analysis is easier to use in providing independent information on both the overall number 
of binding sites for an interaction and the equilibrium constants for these interactions.40,20  
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Figure 1.8 (a) Typical chromatograms (i.e., breakthrough curves) obtained for a 
frontal analysis experiment, as obtained here for the application of various 
solutions R-propranolol to a 5 cm × 2.1 mm i.d. column containing 
immobilized high-density lipoprotein (HDL).  (b) Analysis of frontal 
analysis data obtained for R-propranolol on the HDL column by fitting to 
the results to a model based on a combination of a saturable binding site 
and a non-saturable interaction.  Reproduced with permission from Ref. 
87. 
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On the other hand, zonal elution competition experiments, as discussed in the previous 
section, are more convenient for identifying interaction sites and measuring binding 
constants specifically at these sites.  Frontal analysis tends to require more solute than 
zonal elution, but column overloading effects are not a problem in frontal analysis 
because column saturation is actually a desirable feature for at least part of such an 
experiment. 20 In addition, the higher amounts of a target that are typically used in frontal 
analysis can make it easier to detect an interaction with this method than when using 
zonal elution.20, 54,58  
 
Estimating binding strength and number of sites using affinity microcolumns 
An important application of frontal analysis is obtaining information on both the 
overall number of interaction sites an applied target has with an immobilized affinity 
ligand and the equilibrium constants for these interactions.  Data can be obtained for this 
purpose by applying to the affinity column a wide range of target concentrations, as 
demonstrated earlier in Figure 1.8(a).  The mean position of the breakthrough curve is 
then measured at each applied concentration of the target, and the resulting data are fit to 
various binding models, as illustrated in Figure 1.8(b). 87 For instance, either Equation 1.8 
or 1.9 can be used to describe a system in which a single-site interaction is occurring 
between the target and the immobilized binding agent. 20 
             𝑚L,app =
𝑚 L 𝐾a [𝐴]
1+ 𝐾a [𝐴]
                 (1.8) 
          
1
𝑚L,app
=
1
𝐾a 𝑚L [A]
+
1
𝑚L
            (1.9) 
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In these equations, mL,app is the apparent moles of target that is required to reach the mean 
position of the breakthrough curve at a given concentration of the applied target or 
analyte ([A]).  The term Ka is the association equilibrium constant for this process, and 
mL is the total moles of active binding sites that are involved in this interaction.  By using 
a non-linear fit of mL,app versus [A] to Equation 1.8, or a linear fit of 1/mL,app versus 1/[A] 
to Equation 1.9, the values of both Ka and mL can be obtained for this system.  If multiple 
types of binding sites or interactions are present, alternative binding models and 
equations can also be fit to the data. 20,141,142  
An example of this type of analysis when using an affinity microcolumn is 
provided in Figure 1.8(b).  This example shows the use of a model based on both a 
saturable binding site and a non-saturable interaction to describe the interactions of R-
propranolol with HDL. 87 This approach has been employed with small columns in HPAC 
and with other drugs and serum agents, such as the binding of S-propranolol and 
verapamil with HDL, 87 the interactions of R- and S-propranolol with LDL,88 the binding 
of drugs with AGP,83,143-147 and the interactions of various drugs and solutes with HSA or 
modified HSA. 104,105,78,80,100,103,111  Frontal analysis was used to determine the binding 
capacity of adenosine on a packed capillary containing cyclin G-associated kinase 93 and 
FAC-MS has been used with open-tubular capillaries containing peroxisome proliferator-
activated receptors to compare and rank the binding of the agents to various 
urediofibrate-like dual agonists. 48 Capillary monolith columns containing lectins or 
enzymes have been employed with FAC-MS to examine the equilibrium constants of 
applied targets with these affinity ligands. 52,54, 56 FAC-MS has also been coupled with 
capillary columns for the high throughput screening of enzyme inhibitors, 
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oligosaccharides, and other targets for immobilized binding agents. 140 
The effect of column size on the results of frontal analysis experiments has been 
recently examined for systems with low-to-moderate affinity interactions.72 This work 
used HSA as the immobilized binding agent and warfarin as a model target (i.e., a drug 
with single-site binding to HSA and a well-characterized affinity for this site).  Table 1.1 
shows the results obtained for 2.1 mm i.d. microcolumns with lengths ranging from 2 cm 
down to only 1 mm and packed with silica particles.  Each of these columns gave a good 
fit for their frontal analysis data to a single-site model, and the measured binding capacity 
decreased in proportion to the total column volume.  It was also found that all of these 
columns gave association equilibrium values that were in good agreement with literature 
values; however, the results obtained for the short columns did have less precision that 
those obtained for the longer columns.  The main benefit of using the shorter columns 
was the much smaller amount of immobilized binding agent that they required and their 
shorter residence times.  These features made these affinity microcolumns appealing for 
future use in the high-throughput screening of drug candidates and in rapid studies of 
drug-protein binding. 72 
   
Competition and displacement studies using affinity microcolumns 
Frontal analysis, and especially FAC-MS, has also been used to examine the 
competition between potential targets and immobilized binding agents on affinity 
microcolumns. 48,49,27 In this type of study, a competing agent is added with the target in 
the mobile phase.  The resulting chromatograms are then analyzed by measuring the 
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change in breakthrough time or volume of the target as a function of the competing 
agent’s concentration (see Figure 1.9).49 Direct competition or negative allosteric effects 
between the target and competing agent can be detected when the breakthrough time 
decreases with an increase in the competing agent’s concentration.  Alternatively, positive 
allosteric effects can lead to a larger breakthrough time for the target as the concentration 
of the competing agent is increased. 27  
It is possible to obtain a qualitative ranking of the strength of displacing agents 
based on chromatograms like those in Figure 1.9, but a quantitative analysis of such data 
is possible as well.  For instance, Equation 1.10 has been used to describe the interactions 
between a competing agent (I) and the target during such an experiment. 48,49,148-150 
        𝑉R − 𝑉min = 𝑃/(𝐾d,IL + [I])      (1.10) 
In this expression, Kd,IL is the dissociation equilibrium constant of the competing agent 
with the immobilized affinity ligand, [I] is the concentration of the competing agent, VR is 
the breakthrough volume of the target, and Vmin is the breakthrough volume of the target 
when the interaction being examined is completely suppressed (i.e., as can be determined 
by running the target with a high concentration of the competing agent).  The term P is 
the product of the number of active binding sites and the term Kd,IL/Kd,AL, where Kd,AL is 
the dissociation equilibrium constant for the target (or analyte) with the immobilized 
ligand. 
Several reports have used Equation 1.10 or equivalent relationships in 
displacement studies based on FAC-MS and affinity microcolumns. 48,49 The example in 
Figure 1.9 utilized an open-tubular capillary that contained the histone deacetylase 
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Figure 1.9  Example of a displacement experiment using frontal analysis and with 
detection based on mass spectrometry.  These chromatograms show the 
effects of adding (B) vitexin, (C) naringenin, (D) apigenin, (E) quercetin, 
(F) kaempferol, or (G) luteolin to a solution containing (A) quercetin as 
the target and applied to a 30 cm × 100 µm i.d. open-tubular capillary 
column containing an immobilized form of the histone decarboxylase 
SIRT6.  Adapted with permission from Ref. 49. 
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SIRT6.  This column was used with FAC-MS to estimate the dissociation equilibrium 
constants for several structurally-related flavonoids based on their ability to displace 
quercetin, a known inhibitor for SIRT6. 49 Open-tubular capillaries containing the ligand 
binding domains of peroxisome proliferator-activated receptors were employed in a 
similar manner to examine the interactions and rank the affinities of ureidofibrate-like 
dual agonists with these columns. 48 
 
Other applications of frontal analysis with affinity microcolumns  
As mentioned earlier, changes in factors such as the temperature or mobile phase 
can alter a biomolecular interaction.  Like zonal elution, frontal analysis can be employed 
to see how such changes may alter an interaction.  One advantage of using frontal 
analysis for this purpose is it can be used to independently examine how both affinity and 
moles of binding sites are affected by a change in the temperature or reaction 
conditions.20,116As an example, the effect of temperature on the binding for R- and S-
propranolol with HDL and LDL has been studied using affinity microcolumns. 87-89 The 
results showed that a change in temperature had little effect on either the association 
equilibrium constants or the binding capacities between these drugs and binding agents. 
87-89   
Frontal analysis has also been used to examine the binding of solutes to modified 
proteins. This technique has been utilized to compare the binding of several solutes to 
HSA that has been modified to various extents by glycation. 104,105,100,103 Both the 
affinities and binding capacities for targets such as warfarin, L-tryptophan and 
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sulfonylurea drugs were investigated in going from normal HSA to in vitro or in vivo 
samples of glycated HSA. 100,103,104, 105   Warfarin and L-tryptophan were found to bind to 
both sets of proteins through a single-site interaction,92,101 but the sulfonylurea drugs 
interacted through a two-site model that involved a set of high and low affinity sites. 100 
The results indicated that the glycation of HSA could affect the affinity of this protein for 
L-tryptophan and some of the sulfonylurea drugs, but no appreciable change was noted 
for warfarin under modification conditions similar to those seen in diabetes.101,104 Affinity 
microcolumns and frontal analysis have been used in a growing number of reports for the 
high-throughput screening of compound mixtures with regards to their binding to 
biological ligands.  This research has used FAC-MS to rank and measure the binding of 
several applied compounds in a single experiment, as demonstrated with columns that 
have contained enzymes, antibodies, lectins or human estrogen receptor β. 140 FAC-MS 
and such columns have been employed to screen the binding of enzyme inhibitors, 
oligosaccharides and peptide libraries.57,140,149,150 For instance, an open-tubular capillary 
containing an immobilized nuclear receptor was used in FAC-MS to determine the 
relative affinities for a series of chiral fibrates with this receptor. 47 
Another application of frontal analysis is its use in kinetic studies of biomolecular 
interactions.  This can be performed with frontal analysis by using peak fitting methods.  
As was mentioned earlier for zonal elution, more details about the principle of this set of 
kinetic methods will be given in Chapter 2. The advantages and possible limitations of 
these methods will be considered. Applications of these methods will also be discussed in 
that chapter. 
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Overall Goal and Summary of Work 
The overall objective of this work is to develop new HPAC methods and affinity 
microcolumns that could be used to examine the biological interactions and providing 
information on thermodynamic and kinetic of these binding systems. Chapter 2 will 
review the analytical methods that have been used for kinetic studies of biological 
interactions. Chapter 3 will develop a method based on ultrafast affinity extraction and 
HPAC method to examine both the dissociation rate constants and equilibrium constants 
for drug-protein interactions in solution in a single experiment. The results will be used to 
demonstrate that ultrafast affinity extraction can be used as a rapid approach to provide 
information on both the kinetics and thermodynamics of a drug−protein interaction in 
solution. 
Chapter 4 will develop a multi-dimensional system based on ultrafast affinity 
extraction and chiral separations to measure the free fractions of drug enantiomers in 
samples that also contained a binding protein or serum. The binding of each enantiomer 
with serum transport proteins will also be studied by this method. R/S-Warfarin and the 
HSA will be used as drug and protein models to test this approach. The association 
equilibrium constants and free fractions of drug enantiomers that are determined by this 
method will be compared with the results estimated by reference methods (i.e. 
ultrafiltration) or with the literature values. The work will describe the possibility to 
automate and complete both the ultrafast extraction and the chiral separation through 
using a single system.  
 Chapter 5 will show the use of ultrafast affinity extraction and a multi-
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dimensional affinity system to examine the effect of protein modification on drug binding 
in the sample prepared at therapeutic levels. The model analytes in this chapter will be 
sulfonylurea drugs, normal HSA or HSA glycated at various levels, as are produced 
during diabetes. The results will indicate how HSA glycation can alter the global affinity 
constants and free fractions of sulfonylurea drugs at typical therapeutic levels and how 
the size of this change varies with the level of HSA glycation.   
In Chapter 6, a similar system will be used to measure the free fraction of drugs in 
human serum and to examine the interactions of these drugs with HSA. These studies 
will be conducted at typical therapeutic drug concentrations that will be prepared in 
control human serum. Various drugs will be examined in this work including quinidine, 
diazepam, gliclazide, tolbutamide and acetohexamide. The dissociation rate constant and 
association equilibrium constants for each drug with HSA in human serum will be 
determined as well. The results obtained in Chapter 6 should provide important 
information on the use of ultrafast affinity extraction for examining free drug fractions 
and drug-protein interaction directly in biological samples. 
In Chapter 7, ultrafast affinity extraction method will be used to study the 
interaction between hormone and protein. The binding of testosterone with human serum 
albumin and sex hormone binding globulin (SHBG) will be used as models. Both the 
association equilibrium constants and dissociation rate constants for these interactions 
will be determined. The free fraction of testosterone in the sample containing HSA or 
SHBG at clinically-relevant concentrations will also be studied by using a multi-
diemensional affinity system. The results of this study should provide a better 
understanding about the interactions of testosterone with proteins such as HSA and 
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SHBG, and important information that can be used to extend this approach to alternative 
hormone-protein systems or other solutes and binding agents. 
Chapter 8 will develop and examine a hybrid immobilization method for 
increasing the binding capacity and activity of protein-based affinity columns. This will 
be accomplished by combining protein cross-linking/modification and the covalent 
immobilization. HSA will be used as the model protein for this study. A homobifunctional 
maleimide, bismaleimidohexane (BMH), will be used to modify and/or cross-link HSA 
through the single free sulfhydryl group that is present on this protein.  Various studies 
will be performed to examine the protein content and relative activity of HSA in this 
affinity column, and the use of this column in drug-protein binding studies and free drug 
fraction measurement. This method could be extended to other proteins or alternative 
applications that may require protein-based affinity columns with enhanced binding 
capacities and activities. 
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CHAPTER 2 
Analytical Methods for Kinetic Studies of Biological Interactions 
Portion of this chapter have previously appeared in X. Zheng, C. Bi, Z. Li, M. Podariu, D.S. Hage, 
“Analytical Methods for Kinetic Studies of Biological Interactions: A Review” Journal of Pharmaceutical 
and Biomedical 2015, in press. 
 
Introduction  
Biological interactions are important in determining many of the processes that 
occur in living systems.  For example, enzymes catalyze reactions by binding and 
modifying their substrates, transport proteins bind to and carry lipids, hormones or 
nutrients within the circulatory system, and antibodies are utilized by the immune system 
to bind and remove foreign substances from the body.  Many of these events make use of 
non-covalent binding and may involve proteins, peptides, lipids, nucleic acids, lipids, 
metal ions, hormones or drugs.
1-8
  Because of the widespread occurrence and importance 
of these interactions, various techniques have been developed to investigate and 
characterize such reactions. 
4-19
 The overall strength, or thermodynamics, of these 
processes is one item of interest in these studies; however, the rate of these interactions, 
or their kinetics, is also important to consider. 
1-8
 Obtaining such information can provide 
a better understanding of the function of individual interactions in a biological system, 
the mechanisms through which these interactions occur, and the effects that a change in 
conditions may have on these processes. 
1-8
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This chapter examines several analytical techniques that have been used in kinetic 
studies of biological interactions.  The methods that will be discussed include common or 
traditional techniques such as stopped-flow analysis and surface plasmon resonance (SPR) 
spectroscopy, as well as separation-based approaches that make use of affinity 
chromatography or capillary electrophoresis (CE).
1,3,7,20
 The general principles and theory 
behind each of these techniques will be described, with particular attention being given to 
the use of each method for investigating the rates of biological interactions.  An overview 
of the conditions and models that are used in each technique for kinetic studies will be 
provided, and examples of applications will be given to illustrate each approach.  Finally, 
the advantages and possible limitations of each method will be discussed with regards to 
use of the technique in studying the rate of a biological interaction. 
 
Stopped-Flow Analysis  
General principles 
Many methods for kinetic studies are based on the measurement of a change in 
the concentration of a reagent or product as a function of time after the reagents have 
been mixed.
21-27
  This approach requires that the process of interest be slow enough to 
give a reaction time that is longer than the time needed for reagent mixing and instrument 
activation.  However, many biological interactions can occur within seconds (s) or 
milliseconds (ms), a fact which has limited the application of many traditional kinetic 
methods to such systems.
21
   
  
 
63 
Stopped-flow analysis is one technique that can be employed to study the kinetics 
of biological interactions.  The mixing time for samples and reagents in stopped-flow 
analysis can be as short as 1-2 ms, making this approach useful for examining 
interactions that occur even on the millisecond-to-second timescale.  Examples of 
biological interactions that have been investigated with this method in kinetic studies are 
protein folding
28-30
, enzyme inhibition.
31,32
, and the binding of proteins or DNA to 
hormones, drugs, or small molecules.
33-40
  The reactants that can be used in stopped-flow 
analysis include proteins, DNA, drugs, hormones, and metal ions, among others.
28-80
   
In this technique, a small volume of each desired reagent is rapidly applied by a 
device such as a syringe and passed through a mixer to initiate the reaction (see Figure 
2.1).  This mixture is then moved into an observation chamber, and the flow is stopped.  
Data acquisition of a signal that is produced by one of the components in the observation 
chamber is begun at this time.  The time interval between the mixing of the reagents and 
the beginning of signal observation is usually only 1-2 ms and is referred to as the “dead 
time”.21,24   
Detection in stopped-flow analysis can be accomplished by using various methods 
that are able to selectively monitor a reagent or product in the reaction.  Absorbance and 
fluorescence are two common detection methods that are employed for this type of 
experiment.
21,25,28
  For instance, reactants or products with a specific chromophore or 
fluorophore (e.g., NADH, pyridoxal phosphate, or tryptophan residues on a protein) can 
be used to follow the rate of a biological reaction.
21
 Alternatively, a tag such as 
fluorescein can be added to one of the reagents to monitor the progress of the reaction.
21
  
Circular dichroism has also been used in stopped-flow analysis for studies involving 
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Figure 2.1 General design of an instrument for carrying out stopped-flow analysis, as 
illustrated here for a device that can be used with either fluorescence or 
absorbance detection.  This figure is based on information that was 
obtained from Refs. 22-24. Reproduced with permission from X. Zheng, C. 
Bi, Z. Li, M. Podariu, D.S. Hage, J. Pharm. Biomed. Anal. (2015) in press. 
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protein folding and unfolding.
28-30
  In addition, fluorescence lifetime measurements, 
47,48
 
nuclear magnetic resonance spectroscopy, 
41,42,49,50
 and small-angle X-ray scattering 
51
 
have been coupled with stopped-flow analysis to study the kinetics of protein folding or 
drug metabolite degradation.   
Once the response has been obtained, the data from a stopped-flow experiment 
are fit to one or more reaction models to obtain rate constants for the desired interaction.  
These models can range from reactions that involve the conversion of a single type of 
molecule from one form to another, to a bimolecular interaction or a multistep reaction.
21
  
Each of these models and applications will be discussed in more detail in the following 
sections. 
   
Applications involving single-molecule reactions 
The simplest type of reversible reaction that can be examined by stopped-flow 
analysis is the change of a single molecule from one form or conformation into another.  
This type of unimolecular reaction is represented by the model in Equation 2.1.  In this 
model, the reversible conversion of molecule P (e.g., a protein) into form P* is described 
by the first-order forward and reverse rate constants k1 and k-1.  The ratio of these rate 
constants also provides the equilibrium constant for this process (K1), where K1 = k1/k-1.
21
    
     𝑃  
𝑘1
 
𝑘−1
  𝑃               (2.1) 
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An appropriate detector is used during this experiment to monitor the concentration of the 
probed molecule in either its initial or final form (i.e., P or P*).  The observed signal (S) 
as a function of the reaction time (t) is then obtained and can be fit to the following 
equation.
21,24
  
 ( ) =    − (   −   ) 
−𝑘   𝑡                          (2.2) 
In Equation 2.2, S(t) is the signal measured at time t, S0 is the signal observed at the 
beginning of the experiment (t = 0), Seq is the signal obtained at a sufficiently long time 
that equilibrium has been reached, and (Seq − S0) is the total change in signal during the 
reaction.  The term kobs is the observed rate constant for the reaction. This latter parameter 
is related inversely to τ, the “relaxation time” for the system, where kobs = 1/τ.   
In a unimolecular reaction, the value of kobs in Equation 2.2 will be equal to the 
sum of k-1 and k1, regardless of the concentrations of P and P*.
21
  The values of k-1 and k1 
can be obtained from kobs if the value of K1 is also known, as can be accomplished by 
using the expressions in Equations 2.3 and 2.4.
21
   
𝑘1 =
𝐾1𝑘   
1 + 𝐾1
                (2.3) 
𝑘−1 =
𝑘   
1 + 𝐾1
     (2.4) 
A unimolecular model has been found to describe some conformational changes in 
proteins.  For example, this model has been used to study the conformational changes that 
occur in apotransferrrin following the binding of this protein with Fe
2+
 or Zn
2+
, as 
illustrated in Figure 2.2.
52
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Figure 2.2  Fluorescence intensity measured over time for apotransferrin after mixing 
a solution of this protein with an excess of Zn
2+
.  The observed processes 
include (a) a rapid interaction between apotransferrin and Zn
2+
 (i.e., the 
“1st rapid kinetic process”), as described by Equation 2.5; and (b-c) 
changes in the conformation of apotransferrin (i.e., the “2nd” and “3rd” 
kinetic processes), as described by Equation 2.1.  The graph in (d) shows a 
plot of kobs (or τ
-1
) vs. the concentration of Zn
2+
 during studies of the first 
kinetic process, which follows the linear relationship that is predicted by 
Equation 2.6.  Adapted with permission from Ref. 52. 
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Applications involving bimolecular reactions 
Another type of reaction that can be examined by stopped-flow analysis is the 
reversible interaction between two molecules to form a new species.  For instance, 
Equation 2.5 describes a bimolecular reaction between a molecule or protein (P) and a 
second molecule or ligand (L) that forms the reversible complex or product PL. 
𝑃 +  
𝑘1
 
𝑘−1
𝑃                    (2.5) 
The terms k1 and k-1 in this reaction are the second-order association rate constant and 
first-order dissociation rate constant for the interaction of P with L, respectively.  The 
ratio of these rate constants gives the association equilibrium constant for this reaction 
(K1, where K1 = k1/k-1).
21
   
A bimolecular reaction is often examined in stopped-flow analysis by using 
conditions that convert this process into a pseudo first-order reaction.  This can be 
achieved by using at least a ten-fold higher concentration of one reagent (X) versus the 
other reagent.  Under these conditions, the concentration of the excess reagent, [Xtot], 
changes negligibly during the reaction and is approximately constant.  The result is that 
the product of this concentration and the second-order rate constant k1 can now be used to 
describe a pseudo first-order rate constant that is equal to k1 [Xtot].  The observed rate 
constant, kobs, that is measured for this reaction by stopped-flow analysis is described by 
Equation 2.6.
21,53
 
𝑘   = 𝑘1[    ]  +  𝑘−1             (2.6) 
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The value of the observed rate constant, kobs, is obtained by fitting the stopped-flow 
analysis data to the expression that was given earlier in Equation 2.2.  However, 
experiments are now usually carried out at various concentrations of X, which is still in 
excess of the other reagent, and a plot is made of kobs versus [Xtot]. If the reaction between 
P and L is described by Equations 2.5-2.6, a linear relationship should be obtained for 
this plot, with a slope that is equal to k1 and a y-intercept that is equal to k-1. 
21,53
 
Figure 2.3 shows an example of this approach, in which stopped-flow analysis 
and fluorescence detection were used to investigate the kinetics of a DNA-protein 
interaction.  This particular application examined the binding of high-mobility group 
(HMG) domain proteins with cisplatin-modified DNA.
54
  A platinum-containing, 
fluorescent DNA probe was mixed with an excess of HMG1 or a domain from this 
protein, which were prepared at various concentrations.  The data gave a good fit to 
Equation 2.2 and the resulting values of kobs were plotted against the total concentrations 
of HMG1 or its domains in various mixtures.  This latter plot provided the association 
and dissociation rate constants for the DNA-protein interaction.   
This type of method has also been used in drug-protein binding studies.  
Interactions of the drug warfarin with the protein human serum albumin (HSA) have been 
investigated by using stopped-flow analysis under pseudo first-order conditions (i.e., by 
mixing HSA with solutions containing a known excess of warfarin).
53
  The enhancement 
in the fluorescence of warfarin when binding to HSA was used to examine the kinetics of 
this interaction.  Kinetic data for the interactions between isonicotinic hydrazide and its 
analogues with Mycobacterium tuberculosis catalase-peroxidase (KatG) have also been 
obtained and analyzed according to this technique, by detecting the change in the 
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Figure 2.3 Stopped-flow kinetic studies of the reaction between high-mobility group 
(HMG) 1 domain A and platinated 16-mer DNA probes containing a 
fluorescein-dU label.  The plot in (a) shows the change in fluorescence 
over time after the mixing of HMG1 domain A with the DNA probes.  The 
plot in (b) shows the relationship that was seen between the observed rate 
constant (kobs) and the concentration of HMG1 domain A.  Equation 2.6 
was used with this second plot to determine association and dissociation 
rate constants for this protein-DNA reaction.  Adapted with permission 
from Ref. 54.  
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absorbance of KatG as it binds to hydrazide.
55
  In addition, a bimolecular reaction model 
has been used to investigate enzyme interactions with peptides or coenzymes, protein-
protein interactions, the binding of ATP with proteins, and lipid-protein interactions.
56-61
 
Even though, in theory, both the association and dissociation rate constants for a 
bimolecular reaction can be estimated by using Equation 2.6, this equation does have 
some limitations when it is used to study reactions with relatively high equilibrium 
constants.  For instance, the small dissociation rate constants that can be present for this 
type of reaction may make it difficult or impractical to determine k-1 from the intercept of 
Equation 2.6.  This problem has been noted in the use of stopped-flow analysis to 
examine the interactions of some drugs or metal ions with proteins and in some enzyme-
peptide or protein-protein interactions.
52,53,56,59
  
 
Applications involving competition studies 
Competition experiments can also be utilized in stopped-flow analysis to examine 
the rates of biological interactions.  For instance, this might involve a bimolecular 
reaction like the one between P and L in Equation 2.5, along with the use of a competing 
agent (C) that is known to bind to the same site on P as L.  In this situation, the addition 
of C to a pre-incubated mixture of P and L will cause C to displace some of L from its 
complex with P.  The reactions that take place in this system are shown in Equation 2.7. 
𝑃 +  
𝑘1
  
𝑘−1
𝑃                            𝑃 +  
𝑘 
 
𝑘− 
 𝑃            (2.7) 
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In these reactions, k1 and k-1 are again the second-order association and first-order 
dissociation rate constants for the reversible interaction of P with L, while k2 and k-2 are 
the corresponding association and dissociation rate constants for the reversible interaction 
of P with C at the same binding region that can be occupied by L.
21
   
To study the dissociation rate of L from P in this type of system, the concentration 
of L in the premixed solution of P and L is chosen to ensure that there is a reasonable, 
initial saturation of P.  However, the concentration of C that is added needs to be present 
in a large excess compared to the concentrations of both P and L, thus avoiding re-
association of L after it has been dissociated from its complex with P.  A signal is then 
measured that reflects a change in one of the products or reactants, and this signal is 
analyzed according to an expression like Equation 2.2.  Ideally, experimental conditions 
should be selected so that if C and L do compete for sites on P and the concentration of C 
is sufficiently large, the observed rate constant kobs will be equal to k-1 and independent of 
the concentration of C.
21,53
   
Stopped-flow analysis and the model in Equation 2.7 can be further used to 
determine the dissociation rate constant for the interaction of C with P.  This can be 
achieved by using a large excess of L to displace C from P in a solution that initially 
contains a pre-incubated mixture of P and C.  Another binding agent, P’, which is able to 
bind to C, can also be used to displace C from its complex with P by forming the 
alterative complex, P’C.21 
Competition experiments in stopped-flow analysis have been used to examine the 
rates of interactions such as drug-protein, DNA-protein, protein-protein, and enzyme-
  
 
76 
peptide binding.
53,54,56,59,62-65
  For instance, phenylbutazone has been utilized as a 
competing agent in kinetic studies of warfarin’s interactions with HSA.  The observed 
rate constant was then used to estimate the dissociation rate constant for warfarin from 
HSA.
53
  This general approach was also used to measure the dissociation rate constant for 
DNA from HMG1 domain A, in which a DNA sequence without a fluorescent tag was 
used as the competing agent.
54
 A similar technique was employed to follow the 
dissociation of pyrene-labelled actin and ADP from their complexes with myosin by 
using unlabeled actin or ATP as a competing agent.
62-65
 
Competition experiments can be modified to measure the association rate 
constants for the interactions of L and C with P.  This can be carried out by premixing 
solutions of C and L, followed by the addition of P.  If the dissociation rate constants for 
this system (k-1 and k-2) are small compared to the pseudo first-order association rate 
constants, the observed rate constant will now be described by Equation 2.8.  
𝑘   = 𝑘 [    ] + 𝑘1[    ]                (2.8) 
In this type of experiment, the concentration of C ([Ctot]) is varied and mixed with L that 
has been prepared at a fixed concentration, [Ltot].  Both the concentrations of C and L are 
selected so that they are much higher than the concentration of P that will be present.  
After P has been added to the premixed solution of C and L, the change in signal for the 
system is measured as a series of kobs values are obtained for various mixtures of C and L.  
A plot of kobs versus [Ctot] is then prepared according to Equation 2.8, resulting in a linear 
relationship with a slope that provides k2 and a y-intercept that is equal to k1 [Ltot]. 
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Another use for Equation 2.8 has been in examining the type of competition that 
solutes may have at their binding sites on a protein.  In one report, podophyllotoxin (POD) 
was used as a competing agent to study binding by tubulin to two analogs of colchicine 
(2,3,4-trimethoxy-4’-carbomethoxy-1,1’-biphenyl, or TCB, and 2,3,4-trimethoxy-4’-
acetyl-1,1’-biphenyl, or TKB); this reaction was followed through stopped-flow analysis 
by monitoring the increase in fluorescence that occurred upon binding.
66
  A plot of kobs 
versus the concentration of POD was then made according to Equation 2.8.  The linear 
relationships in this plot indicated that POD was competing with both TCB and TKB for 
their binding sites on tubulin and provided the association rate constant for POD with this 
protein.  If this system had instead given a non-linear relationship, this would have 
indicated that a different binding site was involved in the interactions of C and L with P 
or that a process other than simple direct competition was present in the system.
66,67
 
 
Applications involving multistep reactions 
Even though a reversible bimolecular interaction like the one in Equation 2.5 can 
be utilized to describe many types of biological interactions, there are situations in which 
additional steps are needed to provide a suitable description of the system.  For instance, 
the fast binding of P with L to form PL may be followed by a slower conformational 
change to create an alternative form of this product, PL*, as is shown in Equation 2.9.   
𝑃 +  
 𝑘1
   
 𝑘−1
 𝑃   
𝑘 
   
𝑘− 
𝑃                      (2.9) 
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The first step of this process is described by the second-order association and first-order 
dissociation rate constants k1 and k-1.  The second step, involving a unimolecular change, 
is described by the first-order forward and reverse rate constants k2 and k-2, respectively.
21
 
The experimental conditions that can be used in stopped-flow analysis to examine 
this type of system are similar to those described for a simple bimolecular reaction in 
Section of Applications involving bimolecular reactions.  One of the reagents (e.g., L) is 
prepared at a series of concentrations that are much higher than the concentration of the 
other reagent (e.g., P).  To detect a two-step reaction like the one in Equation 2.9, a 
comparison can be made when the data are fit to both the single-exponential expression 
in Equation 2.2 and the double-exponential expression given in Equation 2.10, where 
these two expressions represent one- or two-phase association models.
66-72
  
  ( ) =   +   (   −   ) 
−𝑘   1𝑡 +   (   −   ) 
−𝑘   2𝑡                (2.10) 
In Equation 2.10, the terms Ff and Fs are the fractions of the change in response due to 
the fast and slow reaction steps, where the sum of these fractions is equal to one.  In this 
type of multistep system, the observed rate constant for the fast bimolecular reaction, kobs1, 
should increase in a linear manner with the value of [Lot] when PL is forming, as is 
described by Equation 2.6.  The term kobs2, which is the observed rate constant for the 
slower unimolecular reaction, should have a non-linear relationship with [Lot], as 
indicated by Equation 2.11 for a case in which the concentration of L is much larger than 
that of P.
21,68-70,73-75
   
𝑘    = 
𝑘2[    ]
𝐾 1 + [    ]
+ 𝑘−              (2.11) 
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The term K-1 in Equation 2.11 is the dissociation equilibrium constant for the fast 
bimolecular reaction, where K-1 = k-1/k1. 
This method has been used to examine the interactions of genome-linked protein 
with wheat germ translation initiation factors.
68
  It was further employed in a study 
examining the reactions between J-binding protein 1 and its J-DNA-binding domain with 
DNA oligomers that contained base J or glucosylated 5-hydroxymethylcytosine.
69
  The 
rate constants for the binding of phosphatidylserine-containing vesicles to lactadherin 
have also been determined by using Equations 2.10-2.11.
70
  In addition, other biological 
interactions (e.g., enzyme catalysis) have been investigated by using stopped-flow 
analysis and a multistep model.
73-75
 
If the dissociation equilibrium constant K-1 is small compared to [Ltot], the value 
of kobs2 in Equation 2.11 will become independent of [Ltot] and approximately equal to the 
sum of k2 and k-2.  The kinetic parameters for each step in the reaction can then be 
determined by employing Equation 2.6 or Equations 2.3-2.4 to analyze data acquired 
over appropriate time periods during the experiment.  This type of analysis has been used 
in kinetic studies of the binding of Fe
2+
 and Zn
2+ 
to human serum transferrin, as 
illustrated earlier in Figure 2.2.
52
  This model has also been used to investigate the 
binding and subsequent change in conformation that occurs for the complex between 
melittin and Ca
2+
-saturated calmodulin, as well as the interaction of a transcriptional 
activator-DNA complex with a coactivator, and the interaction of N-phenyl-1-
naphthylamine with pheromone-binding proteins.
 76-78 
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If the value of k-2 is small, Equation 2.11 can be simplified to one of the forms 
shown in Equations 2.12-2.13.  For instance, Equation 2.13 indicates that such a system 
will provide a linear relationship between 1/kobs2 and 1/[Ltot], which can be used to find 
the values of k2 and K-1.
 
𝑘    = 
𝑘2[    ]
𝐾 1 + [    ]
                          (2.12) 
1
𝑘   2
= 
𝐾 1 
𝑘2[    ]
+
1
𝑘2
                      (2.13) 
This type of analysis has been utilized to study the interaction kinetics when an excess of 
rifampicin is combined with RNA polymerase.
72
  These equations have also been used to 
study protein-protein interactions.
79
 
 
Advantages and potential limitations 
As has been shown in this section, stopped-flow analysis can be applied in 
studying the kinetics of various biological interactions, including both simple and 
relatively complex systems.  In addition, this technique can be used to examine either 
slow or relatively fast events.  Rate constants that have been determined by stopped-flow 
analysis have ranged from 10
-6
 to 10
6
 s
-1
 for first-order reactions and from 1
 
to 10
9
 M
-1
s
-1
 
for second-order reactions.
40,62,71,76
  It is necessary, however, for the observed reaction to 
have a half-life that is longer than the mixing time and dead time of the stopped-flow 
instrument, which limits the use of this method in the study of some very fast reactions.
80
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An important advantage of stopped-flow analysis is it can be used directly with 
solution-phase reactions, provided some means is available to selectively monitor a 
change in the concentration of a reactant or product in this reaction (e.g., through 
fluorescence or absorbance detection).  It is also necessary to have sufficient volumes of 
the reagents for use in the solution delivery component of the stopped-flow instrument.  
A sufficient concentration of the reagents and/or products is also needed for a change in 
these components to be measured over time.  This latter requirement, and the detectable 
range of the reagent or product, will depend on the detection method that is employed.  
However, a relatively low detection limit (e.g., low nM levels) can be obtained when a 
method such as fluorescence is used in stopped-flow analysis.
21,24,59,69
 
 
Surface Plasmon Resonance  
General principles  
Surface plasmon resonance (SPR) spectroscopy is another method that has been 
widely used for the analysis of biological interactions.
81
  This method has been utilized to 
study systems such as protein-ligand, protein-protein, and protein-DNA interactions.
3-
5,82,83
  Figure 2.4(a) shows a typical SPR instrument that is used for biological interaction 
studies.  This particular device makes use of prism coupling, but other possible 
configurations include those based on optical waveguide coupling and grating 
coupling.
82,83
 
 
  
 
82 
 
 
 
 
 
Figure 2.4  (a) Typical design for a surface plasmon resonance (SPR) biosensor based 
on a prism configuration.  The plot in (b) shows a typical experimental 
cycle and general response (or sensorgram) that can be obtained with this 
type of instrument in a kinetic analysis for an applied target that is 
interacting with an immobilized binding agent to form a reversible 
complex.  This figure is based on information that was obtained from Ref. 
4. Reproduced with permission from X. Zheng, C. Bi, Z. Li, M. Podariu, 
D.S. Hage, J. Pharm. Biomed. Anal. (2015) in press. 
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In an SPR system, a binding agent such as a protein is immobilized onto the 
sensor surface, which typically consists of a thin film of a metal (e.g., gold or silver) that 
is placed onto a glass surface.
82,83
  This sensor surface is then placed within a flow cell.  
A target, or ligand, that is to be tested for its binding to the immobilized agent is then 
applied to the flow cell and in the presence of an appropriate buffer.  Surface plasmons 
are generated when an incident beam of light is directed towards the metal surface at a 
critical angle. This critical angle depends on the refractive index of the medium near the 
surface and changes when targets bind to the immobilized binding agents at this 
surface.
84
  The change in the refractive index at the surface, as a result of the interaction 
between the applied target and immobilized agent, is then measured and provides an 
index of the extent of binding that has occurred.
81-85 
Figure 2.4(b) shows a general plot (or sensorgram) that is obtained with this type 
of instrument.  In this plot, an increase in response is generated as the applied target binds 
to the immobilized agent in the flow cell.  A plateau in this response is obtained as 
equilibrium is reached between the applied target and the immobilized binding agent.  
Dissociation of the target from the immobilized binding agent can also be monitored as 
the bound target is later washed away from the surface.  After the bound target has been 
removed, the surface and binding agent can often be regenerated and are placed back in 
contact with the initial buffer prior to the application of more target.
4,83,85 
 
Data analysis methods 
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For a bimolecular reaction between P and L, as described earlier in Equation 2.5, 
the change in the concentration of product PL with time can be described by using 
Equation 2.14.
83,86-87
  
 [  ]
 𝑡
= 𝑘1[𝑃][ ] − 𝑘−1[𝑃 ]                    (2.14) 
In this equation, k1 is the second-order association rate constant for the interaction of P 
with L, and k-1 is the first-order dissociation rate constant for this interaction, as defined 
earlier in Section of Applications involving single-molecule reactions.  This binding event, 
and the concentration of PL, is monitored by using the change in the refractive index at 
the surface of the sensor. 
By varying [L], the SPR response for the system in Equation 2.14 can be fit to the 
following integrated rate expression.
83,86-87
 
  = 
  a 𝑘1[ ]
𝑘1[ ] + 𝑘 1
(1 −  −(𝑘1[ ] + 𝑘 1)𝑡)          (2.15) 
In Equation 2.15, Rt is the response measured at time t, and Rmax is the maximum 
response that is obtained upon the saturation of P with L.  If the value of [L] is varied, a 
fit of Equation 2.15 to these curves will provide a series of observed rate constants (kobs), 
in which kobs is equal to the following set of terms.
83,86-87
  
 𝑘   = 𝑘1[ ] + 𝑘−1           (2.16) 
A plot of kobs versus [L] can then be made according to Equation 2.16, and the values of 
k1 and k-1 can be determined from the slope and the y-intercept of the best-fit line. 
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To accurately determine k-1 and k1 by this method, an appropriate range for the 
concentrations of L should be used.  One study examined how kobs varied with the 
concentration of L during the binding of a 50 kDa target ligand to immobilized 
chymotrypsin.
86  Ligand depletion occurred at low ligand concentrations and resulted in 
curvature in the kinetic plots.  This deviation became more pronounced at a higher value 
for Rmax and lead to an underestimation of k1 and an overestimation of k-1.  It was 
determined that these errors could be minimized by using ligand concentrations that were 
1-100 times that of the dissociation equilibrium constant for the system (K-1, where K-1 = 
k-1/k1).
86
 
Data generated during the dissociation step in SPR can be used to provide 
additional kinetic information.  This can be accomplished by using a first-order 
expression to describe the release of L from P, as shown in Equation 2.17.
86,87
 
    =   ( 
−𝑘 1𝑡)            (2.17) 
Most of the terms in this relationship are the same as in Equation 2.15, with the additional 
term R0 representing the response at the beginning of the dissociation step.  Equation 2.17 
is applicable only in the case of the simple, monophasic dissociation of PL, and where the 
re-association of L to the immobilized binding agent P is negligible after L has 
dissociated from the surface of the SPR sensor.
87
  
 
Applications in kinetic studies   
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SPR has been widely utilized in dissociation and association rate measurements 
for various biological systems.
3-5,88
  One recent report examined the choice of suitable 
conditions for the kinetic analysis of G-protein signaling, based on the use of 
immobilized native rhodopsin (Rho, a G-protein coupled receptor) and transducin.
89
  A 
number of antibody-antigen interactions have been examined by using SPR, 
90-92
 and this 
technique has been applied in studying the DNA-protein interactions.
93,94
  For instance, 
SPR has been used to measure the interaction rates of DNA-based aptamers with human 
immunoglobulin E.
93
 
SPR has been further employed in investigating the interaction kinetics between 
biomacromolecules and small targets.
3,85,88,95,96
  For instance, SPR has been used to 
examine the interactions of human carbonic anhydrase I with various sulfonamide 
inhibitors.
93
  One report used SPR to study the kinetics of small target interactions with 
modified binding sites on an inverse agonist stabilized receptor of the adenosine A2A 
receptor.
96
  In another paper, a group of investigators used a commercial SPR instrument 
to separately characterize the rate constants and binding constants for 10 sulfonamide 
inhibitors with the enzyme carbonic anhydrase II.
97
 
SPR has been used in some situations with a small immobilized binding agent.  
This format was employed to measure rate constants for the interactions between small 
targets and FK506 binding protein 12.  The results suggested that the use of immobilized 
targets for the SPR experiments eliminated subtle constraints to the protein’s rotational 
and diffusional freedom that would have been present if the protein were instead 
immobilized.
98
  Another report that used small immobilized targets involved kinetic 
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Figure 2.5 (a) A 1020-spot protein microarray as imaged by SPR microscopy, and (b) 
sensorgrams that were obtained at some of the spots in this protein 
microarray following the application of streptavidin, anti-bovine serum 
albumin (BSA) antibodies or human immunoglobulin G (IgG).  Adapted 
with permission from Ref. 88. 
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studies on the binding of streptavidin to mixed biotin-containing alkylthiolate 
monolayers.
99
 
Several variations of SPR systems have been reported.  A method for SPR 
imaging (or SPR microscopy) has been developed for simultaneously monitoring 
thousands of biomolecular interactions.
88,104
  Figure 2.5 shows an example of an image 
that was generated for a 1020-spot protein microarray.  In this case, twenty different 
proteins were spotted across the surface of the array and utilized to generate a series of 
kinetic curves.  The results suggested that SPR imaging could be used to carry out kinetic 
measurements on more than 1000 spots with a one second time resolution, making this 
approach of interest in applications such as proteomic analysis and drug discovery.
88,99,101
  
SPR has also been combined with mass spectrometry, which has been used to provide 
structural information on interacting proteins.
81,101-103
 
 
Advantages and potential limitations 
There are several advantages in the use of SPR for kinetic studies.  One advantage 
is that this method can be carried out using commercial systems that provide flexible 
platforms for examining both the equilibrium constants and rate constants for biological 
interactions.
104
  These systems require only a small amount of the binding agent and 
applied target.  The fact that the binding agent is immobilized can also help minimize 
batch-to-batch variations when the same sensor is used for multiple studies. 
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The use of SPR as a detection mode is appealing in that it provides a “label free” 
means for following the course of a biological interaction.
4,5,85
  However, this does 
require a specific type of surface for the analysis (i.e., one containing a thin metal film 
such as gold), and it is necessary to immobilize one of the agents that is taking part in the 
interaction.  There are several immobilization methods available for this purpose.
3,104
  
Common methods for protein immobilization include the coupling of groups such as 
amines or thiols on a protein to a coating of dextran on the sensor.
81
  It is also possible to 
capture a biotinylated agent on a surface that contains immobilized streptavidin, or to 
capture a histidine-labeled agent on a surface that contains immobilized nitrilotriacetic 
acid and its complex with nickel ions.
3,81,103
  For small molecules, the number and types 
of functional groups that are present may limit the options for immobilization.  Improper  
coupling conditions, whether it is applied to a a large or small molecule, can lead to some 
changes in the binding properties of the immobilized agent.
3,5,89
  Validation of SPR with 
reference methods is ideally required when this system is used to study what is normally 
a solution-phase interaction.  However, if the immobilization method and conditions are 
properly selected, the results obtained by SPR can give good agreement with those seen 
in solution and by other techniques.
89,97
 
SPR has been used to investigate biological interactions with a wide range of rate 
constants.  This has included second-order association rate constants ranging from 10
2 
to 
10
8
 M
-1
 s
-1
 and first-order dissociation rate constants that have spanned from 10
-6
 to 1 s
-
1
).
4,81
  The level of accuracy and precision of SPR does depend on the rates and affinity of 
the system being examined, since this will determine the time period over which useful 
data can be acquired.  Systems that have moderate-to-weak interactions (i.e., K1 values of 
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10
4
 to 10
5
 M
-1
 or less) and fast association or dissociation rates are the most difficult to 
measure by this approach.
97,106
  In addition, mass transfer effects that occur during the 
transport of the target in solution should be considered when examining the kinetics of 
biological interactions by SPR.
81,97,104,106
 
 
Affinity Chromatography 
General principles 
Affinity chromatography is a liquid chromatographic technique in which a 
biologically-related agent known as the “affinity ligand” is used as the stationary 
phase.
107-111
  The retention and separation of a target analyte from other sample 
components by this method is based on the specific and reversible interactions that occur 
in many biological interactions.
6,8,9,107-111
  High-performance affinity chromatography 
(HPAC) is a type of affinity chromatography that uses the supports and instrumentation 
of high-performance liquid chromatography to provide both rapid and efficient 
separations based on biological interactions and affinity ligands.
112
  The development of 
HPAC has also lead to the creation of various new or improved techniques that can use 
affinity chromatography to study the kinetics and thermodynamics of biological 
interactions.
6,112,113
   
Figure 2.6 shows the general way in which affinity chromatography can be 
employed for studying biological interactions.  Affinity chromatography and HPAC are 
most often used to examine the binding and/or dissociation of an applied target with an  
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Figure 2.6  General models for the use of affinity chromatography for kinetic analysis 
of interactions between an applied target and an immobilized binding agent. 
The terms k1 and k-1 represent the association rate constant and dissociation 
rate constant, respectively, for the target with the given binding agent. 
Reproduced with permission from X. Zheng, C. Bi, Z. Li, M. Podariu, D.S. 
Hage, J. Pharm. Biomed. Anal. (2015) in press. 
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immobilized binding agent. These chromatographic-based experiments are similar to SPR 
in that they can provide information on both binding affinities and association or 
dissociation rates under typical sample application conditions.  It is further possible to use 
affinity chromatography to examine the binding strength and association/dissociation 
kinetics under other conditions, such as those that might be used for target elution or for 
the release of this target from the immobilized binding agent.
7,106
 
 
Band broadening methods 
The use of band broadening measurements was the first method developed in 
affinity chromatography for kinetic studies of biological interactions.
7,106
  Two variations 
on this approach are the plate height method and peak profiling.
106
  In the plate height 
method, the total plate height for a small amount of an applied target is measured at 
several flow rates on both a column that contains an immobilized binding agent and on a 
control column that contains no binding agent.  The resulting plate height and flow rate 
data are then used to determine the contribution of plate height due stationary phase mass 
transfer (Hs). 
This latter process is of interest because it is directly related to the kinetics for the 
binding of the applied target with the immobilized binding agent.  This process is 
described by the reaction given earlier in Equation 2.5 and the plate height equation that 
is shown in Equation 2.18.
7,106
    
  =
    𝑘
𝑘 1 (1 + 𝑘)2
                   (2.18) 
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In Equation 2.18, u is the linear velocity of the mobile phase in the column, k is the 
retention factor of the injected target, and k-1 is the dissociation rate constant for the target 
from the immobilized binding agent.  When a plot of Hs versus (u k)/(1 + k)
2
 is prepared, 
the result is a linear relationship that can provide the value of k-1 from the slope.   
The plate height method has been used in HPAC to examine the interaction 
kinetics for drugs and solutes such as R/S-warfarin and D/L-tryptophan with HSA.
114,115
  
Similar experiments were performed to look at the effects of temperature on the rates of 
these processes,
114,115
 as well as the effects of pH, ionic strength and solvent polarity on 
the interaction rates of D/L-tryptophan with HSA.
115
 This method has also been 
employed in evaluating the use of small affinity columns and monoliths for screening the 
interactions of HSA with drugs or solutes such as carbamazepine, L-tryptophan and R-
warfarin.
116,117
   
The plate height method has generally been used to study systems that have 
relatively fast interaction rates compared to the time of the chromatographic analysis.  
For instance, the dissociation rate constants that have been determined by this method 
have ranged from roughly 10
-2
 to 10
1
 s
-1
.
6,114,117
 This method also has been successfully 
used with systems that have weak-to-moderate binding (i.e., K1 values of 10
5 
M
-1
 or 
less).
6,7,106,114-117
 The injection of only a small amount of the target is needed and 
desirable in this method to ensure that linear elution conditions are present.  Also, 
columns and support materials should be selected for this technique that will minimize or 
provide reproducible values for other plate height contributions, such as those due to 
mobile phase mass transfer, eddy diffusion, longitudinal  diffusion, and stagnant mobile 
phase mass transfer.
6,7,106
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Peak profiling is a related method that examines the band broadening of a target 
and a non-retained solute on an affinity column (and possibly on a control column) under 
linear elution conditions.
106,112
  Equation 2.19 is often used in peak profiling studies to 
provide information on the dissociation rate constant k-1 from band broadening 
data.
112,118-120
 
       R −   =
    𝑘
𝑘 1 (1+𝑘)2
=                (2.19) 
In this equation, HR and HM refer to the plate heights for the retained target and a non-
retained solute on the affinity column, respectively, although the plate height for the 
target on a control column is also sometimes used for HM.  Equation 2.19 can be used 
with data obtained at a single flow rate to calculate the value of k-1, or data acquired at 
several flow rates can be used to construct a plot of (HR - HM) versus (u k)/(1 + k)
2
 and 
the dissociation rate constant can be obtained from the slope of the best-fit 
response.
112,118-120
 
Peak profiling has been used to investigate the dissociation rates of several drugs 
and small solutes from serum proteins.  For example, this method has been used to 
measure the dissociation rate constants for carbamazepine, imipramine and L-tryptophan 
with HSA..
112,118
  A typical plot of (HR - HM) vs. (u k)/(1 + k)
2
 that was obtained in this 
work is provided in Figure 2.7.
118
  In addition, this method has been used to 
simultaneously determine the dissociation rate constants of HSA with two chiral 
metabolites of the drug phenytoin: 5-(3-hydroxyphenyl)-5-phenylhydantoin and 5-(4-
hydroxyphenyl)-5-phenylhydantoin.
121
 The rate constants for the interactions of β- 
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Figure 2.7   Peak profiling plots based on Equation 2.19 for describing the dissociation 
of carbamazepine from immobilized HSA in a high-performance affinity 
column.  Reproduced with permission from Ref. 118.   
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cyclodextrin with acetaminophen and sertraline have also been measured by this 
method.
122
  
Peak profiling has similar requirements, advantages and limitations to the plate 
height method.  For instance, peak profiling is again mainly used for systems with 
relative fast association and dissociation rates and weak-to-moderate strength binding. 
The dissociation rate constants that have been determined by this method have been in 
the range of 10
-1
 to 10
1
 s
-1
.
112,118,121,122
  One advantage of peak profiling is it can 
sometimes be conducted at only a single flow rate, or at higher flow rates than the plate 
height method.  However, a fast sampling rate and stable response is required for work at 
high flow rates to provide an accurate measure of peak variances and consistent plate 
height values.
106
   
 
Peak fitting methods 
Peak fitting has also been used for kinetic analysis in affinity chromatography.  
This approach differs from those described in the last section in that the amount of 
applied target can now be sufficiently high to create non-linear elution conditions.
106
  
Peak fitting can be conducted with either narrow injections of the target (i.e., zonal 
elution) or continuous application of the target (i.e., frontal analysis).
106
  When this 
method is used with zonal elution, Equation 2.20 can be used to fit the resulting elution 
profiles.
123,124
 
  
 
101 
 =
𝑎0
𝑎 
[1 −  
(−
  
 2
)
] [
√
 1
 
 1(
2√ 1 
 2
) 
   
 1
 2
1− (
 1
 2
,
 
 2
)[1− 
 
  
 2]
]         (2.20) 
In this equation, y is the intensity of the measured signal at a given point in time in the 
peak profile, x is the reduced retention time at which y is measured, T is the switching 
function, and I1 is a modified Bessel function.  The terms a0, a1, a2 and a3 are the best-fit 
parameters to be obtained by fitting the experimental data to Equation 2.20.  These fitted 
results are then used to estimate the rate constants and equilibrium constant for the 
interaction between the injected target and immobilized binding agent.  For instance, the 
dissociation rate constant and association equilibrium constant (k-1 and K1) for the system 
are represented by the terms 1/a2tM and a3/C0, respectively, where tM is the column void 
time and C0 is a term related to the concentration of the injected target.
106,125
   
This form of peak fitting has been used to examine the interaction kinetics of the 
drug verapamil with nicotinic acetylcholine receptor.
126
  Related peak fitting methods 
have been utilized to estimate the dissociation rate constant for IgG from immobilized 
protein A in the presence of a pH 3.0 buffer.
127
  A similar approach has been utilized to 
examine the elution of lysozyme from a Cibacron Blue 3GA column in the presence of 
buffers that contained various concentrations of sodium chloride.
128
 
Peak fitting can also be used with frontal analysis to examine the interaction 
kinetics between an applied target and an immobilized binding agent.  As an example, the 
apparent association rate constant (k1,app) can be measured and used to determine the true 
association rate constant (k1) by using Equation 2.21.  This equation makes use of the 
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reaction model in Equation 2.5, with an assumption that dissociation of the target for the 
binding agent is negligible on the timescale of the experiment.
106,129
   
1
𝑘1,app
=
  𝑉M
 𝑛  
+
1
𝑘1
         (2.21) 
In this equation, nmt is the global mass transfer coefficient (which is dependent on the 
packing size and column dimensions), F is the flow rate, VM is the column void volume, 
and qx is the column loading capacity per unit volume of the mobile phase.  A plot of 
1/k1,app versus qx that is made according to Equation 2.21 should give a linear relationship 
with an intercept that is equal to k1.
129
  This method makes it possible to correct for the 
effects of stagnant mobile phase mass transfer on the apparent association rate constant 
and has been used to estimate the association rate constant of HSA with immobilized 
anti-HSA antibodies.
129
  
Another peak fitting approach that makes use of frontal analysis is based on 
Equation 2.22. 
𝑘−1 =
 (𝑉A− 𝑉A
 )
d A
2 d ⁄
       (2.22) 
The terms VA and VA
*
 in this equation are the breakthrough volumes for the retained 
target and a non-retained solute, respectively, and σA
2
 is the variance of the breakthrough 
curve for the target.  When using Equation 2.22, a plot of σA
2 
versus F should give a 
response that has a slope equal to (dσA
2
/dF).
106
  This type of experiment can be 
conducted at several concentrations of the applied target to provide a series of (dσA
2
/dF) 
values, which can then be used to find k-1.
106
  This method has been used to measure the 
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dissociation rate constant for p-nitrophenyl-α-D-mannopyranoside from immobilized 
concanavalin A.
130,131
   
One advantage of peak fitting methods is they can be carried out with both zonal 
elution and frontal analysis under non-linear elution conditions and to study systems with 
weak-to-moderate binding affinities.
106
  The association and dissociation rate constants 
that have been measured by peak fitting have been in the range of 10
4
 to 10
7
 M
-1
s
-1 
and 
10
-1
 to 10 s
-1
, respectively.
106,116,123,128,131,132
  However, it is necessary to test and verify 
any assumptions that are made in this approach, such as whether mobile phase mass 
transfer is negligible or needs to be considered when examining the rate of a target’s 
interaction with the immobilized binding agent.
106,129-131
   
 
Split-peak method 
The split-peak method is another technique for carrying out kinetic studies by 
affinity chromatography.
7,106
 This approach is based on the finite probability that a small 
fraction of an applied target may elute from the affinity column without interacting with 
the stationary phase.  This effect can be utilized to provide information on the association 
rate constant k1 for an injected target with an immobilized binding agent by using an 
expression such as Equation 2.23.
133
 
−
1
 𝑛 
=  (
1
𝑘 1𝑉 
+
1
𝑘1𝑚L
)             (2.23) 
In this equation, f is the non-retained fraction of the target, F is the flow rate, mL is the 
moles of immobilized and active binding sites in the column, and Ve is the excluded 
  
 
104 
volume in the column.  The term km1 is the forward mass transfer rate constant for the 
target as it moves from the flowing mobile phase to the stagnant mobile phase within the 
support.  According to Equation 2.23, a plot of -1/ln(f) versus F should give a linear 
relationship when a small amount of target is applied to the column.
7
  If adsorption of the 
target to the immobilized binding agent is the rate-limiting step in retention, the slope of 
Equation 2.23 will be 1/(k1 mL), which can provide the value of the association rate 
constant k1 if the value of mL is also known or obtained through some other means.
106,133
      
The split-peak method was initially used to examine the binding rate of rabbit 
immunoglobulin G (IgG) to various columns containing immobilized protein A.
133,134
  
This method was also used to provide rate information for the optimization of an affinity-
based analysis for human IgG in clinical samples,
135
, and to evaluate the association rate 
constants for IgG on columns containing protein A,  protein G, or a mixed-bed of protein 
A and protein G.
136
  The split-peak method has been modified for use under non-linear 
elution conditions when the rate-limiting step is the association of a target with the 
immobilized binding agent.  This latter approach has been used to examine the 
association rates of HSA with immobilized anti-HSA antibodies.
137-139
  The association 
rate constants that have been determined by this method have ranged from 10
4
 to 10
6
 M
-1
 
s
-1.131-139
 
A significant advantage of the split-peak method in kinetic studies is it only 
requires the measurement of peak areas.  This feature makes it easier to perform in 
comparison with the previous chromatographic methods, in which peak variances or 
profiles are required.
106
  However, the split-peak method can only be used for systems 
with relatively high affinities and/or slow dissociation rates, which is needed to allow a 
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good separation to be obtained between the non-retained and retained target fractions.
106
  
In addition, this technique needs to be carried out under experimental conditions that 
make it possible to observe the split-peak effect.  As shown by Equation 2.23, this effect 
can be enhanced by increasing the application flow rate for the target or decreasing the 
size of the column, as well as lowering the amount of active binding agent that is 
present.
106
 
 
Peak decay method 
The peak decay method is used to determine the dissociation rate constant for the 
release of a target from an immobilized binding agent.
6,7,106
  In this technique, the target 
is first applied to a column that contains the binding agent.  One variation of the peak 
decay method then has a mobile phase applied that contains a high concentration of a 
competing agent, which will bind to the immobilized agent and prevent the re-association 
of any target that dissociates from this binding agent.
6,7
  Another variation of this method 
uses small affinity columns and a large amount of target that is initially applied to the 
column, which also minimizes the chance that any dissociated target will rebind to the 
immobilized ligand.
7,106
  In both of these approaches, a high flow rate is usually used 
during the dissociation step to minimize the effects of stagnant mobile phase mass 
transfer during dissociation and to prevent the released target from coming into further 
contact with the immobilized binding agent.
106 
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Work under these conditions results in elution of the target from the affinity 
column in the form of a decay curve.  This elution profile can then be converted into a 
plot of the logarithm of the response versus time, as is described by Equation 2.24.
7,106
 
   (
 𝑚  
 𝑡
) =   (𝑚  𝑘−1) − 𝑘−1           (2.24) 
In this equation, mEo is the initial moles of target that was retained by the immobilized 
binding agent, mEe is the moles of target that elutes from the column at time t after the 
competing agent has been applied or the dissociation step has begun, and k-1 is the 
dissociation rate constant for the target from the immobilized binding agent.  Based on 
Equation 2.24 the slope that is obtained for a plot of the natural logarithm of the response 
versus time should provide the dissociation rate constant k-1.
6,140
    
The peak decay method was first used to estimate the dissociation rate constant 
for concanavalin A with the sugar 4-methylumbelliferyl α-D-mannopyranoside by using 
4-methylumbelliferyl α-D-galactopyranoside as a competing agent.141  In more recent 
work, the peak decay method has been adapted to measure the dissociation rate constants 
of drugs from serum proteins.  This is illustrated in Figure 2.8 for racemic warfarin that 
had been applied to immobilized HSA in a small silica monolith column.
142
  Other drugs 
(e.g., diazepam, imipramine, acetohexamide, tolbutamide, amitriptyline, quinidine, 
verapamil, amitriptyline, lidocaine, and nortriptyline) and binding agents (e.g., alpha1-
acid glycoprotein) have also been studied with this method.
142,143
  The peak decay method 
has further been employed to study the dissociation rates of various targets from 
immobilized antibodies during the selection of elution conditions for immunoaffinity 
chromatography.
144
  In addition, this method has been used to characterize the elution 
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Figure 2.8  Typical results for a peak decay experiment, as obtained from the 
application of racemic warfarin onto a control monolith column and a 
monolith column containing immobilized human serum albumin (HSA).  
The results in (a) give the original elution profiles and the plots in (b) show 
the natural logarithm of these elution profiles.  These results were obtained 
for a 100 µL injection of 10 µM racemic warfarin.  Reproduced with 
permission from Ref. 143.   
 
  
 
108 
 
 
  
 
109 
kinetics of thyroxine from columns containing anti-thyroxine antibodies or aptamers, and 
the dissociation of IgG-class antibodies from immobilized protein G.
145,146
  
The peak decay method has been used with application buffers to examine several 
systems with weak-to-moderate affinities (i.e., K1 < 10
6
 M
-1
).
140-144
  It has also been used 
to study the elution conditions needed for systems with stronger binding (e.g., protein G, 
antibodies and aptamers).
145,146
  The dissociation rate constants that have been measured 
by the peak decay method range from 10
-2
 to 10
1
 s
-1.6,106,140-146
  Data analysis in this 
method is relatively easy to carry out, because it is based on linear regression of a 
logarithmic elution profile, and this method is valuable in characterizing elution 
conditions.  However, non-specific interactions of the target within the column must be 
considered and corrected for by using a control column, especially for targets that may 
have weak-to-moderate interactions with the immobilized binding agent.  This tends to 
limit the use of this method in these latter cases to the measurement of dissociation rate 
constants that are less than about 1-2 s
-1
.
144
  Moreover, the experimental conditions that 
are required to make dissociation the rate-determining step in elution, and target re-
association negligible, may be difficult to obtain for some systems.
141-144
  
 
Advantages and potential limitations 
One general advantage of using affinity chromatography or HPAC to examine the 
kinetics of a biological interaction is the ability to reuse the same immobilized binding 
agent for many experiments.
6-10
  This feature helps to improve the reproducibility of the 
method and lowers the cost per analysis.  The variety of approaches that are available for 
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kinetic measurements in affinity chromatography is another valuable feature of this 
technique.  Altogether, the chromatographic methods that were described in this section 
have been used to measure association rate constants that have spanned from 10
3
 to 10
7
 
M
-1
 s
-1
 and dissociation rate constants that have ranged from 10
-2
 to 10
1
 s
-1
.  Several of 
these techniques work well with systems that have relatively weak interactions, a feature 
which makes these methods complementary to SPR for such work.
97,106
 
Like SPR, these affinity methods are usually “label free” but often use an 
immobilized binding agent as one of the interacting partners.
6-10,19
 One difference from 
SPR is that various supports and surfaces can now be used for the immobilizing binding 
agent since detection is carried out after the target or other sample components have 
eluted from the column.
6-10,19
 Many detection methods can be used with these affinity 
columns (e.g., absorbance, fluorescence, or mass spectrometry), which further aids in 
allowing this group of methods to be used in examining a variety of biological systems.
6-
10
 
Various immobilization methods are available for coupling binding agents within 
affinity columns.  These methods might again involve the use of amines, thiols, or other 
groups for the immobilization of proteins or alternative binding agents. It is further 
possible to use capturing agents such as immobilized streptavidin for biotin-labeled 
binding agents or protein A for immunoglobulins.
81,107,111,113,147
  The correct selection and 
validation of the immobilization conditions are needed to provide a binding agent in the 
affinity column that is a good model for the same binding agent in its native environment.  
However, as was noted for SPR, there are needs in the methods that can use affinity 
chromatography to investigate solution-phase reactions.
7,8,106
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Capillary Electrophoresis 
General principles 
CE is a second separation technique that has been used to investigate the kinetics 
of biological interactions.  In CE, a narrow-bore capillary is filled with a running buffer 
or electrolytic solution.  A defined volume of sample is then introduced into the capillary, 
and an electric field is applied across this capillary.  The components of the sample are 
separated based on their differences in migration rates and electrophoretic mobilities.  A 
detector, which is located at the opposite side of the capillary, is used to monitor the 
migration of these components.
148
  
When CE is used in kinetic studies, the free forms of P or L in a sample can be 
separated from their complex PL if there are differences in the electrophoretic mobilities 
and migration rates of these reactants and product in the capillary.  The rate of the 
interaction for P with L, or for the dissociation of PL, can be determined by monitoring 
the changes in one or more of these peaks as a function of reaction time.
148-157
  Various 
formats for carrying out such studies are discussed in this section.  
 
Analysis of slow biological reactions  
One way CE can be used for kinetic measurements is to study interactions that 
have long reaction times (e.g., hours) and small dissociation rate constants (i.e., k-1 values 
in the range of 10
-3
 to 10
-6
 s
-1
).
148-154
  To investigate this type of reaction, the target and 
binding agent can be mixed prior to their injection onto the CE system.  Samples of this 
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reaction mixture are injected at known times.  The non-bound and bound target are then 
separated based on the differences in their electrophoretic mobilities, with the results 
being used to determine the amount of complex that has formed between the target and 
binding agent at various reaction times.  
For a reaction that is slow on the timescale of the CE separation and that has slow 
dissociation, the interaction of target L with binding agent P can be approximately 
described by the following equation.  
  
[  ]
[    ]
= −𝑘                       (2.25) 
In this equation, [PL] is the measured concentration of the complex at time t, [Ltot] is the 
total concentration of L, and kobs is the observed rate constant for this interaction.   
Figure 2.9 shows an electropherogram that was obtained in this type of 
experiment.  This particular study examined the interaction of a ruthenium(III)-
containing drug with HSA and transferrin, with detection being carried out by CE 
coupled with inductively coupled plasma-mass spectrometry.
149
  A similar method has 
been used to determine rate constants for the interactions of ruthenium(III)-containing 
drugs with holo-transferrin
 
and for platinum(II)-containing drugs with HSA.
 150,151
  
Another report examined the reaction of cisplatin with 2’-deoxyguanosine 5’-
monophosphate, as based on the use of CE coupled with electrospray ionization mass 
spectrometry.
155
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Figure 2.9 (a) Electropherograms used to study the interaction kinetics of albumin 
with indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] 
(KP1019): peaks, (1) trans-[RuCl4(1H-indazole)2]
−
, and (2) ruthenum 
(III)–albumin complex.  The plots in (b) show the relative peak areas for 
the ruthenium (III)-protein complexes as a function of reaction time for 
experiments conducted with KP1019 and albumin (black circles) or 
transferrin (open circles).  Adapted with permission from Ref. 149. 
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Kinetic capillary electrophoresis 
Kinetic capillary electrophoresis (KCE) is another method that can be used to 
determine kinetic parameters for biological interactions.  This is a type of CE in which 
the species in the system of interest are interacting during their separation.
20,156-159
  
Various types of KCE have been developed to measure kinetic and thermodynamic 
parameters for biological interactions.  These methods include non-equilibrium capillary 
electrophoresis of equilibrium mixtures (NECEEM), continuous NECEEM (cNECEEM), 
sweeping capillary electrophoresis (SweepCE), short SweepCE (sSweepCE), short 
SweepCE of equilibrium mixtures (sSweepCEEM), plug-plug KCE (ppKCE), and 
equilibrium capillary electrophoresis of equilibrium mixtures (ECEEM).
20,156-159
  A few 
examples of these methods are shown in Figure 2.10.  
The main model that is used in KCE methods for the measurement of rate 
constants is the biomolecular reaction between P and L to form PL, as described earlier in 
Equation 2.5.  KCE methods are based on the separation of P, L, and PL according to the 
differences in their electrophoretic velocities, as represented by vL, vP, and vPL, 
respectively.  This separation can be described by the following set of partial differential 
equations.
20,156-159
 
 [ ] ,  
 𝑡
+    
 [ ] ,  
  
= −𝑘1[ ]𝑡,  [𝑃]𝑡,  + 𝑘−1[𝑃 ]𝑡,             (2.26) 
 [ ] ,  
 𝑡
+    
 [ ] ,  
  
= −𝑘1[ ]𝑡,  [𝑃]𝑡,  + 𝑘−1[𝑃 ]𝑡,              (2.27) 
 [  ] ,  
 𝑡
+     
 [  ] ,  
  
= −𝑘−1[𝑃 ]𝑡,  + 𝑘1[ ]𝑡,  [𝑃]𝑡,                     (2.28) 
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Figure 2.10 Some typical methods used in kinetic capillary electrophoresis, along with 
their simulated concentration profiles and initial or boundary conditions.  
The methods that are illustrated here are (a) non-equilibrium capillary 
electrophoresis of equilibrium mixture (NECEEM), (b) sweeping capillary 
electrophoresis (SweepCE), and (c) plug-plug KCE (ppKCE).  Adapted 
with permission from Ref. 157.  
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In these equations, [P], [L] and [PL] are the concentrations of P, L and PL at time t (i.e., 
the time that has elapsed since the beginning of separation), and x is the distance from the 
injection end of the capillary.   
The solution to the expressions in Equations 2.26-2.28 is found by using the 
initial and boundary conditions for the given separation system.  These conditions include 
the initial distribution of L, P, and PL along the length of the capillary, and the manner in 
which L, P and PL are injected into and eluted from the capillary.  Based on these 
conditions, the solution to Equations 2.26-2.28 can be determined through numerical or 
non-numerical methods and by making certain assumptions.
156,157,160
  This solution can 
then be tested by fitting the experimental data to the predicted electropherograms, and the 
binding parameters can be determined through non-linear regression.
156,157,160
   
Figure 2.10 includes the initial conditions and boundary conditions for some 
representative KCE methods.
20,157
  The simulated concentration profiles for these 
methods are also provided.  For example, in NECEEM the capillary is originally filled 
with only a running buffer. A small sample plug containing a mixture of P and L at 
equilibrium is injected into this capillary. Separation of the components in this mixture (P, 
L and PL) occurs as the sample passes through the capillary.  However, during this 
separation the initial equilibrium is disturbed and dissociation occurs for the complex PL, 
which is reflected in the shape of the resulting electropherogram.   
Figure 2.11 shows a typical electropherogram for an NECEEM experiment, as 
obtained in experiments investigating the interaction of the AlkB protein from E. coli 
with a fluorescent labeled DNA aptamer.
161
  As the protein-aptamer complex dissociated 
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Figure 2.11  Electropherogram obtained in studies of the interaction between the AlkB 
protein and its DNA aptamer by using non-equilibrium capillary 
electrophoresis of equilibrium mixtures (NECEEM).  Adapted with 
permission from Ref. 161. 
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during the CE separation, the result was a distribution of the aptamer between the peaks 
for the complex and free aptamer.  The areas of the peaks and overlapping regions in the 
electrophoreograms, which were related to the concentrations of the reacting components, 
were measured and used to find the rate constants for this system.
161
 
Examples of applications using other KCE methods can be found in Refs. 20,157-
159,162.  KCE has been utilized to provide binding strengths and rate constants for 
several systems, including protein-oligonucleotide, protein-peptide, protein-small 
molecule, and oligonucleotide-small molecule interactions.
20,156,157,159,161-168
 These 
methods have been used to measure dissociation rate constants that have ranged from 10
-4
 
to 1 s
-1
,
156,157,163,169
 and association rate constants that have ranged from 10
1
 to 10
7
 M
-1
 s
-1
. 
161,162,164,165,166-169
 
A multi-method KCE toolbox has also been developed to examine biological 
interactions.  This approach involves proposing a reaction model between L and P, such 
as the one in Equation 2.5, and then testing this model with several KCE methods.  If a 
significant deviation is seen between the predicted results and the data for one or more 
methods, the reaction model is modified until a satisfactory fit is obtained by each KCE 
method.  This approach has been used with six KCE methods to study the interactions 
between single-stranded DNA and ssDNA-binding protein.  The results indicated that 
both specific and non-specific interactions were present in this system.
20,157
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Advantages and potential limitations 
Advantages to using CE for the study of biological interactions are the efficiency, 
speed and small sample requirements of this method.
148,151-153
  One essential requirement 
for this approach is that a suitable difference in electrophoretic mobility must be present 
between the reactants and products of the interaction.  The degree of separation of these 
species and their concentrations must also be sufficient to allow a measurable signal to be 
obtained that is related to the change in concentration of one or more of these chemicals 
over time.
170
       
The CE methods that were discussed in this section have been used to examine a 
number of systems with a relatively large range of rate constants.  For instance, the 
overall range of dissociation rate constants that have been measured by CE is 10
-6
 to 1 s
-1 
156,157,163,169
 and the association rate constants have spanned from 1 to 10
7
 M
-1
 s
-1 
161,162,164,165,166-169
   
CE allows biological interactions to be studied in solution without the need for 
immobilization of one of the reagents.  It is important to remember, however, that some 
biomolecules such as proteins can adsorb to bare silica capillaries, as are often used in CE.  
This may lead to a loss in peak area or create peak tailing.  If present, this effect needs to 
be considered by adding in an additional term into the differential equations in KCE 
methods.  Alternatively, the running buffer’s composition or pH can be modified or a 
coating on the capillary wall can be employed to minimize this adsorption.
157,171
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Conclusions 
This chapter examined various techniques that are used in the study of biological 
interactions.  Traditional or common methods such as stopped-flow analysis and SRP 
were considered, as well as separation-based measurements based on affinity 
chromatography or CE.  The general principles of these techniques were described, and it 
was shown how each approach could be utilized to provide information on the rate 
constants for a biological interaction.  Several applications were also provided, and the 
advantages or potential limitations of each method were discussed. 
Most of these methods are used to examine reversible bimolecular interactions or 
the dissociation of biological complexes.  However, some of these approaches are also 
suitable for examining unimolecular interactions and multistep processes.  Some of these 
techniques (e.g., stopped-flow analysis and CE) are used with solution-phase interactions, 
while others require an immobilized binding agent (SPR and affinity chromatography).  
These methods have been used to examine many processes, including the interactions of 
enzymes with peptides or coenzymes, protein-protein interactions, and the binding of 
proteins with DNA, RNA or small solutes (e.g., lipids, hormones, drugs, and metal ions).  
A broad range of rate constants can also be measured by this set of techniques.   
The selection of an analytical method for such measurements will depend on the 
nature of the system being studied, the anticipated rate and complexity of the reaction, 
and the detectability and concentrations of the reactants or products, among other factors.  
However, given the set of tools that are already available, it is expected that kinetic 
measurements of biological systems will continue to grow in their scope and availability 
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as work continues in this field.  These efforts should make it possible to obtain even more 
detailed information on the rates and mechanisms of biological interactions, which should 
be valuable in areas such as pharmaceutical science, clinical chemistry, and biomedical 
research.  
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CHAPTER 3 
Improvement of Ultrafast Affinity Extraction for Determination of both the Kinetics 
and Thermodynamics of Drug-Protein Interactions  
Portion of this chapter have previously appeared in X. Zheng, Z. Li, M.I. Podariu, D.S. Hage 
“Determination of Rate Constants and Equilibrium Constants for Solution-Phase Drug−Protein 
Interactions by Ultrafast Affinity Extraction” Analytical Chemistry 2014, 86, 6454-6460. 
 
Introduction 
Studies of the interactions between drugs and serum proteins are important in 
providing information regarding the absorption, distribution, metabolism and excretion 
(ADME) of pharmaceutical agents within the body.
1
  Human serum albumin (HSA) is the 
most abundant transport protein in blood (concentration, 30-50 g/L) and is of interest in 
many drug-protein binding studies.
2
  This protein can interact with a large variety of 
drugs, most of which bind to one or two major sites on HSA: Sudlow sites I and II.
3-8
  
Examples of drugs and small solutes that can bind to this protein include warfarin, 
azapropazone, benzodiazepines, indoles (e.g., L-tryptophan), sulfonylureas, and long-
chain fatty acids.
3-8
 
  Many techniques have been used to examine the interactions of drugs and solutes 
with HSA. These techniques have included ultrafiltration, equilibrium dialysis, 
fluorescence spectroscopy, capillary electrophoresis, UV-Vis spectroscopy, solid-phase 
microextraction, circular dichroism, surface plasmon resonance, nuclear magnetic 
resonance spectroscopy, and X-ray crystallography.
9-15
  High-performance affinity 
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chromatography (HPAC) is another technique that has been used to characterize these 
interactions via developing methods to measure the equilibrium constants or rate 
constants for solute-protein interactions.
1,8,14
 These approaches have included zonal 
elution and frontal analysis for the determination of equilibrium constants; and plate 
height measurements, peak profiling, or peak decay analysis for kinetic studies.
14-17  
One 
limitation of these past HPAC methods is that they require the use of separate 
experiments or conditions for determining equilibrium constants and rate constants.
14,18-23
  
Also, these methods generally use an immobilized protein or binding agent as one of the 
components of the interaction that is being examined.  This feature means proper 
validation with model systems and reference methods are ideally required to ensure these 
HPAC approaches are providing a satisfactory model of how the same protein or binding 
agent will behave in its soluble or native state.
18-23
   
 An alternative HPAC method based on ultrafast affinity extraction has recently 
been described for estimating the equilibrium constants of drugs with HSA, or similar 
biological interactions, in solution.
14,25,26
  As illustrated in Figure 3.1, this method uses an 
affinity microcolumn that contains an immobilized binding agent, such as an antibody or 
serum protein, for extraction of the free (or non-protein bound) fraction of a drug or 
solute in a sample.  If the sample residence time in the column is sufficiently small to 
avoid appreciable release of the drug/solute from proteins in the sample, the amount of 
extracted drug/solute can then be used to measure the free fraction of this compound or 
the equilibrium constant for binding by this drug or solute to a soluble protein in the 
sample.
25,26
  This approach has been shown to give equilibrium constants that are in good 
agreement with those estimated for solution-phase systems when using ultrafiltration as a 
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Figure 3.1 General scheme for measuring a free drug fraction by ultrafast affinity 
extraction.  (a) A sample containing a drug/protein mixture is injected onto 
an affinity microcolumn that contains an immobilized binding agent for 
the drug, such as HSA.  (b) As the sample passes through the 
microcolumn at a suitably high flow rate, only the free drug fraction will 
be extracted; this creates a separation of the free and protein-bound forms 
of the drug in the sample and provides data that can be used to estimate 
the association equilibrium constant (Ka) or global affinity constant (nKa’) 
for the interaction.  (c) If a slower flow rate is used for sample injection, 
part of the protein-bound fraction of the drug in the sample may dissociate 
as it passes through the microcolumn, increasing the apparent free drug 
fraction; these conditions provide data that can be used to estimate the 
dissociation rate constant (kd) for the system.  Reproduced with permission 
from X. Zheng, Z. Li, M.I. Podariu, D.S. Hage, Anal. Chem. 86 (2014) 
6454-6460. 
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reference method.
 
 In addition, this method requires only microliter-size samples and 
provides binding data within a few minutes of injection.
25,26 
   
 
 In this chapter, a new method based on ultrafast affinity extraction is described in 
which both the rate constants and equilibrium constants can be quickly determined for a 
drug-protein interaction in solution.  This work will use HSA as a model protein and will 
examine several drugs that are known to bind to this protein.
18-23
  The theory of this 
approach will be described and various experimental parameters will be considered in the 
optimization of this technique.  This method will then be used to examine the interactions 
of each tested drug with HSA, and the resulting rate constants and equilibrium constants 
will be compared with those reported for other techniques.  The advantages and 
requirements of this method will be discussed, as well as the possible extension of this 
approach to other systems and applications.
8,27
 
 
Experimental 
Materials and reagents 
 HSA (Cohn fraction V, essentially fatty acid free, ≥96% pure), acetohexamide, 
chlorpromazine, gliclazide, tolbutamide, racemic verapamil, and racemic warfarin were 
obtained from Sigma (St. Louis, MO, USA).  The reagents for the bicinchoninic acid 
(BCA) protein assay were from Pierce (Rockford, IL, USA).  The Nucleosil Si-300 silica 
(7 μm particle diameter, 300 Å pore size) was purchased from Macherey Nagel (Dűren, 
Germany).   All buffers and aqueous solutions were prepared using water from a 
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Nanopure system (Barnstead, Dubuque, IA, USA) and were passed through Osmonics 
0.22 μm nylon filters from Fisher (Pittsburgh, PA, USA) 
 
Apparatus 
 The columns were packed using a Prep 24 pump from ChromTech (Apple Valley, 
MN, USA).  The chromatographic system consisted of a PU-2080 Plus pump, an AS-
2057 autosampler, and a UV-2075 absorbance detector from Jasco (Easton, MD, USA).  
An Alltech water jacket (Deerfield, IL, USA) and a Fisher Isotemp 3013D circulating 
water bath were used to maintain a column temperature of 37.0 (± 0.1) °C during all 
experiments.  ChromNAV v1.18.04 software and LCNet from Jasco were used to control 
the system.  Chromatograms were analyzed through the use of PeakFit v4.12 software 
(Jandel Scientific, San Rafael, CA, USA). 
 
Column preparation 
The stationary phase used in these studies consisted of HSA immobilized onto 
Nucleosil Si-300 silica by the Schiff base method.
18  
A control support was prepared in 
the same manner but with no HSA being added during the immobilization step.  The 
protein content of the final HSA support was determined in triplicate by a BCA assay 
using HSA as the standard and the control support as the blank, giving a value of 65 (± 2) 
mg HSA/g silica or an effective concentration of ~440 µM HSA in the affinity 
microcolumns.  The supports were placed into stainless steel columns with an inner 
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diameter of 2.1 mm and lengths of 1 mm (using a frit-in-column design)
 28 
or 5 to 10 mm 
(using traditional stainless steel HPLC housings and end fittings).  The packing solution 
was pH 7.4, 0.067 M potassium phosphate buffer and the packing pressure was 3000-
4000 psi (20-28 MPa). The columns were stored in pH 7.4, 0.067 M phosphate buffer and 
at 4 °C when not in use. 
 
Chromatographic studies 
The mobile phase used for sample application, elution and sample preparation 
was pH 7.4, 0.067 M phosphate buffer.  All mobile phases were degassed for 30 min 
prior to use.  Each affinity microcolumn was used for approximately 200 sample 
injections to provide optimum retention and peak resolution; however, these columns 
were found to be stable for at least 300-400 injections and over six months of use.  The 
free fraction measurements were typically made by injecting 1 μL samples that contained 
10 μM of the desired drug or a mixture of 10 μM drug and 20 μM soluble HSA, although 
other drug and protein concentrations were also considered. These mixtures were 
incubated for at least 30 min prior to injection, with both the sample and mobile phase 
being preheated to 37 ºC before passage through the affinity microcolumn.   
The dissociation rate constants and equilibrium constants for each drug with 
soluble HSA were measured by using the general scheme in Figure 3.1.  For the direct 
measurement of equilibrium constants, an injection flow rate was used that was 
sufficiently high to minimize dissociation of drug-protein complexes in the sample during 
their passage through the column.   By using lower flow rates, and longer residence times 
  
 
147 
for the sample in the column, the conditions were adjusted so that some of the drug-
protein complex could dissociate during passage through the column, thus increasing the 
apparent free drug fraction and making it possible to determine the dissociation rate 
constant for the drug with the soluble protein.  In both types of studies, the free drug 
fractions were measured by dividing the drug’s baseline-corrected retained peak area by 
the total peak area for the same drug in the absence of any soluble protein.  The baseline 
of each chromatogram was normalized using the autofit and subtract baseline method of 
PeakFit 4.12 prior to data analysis.  No significant nonspecific binding with the control 
support was seen for most drugs examined in this study.
18-22  
Some nonspecific binding 
was seen for verapamil, as reported previously;
21
 however, this nonspecific binding did 
not have any notable effect on the free fractions that were measured for this drug with 
soluble HSA. 
 
Results and Discussion 
Optimization of free drug fraction measurements 
 Several model drugs were examined in this chapter.  Warfarin is an anticoagulant 
known to have single-site binding to HSA at Sudlow site I.
15,18,29-30  
Verapamil is a 
calcium channel blocking agent and chlorpromazine is an anti-psychotic drug that each 
have a primary binding site at or near Sudlow site I.
21,31
  Tolbutamide, acetohexamide, 
and gliclazide are sulfonylurea drugs used to treat type 2 diabetes and have two major 
binding regions on HSA, which occur at Sudlow sites I and II.
19-20,22  
The association 
equilibrium constants (Ka, in the case of single-site binding) or global affinity constants 
(nKa’, in the case of multi-site binding) for these drugs with HSA at 37 °C and pH 7.4 are 
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in the general range of 10
4
-10
6
 M
-1
, as is typical for the binding of many drugs with this 
protein.
1,18-24
  Dissociation rates from HSA have been examined previously by other 
methods for four of these drugs (i.e., warfarin, verapamil, acetohexamide and 
tolbutamide),
15,17
 while the other two drugs (i.e., gliclazide and chlorpromazine) have not 
been the subject of prior kinetic studies.  
 In this study, a drug was injected in either the presence or absence of excess 
soluble HSA onto an HSA microcolumn according to the scheme given in Figure 3.1.  As 
the sample passed through the microcolumn at a moderate-to-high flow rate, the protein-
bound fraction of the drug and the excess soluble protein eluted as a non-retained peak, 
while the free fraction of the drug was extracted, retained and later eluted from the 
column.  Results were obtained within 2-10 min for all of the tested drugs (depending on 
the column size, degree of retention and the flow rate) and within 2-6 min for drugs with 
low-to-moderate affinities for HSA. 
 The injected samples that were typically used in this study contained a two-fold 
mole excess of HSA versus each drug (i.e., 20 μM HSA and 10 μM drug).  These 
concentrations avoided the use of an excess of drug vs. protein in the samples and 
provided free drug fractions that could be readily detected.  It has been shown in prior 
work with ultrafast affinity extraction that therapeutic levels of similar drugs
26,32,38 
and 
larger concentrations of soluble HSA,
26
 including physiological levels, could be used in 
this type of experiment.  However, these latter conditions were not required for the 
purpose of this current study.  Samples containing other drug and/or protein 
concentrations were also examined, with no significant changes being noted in the either 
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the rate constants or equilibrium constants that were measured under these alternative 
conditions. 
 As shown in Figure 3.2, the relative size of the free drug fraction was affected by 
the flow rate used for sample injection.  This effect has been noted for other applications 
of ultrafast affinity extraction and is due to the change the flow rate created in the time 
allowed for dissociation of the protein-bound form of the drug as the sample passed 
through the column.
25,26,32,38
  The extraction efficiency for the drug can also vary with the 
flow rate for some types of affinity microcolumns, but this parameter was 95% or higher 
for the HSA microcolumns and experimental conditions used in this study
25,26
 and did not 
lead to any significant changes in the relative size of the retained peaks as a function of 
flow rate.   
 The overall effect of changing the flow rate, and drug-protein dissociation in the 
sample, is also illustrated in Figure 3.2.  At low-to-moderate flow rates (i.e., < 2.0 
mL/min, in this example for a tolbutamide/HSA mixture), the apparent free drug fraction 
increased with a decrease in the flow rate, due to increased dissociation of the drug from 
soluble HSA as the sample passed through the column.  However, the measured free drug 
fraction approached a constant value when the flow rate reached a certain critical value 
(e.g., ≥ 2.0 mL/min, or a column residence time of ~420 ms or less for the 
tolbutamide/HSA mixture).  This effect was employed by using the latter conditions and 
high flow rates to estimate the original free drug fraction that was present at equilibrium 
in the sample and lower flow rates to provide data on the rate of a drug’s dissociation 
from a soluble protein in the sample.   
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Figure 3.2 Effect of injection flow rate on the column residence time (dashed line) 
and apparent free drug fractions (solid line) for 1 μL samples of 10 μM 
tolbutamide and 20 μM soluble HSA injected onto a 5 mm × 2.1 mm i.d. 
HSA microcolumn at pH 7.4 and 37 C. Reproduced with permission from 
X. Zheng, Z. Li, M.I. Podariu, D.S. Hage, Anal. Chem. 86 (2014) 6454-
6460. 
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 Column size is another factor to consider when performing a free fraction analysis 
by ultrafast affinity extraction.  Like flow rate, this factor will affect the time allowed for 
drugs to dissociate from proteins during passage of a sample through the column, 
following the same trend as illustrated in Figure 3.2.  In addition, both the column size 
and flow rate will affect the backpressure of the system (e.g., typical column pressures of 
1.9-3.2 MPa for 5-10 mm × 2.1 mm i.d. columns at 3.5 mL/min).  However, the column 
size will also affect the elution time of the retained free drug fraction and the resolution 
of this peak from the non-retained peak due to the protein-bound drug and excess protein 
in the sample.
25
   
 It was found that drugs with relatively strong binding to HSA (e.g., warfarin, 
tolbutamide and acetohexamide; affinities, ~10
5
-10
6 
M
-1
)
18-22,29,30 
provided measurable 
free fractions when using relatively short 5 mm × 2.1 mm i.d. HSA microcolumns.  Such 
columns not only gave good retention for these drugs, but they made it easy to obtain 
short column residence times for measurement of the small free drug fractions that could 
occur in such systems.  Most drugs with weaker binding to HSA (e.g., gliclazide and 
verapamil; affinities, ~10
4
-10
5 
M
-1
)
21,22
 were examined by using longer 10 mm × 2.1 mm 
HSA microcolumns.  These longer microcolumns provided higher drug retention while 
still providing column residence times sufficient to examine the larger free fractions that 
were present in such systems.  An exception to this trend was chlorpromazine, which had 
fast dissociation kinetics and moderate binding to HSA.
23
  In this specific case, a 1 mm × 
2.1 mm id. HSA microcolumn was used.   
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Determination of dissociation rate constants 
 Measurements of the apparent free drug fractions at low-to-moderate flow rates 
were used in this study to estimate the dissociation rate constant for a drug with a soluble 
protein in the same sample.  This experiment was described by the reactions shown in 
Equations 3.1 and 3.2, which occurred simultaneously as a mixture of the drug/analyte 
and soluble protein (as represented by A and P, respectively) was applied to an affinity 
microcolumn that contained an immobilized binding agent for the drug, P(s).  
         
𝑘d
   
𝑘a
 +                             (3.1) 
          +  ( )  
𝑘a( )
→     ( )                      (3.2) 
The reaction in Equation 3.1 describes the binding and equilibrium that has taken place 
between A and P in the sample prior to entering the column, while Equation 3.2 describes 
the binding and extraction of the free form of A by the immobilized agent P(s) in the 
microcolumn.  The terms ka and kd in Equation 3.1 represent the second-order association 
rate constant and first-order dissociation rate constant of A with P in solution.  The term 
ka(s) in Equation 3.2 is the second-order association rate constant for A as it interacts with 
the immobilized binding agent.   
 The system in Equations 3.1-3.2 was simplified in this study by using a large 
excess of the immobilized binding agent versus the soluble protein.  For instance, the 1-
10 mm × 2.1 mm i.d. microcolumns contained a 76- to 760-fold larger HSA content than 
a 1 μL solution of 20 μM HSA.  In addition, each of these columns had at least a 22-fold 
  
 
154 
larger molar concentration of HSA than was present in even the initial, undiluted samples 
and mixtures that contained soluble HSA.  These conditions meant that P(s) was present 
in a large excess versus soluble P when using the model described by using Equations 3.1 
and 3.2.  This also meant that the pseudo-first order rate constant ka [P] for the binding of 
A with P was much less than the pseudo-first order rate constant ka(s) [P(s)] for the 
extraction of A (i.e., assuming ka and ka(s) had comparable values, as has been noted to be 
the case for soluble HSA and the type of immobilized HSA used in this study).
1,29,39
  
 The result of these experimental conditions is that the extraction of A by the 
immobilized binding agent was much faster than the association of A with P.  This, in 
turn, made it possible to ignore this latter process and simplify the reaction in Equation 
3.1 to that shown in Equation 3.3.  
         
𝑘 
→   +                            (3.3) 
It was then possible with this revised model to obtain the integrated rate expressions 
given in Equations 3.4 and 3.5 
       
(1− 0)
(1−  )
= 𝑘d                   (3.4) 
      
1
(1−  )
= 𝑘d −    (1 −   )                 (3.5) 
In these equations, F0 is the original free fraction of A in the sample, and Ft is the 
apparent free fraction after AP has been allowed to dissociate for time t. The value of t is 
equal to the column void time and can be calculated by employing the flow rate and the 
column void volume (e.g., as found by using the known support porosity, packing density, 
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and column size).  Equations 3.4-3.5 indicate that a plot of either ln[(1 – F0)/(1 – Ft)] or 
ln[1/(1 – Ft)] versus t should provide, under the appropriate experimental conditions, a 
linear relationship in which the slope is directly related to the dissociation rate constant kd 
as A is released from its complex with soluble agent P in the sample.    
 Some typical plots that were obtained when using Equations 3.4 and 3.5 are 
provided in Figure 3.3.  Both types of plots gave a linear response for all of the tested 
drugs, with correlation coefficients ranging from 0.988 to 0.998 (n = 5 to 8) over 
dissociation times that allowed measurable changes to be made in the apparent free 
fractions.  The plots that were prepared according Equation 3.4 gave intercepts that were 
essentially equal to zero, regardless of whether an experimental point at t = 0 and Ft = F0 
for the original sample was included in the data set.  For plots made according to 
Equation 3.5, a positive non-zero intercept was obtained that was related to the value of 
F0.   
 The usable time range for these dissociation studies was dependent on the affinity 
of each drug for soluble HSA (which affected the value of F0) and the dissociation rate 
for the soluble drug-protein complex.  The lower end of this usable time range occurred 
when the free fraction grew close to its equilibrium value (i.e., conditions under which 
little dissociation occurred).  These times were as low as 100-277 ms for chlorpromazine 
or warfarin and as high as 950 ms for verapamil.  The ranking of these drugs with respect 
to this time was correlated with a decreasing order in the overall affinities of the drugs for 
HSA, with the sole exception of chlorpromazine due to its relatively high dissociation 
rate.  The upper end of the usable time range occurred when the drug had sufficient time 
to reach essentially complete dissociation.  For most of the tested drugs, this upper limit  
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Figure 3.3 Measurement of the dissociation rate constant for verapamil and soluble 
HSA at pH 7.4 and 37 C, as determined by measuring apparent free drug 
fractions using ultrafast affinity extraction.  The samples contained 10 μM 
verapamil and 20 μM soluble HSA.  The results were analyzed by using (a) 
Equation 3.4 or (b) Equation 3.5.  The solid line in (a) shows the result 
that was obtained when a point at the origin was included (◊), and the 
dashed line shows the result obtained when this point was not included; 
the equations for these two best-fit lines were y = 0.35 (± 0.02) x - 0.04 (± 
0.06) and y = 0.36 (± 0.02) x - 0.06 (± 0.09), respectively.  In (b), the best-
fit equation was y = 0.36 (± 0.02) x + 1.51 (± 0.09).  The correlation 
coefficients for these plots ranged from 0.993 to 0.995 (n = 5).  The error 
bars represent a range of ± 1 S.D. and, in some cases, were comparable in 
size to the data symbols. Reproduced with permission from X. Zheng, Z. 
Li, M.I. Podariu, D.S. Hage, Anal. Chem. 86 (2014) 6454-6460. 
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occurred over the range of 1.7-6.7 s and, again with the exception of chlorpromazine, 
followed approximately the same order as seen with the lower time limits for these drugs 
and the affinities of these drugs for soluble HSA. 
 Table 3.1 summarizes the kd values that were obtained in this study.  The relative 
precision of these dissociation rate constants ranged from ± 3-9%.  The measured kd 
values differed by only 7-20% from the literature values that have been reported for 
acetohexamide, tolbutamide and racemic verapamil.
15,17
  In the case of warfarin, the 
results of this study fell within the overall range of all previously-reported values for 
racemic warfarin or its enantiomers.
 9,15,40
 Although gliclazide and chlorpromazine did 
not have prior kd values that have been reported, the dissociation rate constants measured 
for these drugs did fit within the range that would be expected for drugs with similar 
affinities to HSA.
15,17,41,42
  The same trends were seen for kd values that were measured 
by ultrafast affinity extraction when 1) a point at the intercept, and representing the 
original sample, was included during analysis of the data by using Equation 3.4; 2) when 
Equation 3.4 was used with no such point being included in the data set; or 3) when the 
data were examined by using Equation 3.5.   
 
Measurement of association equilibrium constants 
It was also possible by using ultrafast affinity extraction to obtain the association 
equilibrium constant (Ka), or the global affinity constant (nKa’) in the case of a system 
with multi-site binding,
1,24
 for each drug with soluble HSA.  For instance, Equation 3.6 
can be used for this purpose by employing the free drug fraction that is measured for a  
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Table 3.1   Dissociation rate constants measured for various drugs with soluble HSA 
by using ultrafast affinity extraction on HSA microcolumns
a 
    Dissociation rate constant, kd (s
-1
) 
Drug Estimate, Equation 3.4
b
 Estimate, Equation 3.5 Literature [Ref.]  
Warfarin 0.80 (± 0.05) 0.72 (± 0.05) 0.41-2 [9,15,40] 
Tolbutamide 0.59 (± 0.03) 0.58 (± 0.04) 0.49 (± 0.15) [15] 
Acetohexamide 0.67 (± 0.03) 0.63 (± 0.03) 0.58 (± 0.02) [15] 
Verapamil 0.35 (± 0.02) 0.36 (± 0.02) 0.38 (± 0.05) [17] 
Gliclazide 0.61 (± 0.02) 0.59 (± 0.04) Not reported  
Chlorpromazine 3.96 (± 0.13) 3.35 (± 0.30) Not reported  
 
a
The kd values were measured at pH 7.4 and at 37 
o
C.  Each of the injected samples 
contained 10 μM of the drug and 20 μM HSA.  The values in the parentheses represent a 
range of ± 1 S.D., as determined from the slopes of the best-fit lines constructed 
according to Equations 3.4 and 3.5. 
b
These values were found by using Equation 3.4 when a point at the origin was included 
in the data set. 
Reproduced with permission from X. Zheng, Z. Li, M.I. Podariu, D.S. Hage, Anal. Chem. 
86 (2014) 6454-6460. 
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drug/protein mixture at equilibrium (F0) and under injection conditions that minimize 
release of the drug from soluble proteins as the sample passes through the column.
25 
 
       𝐾a =
1− 0     
 0([P]    − [A]   +[A]    0 )
                     (3.6) 
In this Equation 3.6, [A]tot and [P]tot are the total concentrations of the drug and soluble 
protein in the original sample, respectively.  This equation was derived for a drug and 
protein interaction that involves 1:1 binding, but the same expression can be used to 
estimate the global affinity constant for a multi-site drug-protein interaction under a given 
set of concentration conditions.
 25,32,35,37
   
 The Ka (or nKa’) values that were obtained by using direct measurements of F0 are 
provided in Table 3.2.  These values had precisions of ± 7-36% and differed by less than 
7% for the drugs with single reference values obtained under similar temperature 
conditions.  In the case of warfarin, the measured Ka fell within the range of previously-
reported values.  A second method for estimating Ka was carried out that utilized the 
value of F0 that was obtained from the intercept of a plot made according Equation 3.5 
during the determination of dissociation rate constants.  This second set of values, which 
are also given in Table 3.2, had precisions of ± 8-22% and differed from the literature 
results by less than 23% or, in the case of warfarin, were similar to the range of 
previously-reported values.  
 A comparison of these two approaches indicates that there are distinct advantages 
to each method for measuring the equilibrium constant for a drug-protein interaction.  As 
the data in Table 3.2 suggest, the approach that uses fast flow rates and ultrafast affinity  
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Table 3.2. Equilibrium constants measured for various drugs with soluble HSA by 
using ultrafast affinity extraction on HSA microcolumns
a
 
              Association equilibrium constant, Ka,  
             or global affinity constant, nKa’ (M
-1
) 
Drug Estimate, Equation 
3.6 
Estimate, Equations 
3.5 and 3.6  
Literature [Ref.] 
Warfarin 2.4 (± 0.4) × 10
5
 1.6 (± 0.2) × 10
5
 2.0-5.7 × 10
5
 [18,29,30] 
Tolbutamide 1.1 (± 0.4) × 10
5
 0.9 (± 0.2) × 10
5
 1.1 (± 0.1)  × 10
5 
[19]
b
 
Acetohexamide 1.8 (± 0.5)  × 10
5
 1.3 (± 0.1)  × 10
5
 1.7( ± 0.1)  × 10
5 
[20]
b
 
Verapamil 1.5 (± 0.4) × 10
4
 1.6 (± 0.2) × 10
4
  1.4 ( ± 0.1)  × 10
4 
[21]
c
 
Gliclazide 8.0 (± 0.6)  × 10
4
 6.9 (± 1.0)  × 10
4
 7.9 (± 0.1) × 10
4 
[22]
b
 
Chlorpromazine 6.2 (± 0.5)  × 10
4
 4.9 (± 0.5)  × 10
4
 6.4 × 10
4
 [23] 
 
a
These results were measured at pH 7.4 and at 37
o
C.  The values in parentheses represent 
a range of ± 1 S.D., as determined by error propagation. 
b
The global affinity constants for these drugs were calculated from data in the given 
references.
  
c
This value represents the average association equilibrium constant for R- and S-
verapamil at their high affinity site on HSA. 
Reproduced with permission from X. Zheng, Z. Li, M.I. Podariu, D.S. Hage, Anal. Chem. 
86 (2014) 6454-6460. 
  
  
 
162 
extraction to directly measure F0 can provide the more precise estimate of Ka or nKa’.  
However, this method does require obtaining appropriate flow rate conditions for such a 
measurement and is carried out at separate flow rates from those that would be used to 
measure a dissociation rate constant.  The second approach, in which the value of F0 is 
obtained from the intercept of a plot made according to Equation 3.5, provides a slightly 
less precise estimate of the equilibrium constant but can be carried out with the same 
experiments and conditions as those used to find kd.  This makes the latter method 
attractive for the simultaneous and rapid determination of both kd and Ka.  This approach 
would also be useful for the estimation of equilibrium constants at column pressures or 
peak resolutions that may prevent the use of sufficiently high flow rates for the direct 
determination of F0 and Ka.   
 
Estimation of association rate constants   
 It was possible from the measured Ka and kd values to also estimate the second-
order association rate constant (ka) for each drug with soluble HSA, as found by using the 
relationship ka = kd Ka. This method provided the actual ka value for a drug-protein system 
with 1:1 interactions or the net, apparent value of ka for a system with multi-site 
interactions.  The average ka for racemic warfarin that was determined by this approach 
was 1.7 (± 0.3) × 10
5
 M
-1 
s
-1
 at pH 7.4 and 37ºC, which gave good agreement with prior 
values reported for this drug.
9,15,40,43  
The association rate constants for tolbutamide, 
acetohexamide and racemic verapamil gave ka values of 6.4 (± 2.4) × 10
4
 M
-1 
s
-1
, 1.1 (± 
0.3) × 10
5
 M
-1 
s
-1
, and 5.4 (± 1.5) × 10
3
 M
-1 
s
-1
, respectively, which were comparable to 
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the results calculated from previously-reported kd and Ka or nKa’ values for these 
systems.
15,17,19-21 
Gliclazide and chlorpromazine gave ka values of 4.7 (± 0.5) × 10
4
 M
-1 
s
-1
 
and 2.1 (± 0.3) × 10
5
 M
-1 
s
-1
, which agreed with the range of values that have been 
reported for drugs with comparable affinities and dissociation rates for HSA.
15,17,41,42
 
 
Conclusions 
 In this chapter, a new method based on ultrafast affinity extraction and affinity 
microcolumns containing immobilized HSA was developed and used to measure both the 
rate constants and equilibrium constants for drug-protein interactions involving soluble 
HSA.  The effects of column size and flow rate were considered in these experiments, 
and several approaches for these measurements were examined and compared.  The 
dissociation rate constants obtained by this approach gave good agreement with previous 
rate constants that have been reported for the same drugs or for other solutes with 
comparable affinities for HSA.  The equilibrium constants determined by this method 
also showed good agreement with the literature.   
 The results indicated that ultrafast affinity extraction can be an effective method 
for studying both the kinetics and thermodynamics of a drug-protein interaction in 
solution.  An important advantage of this method is it can directly examine both the 
equilibrium processes and interaction rates that occur between a drug and the soluble 
form of a protein, thus avoiding any effects immobilization may have on such 
interactions.
18-23
  The moderate-to-high flow rates and small columns used in this method 
make this technique fast, with analysis times on the order of minutes per sample being 
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possible.
25,26 
 In addition, this approach is not limited to HSA or the drugs examined in 
this study but could be applied to other systems (e.g., the interactions of drugs or small 
biomolecules with other soluble proteins or to surface receptors on injected particles). 
Possible applications for this method include the high-throughput screening of drug 
candidates and the rapid characterization of solute-protein interactions. 
1,9,14,17,24
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CHAPTER 4 
Combination of Ultrafast Affinity Extraction and Multi-Dimensional HPAC for the 
Analysis of Free Fractions for Chiral Drugs 
Portion of this chapter have previously appeared in X. Zheng, M.J. Yoo, D.S. Hage “Analysis of Free 
Fractions for Chiral Drugs Using Ultrafast Extraction and Multi-Dimensional High-Performance Affinity 
Chromatography” Analyst 2013, 138, 6262-6265. 
 
Introduction 
Many drugs and small solutes exist in multiple forms in biological systems.  
Drugs are often reversibly bound to carrier agents such as serum proteins in the 
circulatory system, causing these drugs to exist in two forms: a free fraction and bound 
fraction.
1-4
  Because the free drug fraction is generally thought to be the biologically-
active form,
3,4
 there has been ongoing interest in the creation of improved tools for 
measuring free drug fractions and for studying drug-protein interactions in clinical and 
pharmaceutical samples.
1,2,5
 The methods of equilibrium dialysis and ultrafiltration are 
often used for this work but can have long analysis times and large sample requirements 
(e.g., equilibrium dialysis) or can introduce errors due to nonspecific adsorption to a 
membrane (e.g., ultrafiltration or equilibrium dialysis).
6
  
Chromatographic approaches based on high-performance affinity chromatography 
(HPAC) and ultrafast affinity extraction have recently been proposed as an alternative 
means for measuring free drug or free hormone fractions.
1,2,7-9
  In this type of approach, 
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small columns containing immobilized antibodies
1,2,7,8 
or other binding agents, such as 
immobilized transport proteins,
9
 are employed to extract the free form of a target drug or 
solute on a time scale that minimizes release of the target from its protein-bound form in 
a sample. Potential advantages of this approach include its speed, small sample 
requirements, good precision and low detection limits, especially when used with 
detection based on chemiluminescence or near-infrared fluorescence.
1,7,8
 However, 
previous systems based on this method have been designed to look at only a specific drug 
or solute (e.g., warfarin, phenytoin and thyroxine)
1,2,7-9
 rather than samples that may 
contain multiple or related forms of the same target (e.g., a mixture of drug enantiomers).  
This chapter will describe the development of a multi-dimensional HPAC system 
that uses ultrafast affinity extraction and chiral chromatography to simultaneously 
examine the free forms of drug enantiomers in complex samples (e.g., serum) and to 
study the binding of such drugs with proteins.  R/S-Warfarin and its binding protein 
human serum albumin (HSA) were used as models to develop and evaluate this approach.  
Warfarin is an anticoagulant often used as a racemic mixture for the treatment of 
thromboembolic diseases, with the R- and S-enantiomers having noticeable differences in 
their pharmacokinetics and protein binding properties.
3,10,11
  HSA (molar mass, 66.5 kDa) 
is the main binding protein for warfarin and many other drugs in serum and is known to 
have strong interactions with both R- and S-warfarin at a region on this protein known as 
Sudlow site I.
10,12,13
 The data obtained in this study should provide important information 
on interaction between protein and two drug enantiomers, as well as data that can be used 
in future work to extend this method to other chiral analytes. 
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Experimental 
Materials and reagents 
 The HSA (Cohn fraction V, essentially fatty acid free), human serum (from male 
AB plasma, H4522, lot 039K0728; sterile filtered and tested negative for HIV-1/HIV-2, 
hepatitis B and hepatitis C), and racemic warfarin (98% pure) were from Sigma (St. 
Louis, MO, USA).  The reagents for the bicinchoninic acid (BCA) protein assay were 
from Pierce (Rockford, IL, USA).  The Nucleosil Si-300 silica (7 µm particle diameter, 
300 Å pore size) was purchased from Macherey Nagel (Dűren, Germany).  All buffers 
and aqueous solutions were prepared using water from a Nanopure system (Barnstead, 
Dubuque, IA, USA) and were passed through Osmonics 0.22 µm nylon filters from 
Fisher (Pittsburgh, PA, USA) 
 
Apparatus 
 The affinity columns were packed using a Prep 24 preparative pump from 
ChromTech (Apple Valley, MN, USA).  The chromatographic system consisted of a PU-
2080 Plus HPLC pump from Jasco (Easton, MD, USA), two six-port Lab Pro valves 
(Rheodyne, Cotati, CA, USA), and a Shimadzu RF-10AXL fluorescence detector (Kyoto, 
Japan).  An Alltech water jacket (Deerfield, IL, USA) and an Isotemp 3013D circulating 
water bath from Fisher were used to maintain a temperature of 37.0 (±0.1) °C for the 
columns during all experiments described in this chapter.  The chromatographic data 
were collected and processed using in-house programs written in LabView 5.1 (National 
Instruments, Austin, TX, USA).  The ultrafiltration studies were performed using a 
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5702RH centrifuge from Fisher and tubes containing Ultracel YM-T cellulose 
membranes (30 kDa cut-off), as obtained from Millipore (Billerica, MA, USA). 
 
Column preparation 
 The stationary phase used in these studies consisted of HSA that was immobilized 
on Nucleosil Si-300 silica by the Schiff base, as performed according to the literature.
8
 
Control supports were prepared in the same manner but with no HSA being added during 
the immobilization step.  The protein content of the final HSA support was determined in 
triplicate by a BCA assay using HSA as the standard and the control support as the blank.   
 An HPLC column packer was used to place the supports into stainless steel 
columns with dimensions of 1 cm × 2.1 mm i.d., or 5 cm × 2.1 mm i.d.  The columns 
with dimension of 3 mm × 2.1 mm i.d.mm used a frit-in-column design, as described in 
Ref. 14.  The longer columns were prepared using traditional stainless steel HPLC 
housings and end fittings.  The packing solution for all of these columns was pH 7.4, 
0.067 M potassium phosphate buffer, and the packing pressure was 4000 psi (28 MPa). 
 
Chromatographic studies 
 Figure 4.1 shows the general separation and analysis strategy that was used in this 
study to examine the free fractions of R- and S-warfarin.  Ultrafast extraction based on an 
immobilized HSA microcolumn was first used to separate the free and protein-bound 
fractions of R- and S-warfarin in the presence of a sample that contained soluble HSA.  In 
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Figure 4.1 General scheme for separation of the free and protein-bound fractions of a 
drug and resolution of the enantiomers in free drug fraction through the 
use of ultrafast extraction and multi-dimensional HPAC. Reproduced with 
permission from X. Zheng, M.J. Yoo, D.S. Hage, Analyst 138 (2013) 
6262-6265. 
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this process, the protein-bound drug and proteins in the sample were eluted in a non-
retained peak from the microcolumn, while the free drug fraction in the sample was 
extracted and retained.  This retained free drug fraction was later eluted from the 
microcolumn under isocratic conditions and delivered to a second, larger HSA column, 
which was utilized as a chiral stationary phase for the separation and measurement of the 
captured drug enantiomers.
10  
 
To be specific, this work utilized a multi-dimensional system in which a 3 mm × 
2.1 mm i.d. HSA microcolumn was used for the extraction of free drug fractions and a 5 
cm × 2.1 mm i.d. HSA column was used for chiral separations of the retained free drug 
fractions.  The sample loading, injection and column switching were controlled by two 
separate Rheodyne six port valves (Cotati, CA, USA), as shown in Figure 4.2.  The 
mobile phase was pH 7.4, 0.067 M potassium phosphate buffer in the free drug 
extractions and in the initial chiral separations.  All samples containing racemic warfarin 
and HSA were prepared in this buffer and incubated for at least 1 h before injection to 
allow equilibrium to be established between the free and protein-bound fractions of the 
drug in the sample.
9
  
The initial studies examining the free fraction extraction of R- and S-warfarin 
used a 1.0 µL sample of 10 µM racemic warfarin or a 10 µM racemic warfarin/20 µM 
HSA mixture that was injected onto a 3 mm × 2.1 mm i.d. HSA microcolumn at flow 
rates ranging from 0.5 mL/min to 6.0 mL/min.  In the final method that was developed in 
this study, a 1.0 µL sample injection was made onto the 3 mm × 2.1 mm i.d. HSA 
microcolumn at a flow rate of 5.0 mL/min for extraction of the free drug fraction.  
Eighteen seconds later, a switching valve was used to transfer the eluting free drug 
  
 
176 
 
 
 
 
 
Figure 4.2 Valve configurations used in the multi-dimensional HPAC system. The 
first valve was used for (a) loading and (b) injecting a sample onto an 
HSA microcolumn for a free fraction separation. (c) The second valve was 
switched when the protein-bound drug complex and excess protein had 
been passed through the HSA microcolumn and the free drug fraction had 
just begun to exit this microcolumn. The free drug fraction, or a 
representative portion, was then passed on to a second and longer HSA 
column for a chiral separation. Reproduced with permission from X. 
Zheng, M.J. Yoo, D.S. Hage, Analyst 138 (2013) 6262-6265. 
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fraction to a longer 5 cm × 2.1 mm i.d. HSA column for use in a chiral separation at 0.5 
mL/min.  The aqueous samples used in these latter studies contained 5 µM racemic 
warfarin or a 5 µM warfarin/10 µM HSA mixture; 30 µM racemic warfarin or 30 µM 
warfarin/600 µM HSA, to examine the use of this method at clinically-relevant 
concentrations; and a mixture of 30 µM racemic warfarin and human serum (which 
contained approximately 600 µM HSA) to study the feasibility of using this system with 
human serum samples.  The warfarin enantiomers were detected by monitoring their 
fluorescence at an excitation wavelength of 310 nm and an emission wavelength of 390 
nm.  The concentrations of R- and S-warfarin in each sample were determined by 
comparing the resulting peak areas to those obtained for warfarin standards. 
 
Ultrafiltration studies 
Before sample introduction, each ultrafiltration device was washed three times 
with 1 mL water and spun at 1500 × g for 5 min.  The devices were then washed three 
times in the same manner with 1 mL of pH 7.4, 0.067 M potassium phosphate buffer.  
Any remaining buffer in the device was removed by spinning the filtration device at 1500 
× g for 15 min.  Immediately after these washing and pretreatment steps, a 1 mL sample 
containing warfarin or warfarin plus HSA, as prepared in pH 7.4, 0.067 M potassium 
phosphate buffer or human serum, was introduced into three ultrafiltration devices and 
spun at 1500 × g and 37ºC for 2.5 min or 6.0 min, respectively (Note: different spinning 
periods were used to make sure that no more than 0.5 mL of the sample passed into the 
filtrate vial, thus allowing for accurate free drug fraction measurements).
15
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The resulting filtrates were collected for the measurement of their warfarin 
concentrations by using an HPLC-based chiral separation.  This was accomplished by 
making a 5 µL injection of each filtrate sample at 1.0 mL/min onto a 1 cm × 2.1 mm i.d. 
HSA column.  The mobile phase in this case consisted of pH 7.4, 0.067 M potassium 
phosphate buffer containing 1.5% (v/v) 1-propanol.  The elution of warfarin enantiomers 
from this column was again monitored by using a fluorescence detector, as described in 
the previous section, and the concentrations of R- and S-warfarin in each filtrate were 
determined by comparing the resulting peaks areas to those that were obtained by the 
same approach when using warfarin standards. 
 
Results and Discussion 
Optimization of conditions for multi-dimensional affinity system
 
 
 Studies were first performed with this system to find the optimum flow rate 
conditions for extraction of the free fraction of R/S-warfarin without creating significant 
interferences from the portion of the drug that was originally bound to sample proteins 
but was released as the initial free drug fraction was removed.  Figure 4.3 shows the 
apparent free drug fractions that were obtained for warfarin/HSA mixtures at various 
flow rates and at 37 ºC in pH 7.4, 0.067 M phosphate buffer when using a 3 mm × 2.1 
mm i.d. HSA microcolumn for ultrafast affinity extraction.  Based on a measured protein 
content of 57 (± 1) mg HSA/g silica, the microcolumn was determined to contain 4.0 
nmol HSA.  The amount of warfarin applied per injection in Figure 4.3 was 0.25% of the 
estimated binding capacity.  Experiments with injections of only R/S-warfarin indicated 
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Figure 4.3 Effect of flow rate on the measurement of free fractions in mixtures of 
racemic warfarin and HSA when using ultrafast affinity extraction.  
Conditions: 1.0 μL of 10 μM warfarin or 10 μM warfarin/20 μM HSA 
injected onto a 3 mm × 2.1 mm i.d. HSA microcolumn. Reproduced with 
permission from X. Zheng, M.J. Yoo, D.S. Hage, Analyst 138 (2013) 
6262-6265. 
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that more than 99% extraction occurred for this drug’s enantiomers under these injection 
conditions and at all of the flow rates tested in this study.   
 In Figure 4.3, the apparent free drug fractions that were measured for a mixture of 
warfarin with soluble HSA was elevated at lower flow rates because the longer extraction 
period provided in the microcolumn under these conditions allowed for some dissociation 
of this drug from its protein-bound fraction in the sample, as noted previously.
1,9
  This 
process was decreased at higher flow rates and had no significant effect on the measured 
free fractions at a flow rate of 5.0 mL/min or higher, which corresponded to a residence 
time of 100 ms or less for the sample on the HSA microcolumn.  
 A second set of studies examined the ability of the multi-dimensional HPAC 
system to separate warfarin enantiomers in the retained free drug fraction (see Figure 4.4).  
Samples containing 1.0 µL of 5 µM warfarin or a 5 µM warfarin/10 µM HSA mixture 
were applied to the multi-dimensional system.  The upper peak in Figure 4.4(a) was 
obtained by injecting only warfarin onto the HSA microcolumn at 5 mL/min.  The free 
fraction of warfarin that was extracted by this microcolumn eluted with a retention time 
of approximately 17-20 s.  This figure also shows a chromatogram that was obtained 
when the same amount of warfarin and a two-fold mole excess of soluble HSA were 
injected onto the HSA microcolumn under identical conditions.  In this case, a large non-
retained peak was now observed at 5-7 s due to the elution of the soluble HSA and 
protein-bound fraction of warfarin.  The second retained peak in this case represented the 
free fraction of warfarin that was extracted by, and later eluted from, the HSA 
microcolumn.
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Figure 4.4 Chromatograms for 1.0 μL injections of 5 μM racemic warfarin or 5 μM 
racemic warfarin plus 10 μM HSA on (a) an HSA microcolumn at 5.0 
mL/min or (b) a chiral HSA column at 0.5 mL/min after sample passage 
through the HSA microcolumn.  The arrow in (a) shows the time at which 
a valve was switched to pass the retained components from the HSA 
microcolumn onto the larger HSA column that was used for the chiral 
separation.  These results were obtained at 37 ºC using pH 7.4, 0.067 M 
phosphate buffer as the mobile phase for both columns. Reproduced with 
permission from X. Zheng, M.J. Yoo, D.S. Hage, Analyst 138 (2013) 
6262-6265.
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 The free warfarin fraction, or a representative portion of this fraction, that was 
extracted by the HSA microcolumn was then eluted in the presence of the pH 7.4 
phosphate buffer onto a 5 cm × 2.1 mm i.d. HSA column at 0.5 mL/min for a chiral 
separation.  The chromatograms in Figure 4.4(b) show the peaks that were obtained for 
R- and S-warfarin in samples that contained only racemic warfarin or racemic warfarin 
plus soluble HSA.  With this combined approach, it was possible to simultaneously study 
the free fractions for both R- and S-warfarin in the original sample.  Although the chiral 
separation obtained with the pH 7.4 buffer in Figure 4.4(b) provided baseline resolution 
for the warfarin enantiomers and was sufficient for these exploratory studies, the speed of 
this latter step could be reduced to less than 10 min by using a more efficient HSA 
monolith column and/or by adding an organic modifier to the mobile phase.
10,16,17
 
 
Measurement of free drug fractions for warfarin enantiomers  
 The free fraction of R- or S-warfarin in a mixture of racemic warfarin and soluble 
HSA was calculated by dividing the concentration of the enantiomer’s free fraction, as 
represented by lower peaks in Figure 4.4(b), by the concentration measured for the 
enantiomer and at the same total sample concentration but with no soluble protein present, 
as represented by the upper peaks in Figure 4.4 (b).  The concentrations of the R- and S-
warfarin fractions were determined by comparing the sizes of these peaks to those 
obtained with the same chromatographic system and using warfarin standards.  The free 
fractions for R- and S-warfarin in various samples were measured by this approach based 
on multi-dimensional HPAC and by employing a reference method that made use of 
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ultrafiltration followed by a chiral separation using an HSA column.  The results that 
were obtained by each method are summarized in Table 4.1.  
 Table 4.1 shows that there was good agreement between the free fractions that 
were measured in Figure 4.4 by the multi-dimensional HPAC method and by 
ultrafiltration followed with a chiral separation.  For a sample that contained 5 µM 
racemic warfarin and 10 µM soluble HSA, the absolute difference in these free fractions 
was 1-6%, with the results showing no significant difference at the 95% confidence level.  
In addition, these measured free fractions agreed with the range of 33-43% that was 
predicted for R- and S-warfarin based on the known binding constants of this system.
9,10
   
 The multi-dimensional HPAC method was also used to examine other samples.  
One of these samples contained 30 µM racemic warfarin and 600 µM HSA, representing 
a clinically- relevant concentration of HSA and a typical therapeutic concentration for 
warfarin.
18
 Good agreement between the multi-dimensional HPAC system and reference 
method was again obtained, with an absolute difference in the measured free fractions of 
0.3-0.5% and no significant differences at the 95% confidence level.  In addition, the 
measured free fractions were consistent with a range of approximately 0.5-2% that was 
estimated from the reported binding constants for the warfarin-HSA interaction.
9,10
 The 
free fractions of the warfarin enantiomers were also examined in human serum that was 
spiked with a therapeutic level of this drug.  The results for the multi-dimensional HPAC 
system and reference method were again comparable, with an absolute difference of 0.2-
0.5% and no significant differences being noted at the 95% confidence level.  
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Table 4.1 Free drug fractions measured for R- and S-warfarin in samples containing soluble HSA 
or human serum 
 
Sample & Analyte 
Measured free fraction
a  
 
       Multi-dimensional  
      HPAC 
Ultrafiltration  
+ chiral separation 
Racemic warfarin (5 M) + HSA (10 M) 
R-Warfarin 42 (± 4)% 41 (± 4)% 
S-Warfarin 38 (± 5)% 32 (± 3)% 
Racemic warfarin (30 M) + HSA (600 M) 
R-Warfarin 1.8 (± 0.8)% 1.5 (± 0.5)% 
S-Warfarin 1.3 (± 0.2)% 1.8 (± 0.2)% 
Racemic warfarin (30 M) + human serumb 
R-Warfarin 2.7 (± 1.7)% 2.5 (± 0.2)% 
S-Warfarin 1.1 (± 0.3)% 1.6 (± 0.7)% 
a
These values were obtained at 37 
o
C in pH 7.4, 0.0067 M potassium phosphate buffer.  The 
numbers in parentheses represent ± 1 S.D. (n = 3).     
b
The human serum contained approximately 600 M HSA. 
Reproduced with permission from X. Zheng, M.J. Yoo, D.S. Hage, Analyst 138 (2013) 6262-
6265. 
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Simultaneous estimation of association equilibrium constants for R- and S-warfarin with 
soluble HSA 
 The multi-dimensional HPAC system was next used as a screening tool to 
determine the association equilibrium constants for R- and S-warfarin with HSA.  This 
was accomplished by using the free fraction data along with a single-site binding model. 
For a drug and protein interaction that involves 1:1 binding, the relationship between the 
free fraction (F) and the association equilibrium constant (Ka) for this interaction can be 
described by using Equations 4.1 and 4.2,  
                 =
𝐶  − [ − ]     
𝐶  
         (4.1) 
𝐾𝑎 =
[ − ]     
(𝐶  − [ − ])(𝐶  − [ − ])
            (4.2) 
in which Cd is the total concentration of drug in the original sample, Cp is the total 
concentration of protein in the sample, [D-P] is the concentration of the drug-protein 
complex in the original sample.
9
  
In this study, both R- and S-warfarin were present in a sample containing racemic 
warfarin and both enantiomers were able to interact with any HSA that was present.  
Thus, the free fractions for these two enantiomers (FR and FS) and their association 
equilibrium constants (Ka,R and Ka,S) were calculated separately, as described by 
Equations 4.3-4.6,  
                =
𝐶  − [ − ]     
𝐶  
            (4.3) 
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𝐾𝑎, =
[ − ]     
(𝐶  − [ − ])(𝐶  − [ − ]− [ − ])
        (4.4) 
                 =
𝐶  − [ − ]     
𝐶  
          (4.5) 
𝐾𝑎, =
[ − ]     
(𝐶  − [ − ])(𝐶  − [ − ]− [ − ])
         (4.6) 
where CR and CS represent the concentrations of R- and S-warfarin in the original sample.  
According to the information provided by their supplier, the R- and S-warfarin were 
present in identical amounts in their original racemic mixture.  Under these conditions, 
the relationship of their concentrations with Cd can be described by Equation 4.7.   
2 CR = 2 CS = Cd              (4.7) 
According to Equations 4.3-4.7 and the data of free drug fractions that were measured in 
this study, the overall association equilibrium constants for each drug with HSA can 
thereafter be obtained. For instance, by using Equation 4.3 the concentration of the R-
warfarin/HSA complex ([R-P]) could be calculated from the measured free fraction of R-
warfarin (FR).  Substituting the value of [R-P] into Equation 4.4 then made it possible to 
obtain Ka,R.
9
 The same process was employed for the calculation of Ka,S by using 
Equations 4.5 and 4.6.  The results that were obtained by this process are shown in Table 
4.2. 
 Table 4.2 shows the initial results that were obtained for the 5 μM warfarin/10 μM 
HSA mixture.  This table also lists previous binding constants that have been reported for 
R- and S-warfarin at Sudlow site I of HSA under the same pH and temperature 
conditions.
10
 Under these conditions, the association equilibrium constants that were 
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Table 4.2  Association equilibrium constants for R- and S-warfarin with soluble HSA 
based on a single-site binding model 
 
Sample & Analyte 
               Association equilibrium constant, Ka (M
-1
)
a   
 
Multi-dimensional 
HPAC 
Ultrafiltration 
+ chiral separation 
Literature  
value [Ref. 10] 
Racemic warfarin (5 μM) + HSA (10 μM)     
R-Warfarin 2.0 (± 0.4) ×10
5
 2.1 (± 0.4) ×10
5
 2.1 (± 0.2) ×10
5
 
S-Warfarin 2.4 (± 0.6) ×10
5
 3.2 (± 0.4) ×10
5
 2.6 (± 0.4) ×10
5
 
Racemic warfarin (30 μM) + HSA (600 μM)   
R-Warfarin 1.0 (± 0.4) ×10
5
 1.2 (± 0.4) ×10
5
 2.1 (± 0.2) ×10
5
 
S-Warfarin 1.3 (± 0.2) ×10
5
 0.9 (± 0.1) ×10
5
 2.6 (± 0.4) ×10
5
 
Racemic warfarin (30 μM) + Human serumb   
R-Warfarin 0.6 (± 0.4) ×10
5
 0.7 (± 0.1) ×10
5
 2.1 (± 0.2) ×10
5
 
S-Warfarin 1.6 (± 0.5) ×10
5
 1.1 (± 0.5) ×10
5
 2.6 (± 0.4) ×10
5
 
 
a
These values were measured for the given samples at 37 
o
C in pH 7.4, 0.067 M 
potassium phosphate buffer. The numbers in parentheses represent a range of ±1 S.D. 
(n=3) Values from Ref. 10 were measured under the same conditions by using frontal 
analysis. 
b
The human serum contained approximately 600 M HSA. 
Reproduced with permission from X. Zheng, M.J. Yoo, D.S. Hage, Analyst 138 (2013) 
6262-6265. 
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estimated by multi-dimensional HPAC and the reference methods continued to show 
good agreement at the 95% confidence level with one another and with the literature 
values.  Similar calculations to those used for 5 μM warfarin/10 μM HSA mixture sample 
were carried out for the 30 µM warfarin/600 µM HSA mixture and for the spiked serum 
samples. As shown in Table 4.2, the association equilibrium constants that were obtained 
by multi-dimensional HPAC and the reference approach were again consistent with each 
other; however, the estimated binding constants were 38-71% smaller than the literature 
values.  This latter difference is probably due to the greater uncertainty that was present 
for these samples in the measurement of their relatively small free fractions.  It is also 
possible there were some deviations from a single-site binding model due to greater 
nonspecific interactions by warfarin with the much larger amounts of HSA, and other 
proteins in the case of the serum, in this second group of samples.   
 
Conclusions 
 In summary, it was shown that a multi-dimensional HPAC system that used 
ultrafast affinity extraction in combination with a chiral separation could be used to 
simultaneously measure the free fractions of R- and S-warfarin in serum or drug-protein 
mixtures. This approach was also used to estimate the binding constants for these 
enantiomers with HSA.  The results of this method gave good agreement with a reference 
method that was based on ultrafiltration plus a chiral separation.  However, the multi-
dimensional HPAC method had several potential advantages over ultrafiltration.  For 
instance, this method required only 1 μL of sample per injection and could isolate the free 
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warfarin fractions within 20-30 s of injection.  In comparison, a 1 mL sample was needed 
for ultrafiltration and 1 h was required for the separation of a free drug fraction by this 
approach.  It was also possible to directly couple the ultrafast extraction with a chiral 
separation to automate and complete both steps using a single system.  This approach is 
not limited to warfarin or HSA but could easily be extended to other chiral drugs, or drug 
mixtures, and their binding proteins through the use of similar affinity microcolumns and 
chiral stationary phases. 
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CHAPTER 5 
The Use of Ultrafast Affinity Extraction and Multi-Dimensional HPAC to Study the 
Interactions of Sulfonylurea Drugs with Normal or Glycated Human Serum 
Albumin 
Portion of this chapter have previously appeared in X. Zheng, R. Matsuda, D.S. Hage “Analysis of Free 
Drug Fractions by Ultrafast Affinity Extraction:  Interactions of Sulfonylurea Drugs with Normal or 
Glycated Human Serum Albumin” Journal of Chromatography A 2014, 1371, 82-89. 
 
Introduction 
Diabetes is a disease that is associated with insulin deficiency or glucose 
intolerance, which can both result in elevated levels of glucose in the bloodstream.
1
  
Recent reports by the International Diabetes Federation and the American Diabetes 
Association have indicated that diabetes affects 366 million people in the world and 25.8 
million people in the U.S.
1,2
 Type II diabetes accounts for about 90-95% of the confirmed 
cases of diabetes and results from insulin resistance.
1,2
  Sulfonylurea drugs are commonly 
used to treat type II diabetes by stimulating the release of insulin, thereby decreasing the 
level of glucose in blood.
3
 Figure 5.1 shows the general structure of a sulfonylurea 
drug.
4,5
  Examples of common first-generation sulfonylurea drugs are acetohexamide and 
tolbutamide; second-generation drugs include gliclazide and glibenclamide, which tend to 
be more easily excreted and effective than the first-generation sulfonylurea drugs.
6
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 Figure 5.1 Structures of common sulfonylurea drugs.  The portion within the dashed 
box represents the core structure of these drugs. Reproduced with 
permission from X. Zheng, R. Matsuda, D.S. Hage, J. Chromatogr. A 
1371 (2014) 82-89. 
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Sulfonylurea drugs are highly bound to serum proteins and, in particular, to 
human serum albumin (HSA).
7,8
  HSA is the most abundant serum protein, accounting 
for 60% of the total serum protein content and having a normal concentration of 35-50 
g/L (526-752 μM). 9,10  HSA has a mass of 66.5 kDa and is composed of 585 amino acids.  
HSA functions as a transport protein for many low mass hormones, fatty acids, and drugs 
in the bloodstream.
9
  There are two major drug binding sites on HSA, which are often 
known as Sudlow sites I and II.
9,11,12
   
The elevated levels of glucose in blood during diabetes can result in the non-
enzymatic glycation of proteins.
13-16
 Early stage glycation involves the nucleophilic 
addition of a free amine group on a protein to a reducing sugar (e.g., glucose); advanced 
glycation products can also form through further reactions.
7,18-20
  It has been found that 
there can be a 2- to 5-fold increase in the amount of HSA that is glycated in diabetic 
patients when compared with healthy individuals.
7,21
 Structural investigations of glycated 
HSA have further found that glycation-related modifications can often occur at or near 
Sudlow sites I and II.
22-25
  In addition, glycation has been shown to cause changes in the 
affinity of various sulfonylurea drugs for HSA.
26-34
 Such changes are of concern because 
it has been proposed that they may affect the free, or non-protein bound, and active 
fraction of these drugs in the bloodstream.
7,26,32,34
  
Various methods have been developed in the past to measure free drug 
fractions.
35-44
 Two common methods used for free drug analysis are equilibrium dialysis 
and ultrafiltration.  However, these techniques often require long separation or analysis 
times (ranging from 15-30 min to hours) and relatively large sample volumes (i.e., 
typically in the milliliter range).  In addition, the non-specific adsorption of drugs to the 
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membranes or components of these methods can introduce errors in the free fraction 
measurements.
35,37-41
 Ultrafast affinity extraction is an alternative technique that has been 
used to measure the free and protein-bound forms of drugs and hormones in clinical and 
pharmaceutical samples.
37-40,45-47
 In this method, an affinity microcolumn that contains an 
immobilized binding agent with relatively fast and strong binding for the drug or 
hormone of interest is used to extract the free form of this analyte on a time scale that 
minimizes dissociation of the same analyte from its protein-bound form in the sample.  
The advantages of this approach include its speed, ease of automation, good correlation 
with reference methods, and need for only a small amount of the analyte and protein.
35-45
 
This method has been used to measure the free fractions of thyroxine, warfarin and 
phenytoin in clinical samples.
38-40,45,46
 This technique has also been used to estimate the 
association equilibrium constants for various drugs with normal HSA.
37,47
  In addition, a 
multi-dimensional system combining ultrafast affinity extraction with a chiral stationary 
phase has recently been used to simultaneously measure the free fractions of warfarin 
enantiomers in complex samples.
38
 
This chapter will examine the development and use of ultrafast affinity extraction 
in a multi-dimensional system to measure and compare the free fractions of various 
sulfonylurea drugs in the presence of normal HSA or glycated HSA.  The HSA will be 
glycated in vitro at levels similar to those found in patients with prediabetes or diabetes.  
Various factors, such as column size and flow rate, will be considered in the optimization 
of this system for determining the free fractions of sulfonylurea drugs.  The system will 
then be used to measure the free fractions and global affinity constants for these drugs 
with normal HSA or glycated HSA by using samples that have been prepared at typical 
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therapeutic or physiological concentrations of these drugs and proteins.  The results will 
provide insight concerning how glycation may alter the free fractions of sulfonylurea 
drugs in the circulatory system.  The same results will also provide valuable information 
as to how ultrafast affinity extraction can be modified and developed for use in the study 
of drug-protein interactions at clinically-relevant concentrations.    
 
Experimental  
Materials and reagents 
 The HSA (Cohn fraction V, essentially fatty acid free, ≥ 96% pure), tolbutamide, 
acetohexamide, gliclazide, and glibenclamide were from Sigma (St. Louis, MO, USA).  
The reagents for the bicinchoninic acid (BCA) protein assay were obtained from Pierce 
(Rockford, IL, USA).  The Nucleosil Si-300 silica (7 μm particle diameter, 300 Å pore 
size) was from Macherey Nagel (Dűren, Germany).  All buffers and aqueous solutions 
were prepared using water from a NANOpure system (Barnstead, Dubuque, IA, USA) 
and were passed through Osmonics 0.22 μm nylon filters from Fisher Scientific 
(Pittsburgh, PA, USA).   
 
Apparatus 
The microcolumns used in this chapter were packed using a Prep 24 pump from 
ChromTech (Apple Valley, MN, USA).  The HPLC system was comprised of a PU-2080 
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Plus pump, AS-2057 autosampler, and UV-2075 absorbance detector from Jasco (Easton, 
MD, USA), plus a six-port Lab Pro valve (Rheodyne, Cotati, CA, USA).  An Alltech 
water jacket (Deerfield, IL, USA) and an Isotemp 3013D circulating water bath from 
Fisher Scientific were used to maintain a temperature of 37.0 (± 0.1) °C for the columns 
during all experiments in this chapter.  ChromNAV v1.18.04 software and LCNet from 
Jasco were used to control the system.  Chromatograms were analyzed through the use of 
PeakFit v4.12 software (Jandel Scientific, San Rafael, CA, USA). 
 
Column preparation and protein glycation 
Two batches of glycated HSA with different levels of glycation were prepared in 
vitro as described previously.
29,31
 These glycated HSA samples (referred to later in this 
paper as gHSA1 and gHSA2) were made by incubating normal HSA at 37 
o
C and over 
four weeks with either moderate or high levels of D-glucose (i.e., 5 or 10 mM) in sterile 
pH 7.4, 0.067 M phosphate buffer.  The resulting protein solutions were lyophilized and 
stored at -80 
o
C until use.  The glycation levels of these modified proteins were 
determined by using a fructosamine assay from Diazyme Laboratories (San Diego, CA, 
USA), as described in Refs. 29,31.  The glycation levels measured for the normal HSA, 
gHSA1 and gHSA2 samples were 0.24 (± 0.15), 1.39 (± 0.28) and 3.20 (± 0.13) mol 
hexose/mol HSA, respectively.   
Normal HSA was immobilized to Nucleosil Si-300 silica for use as a stationary 
phase in ultrafast affinity extraction and the multi-dimensional affinity system.  This 
immobilization was carried out by using the Schiff base method, as described in Ref. 48.  
A control support, in which no HSA was added during the immobilization step, was 
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prepared by the same process.  A BCA assay was used, according to instructions 
provided by the manufacturer of this assay, to determine the protein content of the final 
HSA support by using HSA as the standard and the control support as the blank.
29-34
 This 
assay gave a protein content of 65 (± 2) mg HSA/g silica.  
Affinity columns with lengths of 5 to 25 mm and 2.1 mm i.d. were packed into 
standard stainless steel housings by using pH 7.4, 0.067 M potassium phosphate buffer as 
the packing solution.  The affinity columns with a length of 1 mm and 2.1 mm i.d. were 
packed in a similar manner but used a frit-in-column design, as described in Ref. 49.  The 
packing pressure was 4000 psi (28 MPa) for the 10 or 25 mm long columns and 3000 psi 
(20 MPa) for the 1 mm or 5 mm long columns.  These columns were stored in pH 7.4, 
0.067 M potassium phosphate buffer at 4 
o
C when not in use. 
 
Chromatographic studies 
The multi-dimensional affinity system had two HSA columns that could be 
connected in series through the use of a six-port valve, as has been shown in Chapter 4.
38
  
In this system, which is illustrated in Figure 5.2, an HSA microcolumn was first used to 
extract a free drug fraction from a sample.  A second HSA column was then placed on-
line with the first column to further separate the extracted fraction from other sample 
components (e.g., drug that had dissociated from proteins in the sample during passage 
through the first column).  The mobile phase for both columns was pH 7.4, 0.067 M 
potassium phosphate buffer.  All samples containing sulfonylurea drugs were dissolved in 
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Figure 5.2  General scheme for the separation of the free and protein-bound fractions 
of a drug in a sample and measurement of the free drug fraction through 
the use of ultrafast affinity extraction and a multi-dimensional affinity 
system. Reproduced with permission from X. Zheng, R. Matsuda, D.S. 
Hage, J. Chromatogr. A 1371 (2014) 82-89. 
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this buffer.  The mixtures of the drugs and normal HSA or glycated HSA were prepared 
by dissolving each protein in the corresponding drug solutions.  These drug/protein 
mixtures were incubated for at least 30 min at 37 ºC before injection to allow equilibrium 
to be established between the free and protein-bound fractions of the drug in the 
sample.
37 
 Replicate injections (n = 4) were made for all samples and standards onto the 
system.  The concentrations of the drugs in the tested samples were representative of the 
therapeutic ranges for these agents (i.e., 184-370 μM for tolbutamide, 61-216 μM for 
acetohexamide, 15-31 μM for gliclazide, and 0.08-0.4 μM for glibenclamide).50,51  The 
samples also contained concentrations of normal HSA or glycated HSA that were 
representative of the physiological levels of this protein (i.e., 526-752 μM).50  
The column sizes and flow rates that were used for ultrafast affinity extraction 
were determined as described in next section.  The HSA microcolumns that were used for 
this purpose in the final system had the following dimensions: 5 mm × 2.1 mm i.d. for 
tolbutamide and acetohexamide, 10 mm × 2.1 mm i.d. for gliclazide, and 1 mm × 2.1 mm 
i.d. for glibenclamide.  A 1.0 L sample injection was made onto each of these HSA 
microcolumns at an initial flow rate of 2.25 mL/min for tolbutamide, 2.5 mL/min for 
acetohexamide, 2.5 mL/min for gliclazide, and 0.35 mL/min for glibenclamide during 
extraction of the free drug fractions.  The valve to which these microcolumns were 
connected was then placed on-line with the second HSA column at 1.5 min after injection 
for tolbutamide, 2.2 min for acetohexamide, 0.85 for gliclazide, and 5.0 min for 
glibenclamide.  The flow rate was changed at the same time to 0.50, 0.75, 0.50 or 0.25 
mL/min, respectively, for the second portion of the separation.  The size of the second 
HSA column was 10 mm × 2.1 mm i.d. for tolbutamide and acetohexamide, 25 mm × 2.1 
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mm i.d. for gliclazide, and 5 mm × 2.1 mm i.d. for glibenclamide.  The following 
wavelengths were employed for absorbance detection: 227 nm for tolbutamide, 248 nm 
for acetohexamide, 226 nm for gliclazide, and 302 nm for glibenclamide.  The free drug 
concentration was determined by comparing the resulting peak area to those obtained for 
standards containing only the drug.  The free fraction was calculated by dividing the free 
drug concentration by the total concentration of the drug in the sample.
37,38,47
 
 
Results and Discussion 
Optimization of conditions for ultrafast affinity extraction 
 The residence time for the sample in the extraction column is one factor to 
consider when using ultrafast affinity extraction to isolate a free drug fraction.  One way 
this factor can be adjusted is by altering the column size that is used for the extraction 
process.
37,38,47
  A relatively short column will provide a smaller column residence time 
than a longer column operated at the same flow rate.  A shorter column will also have a 
lower backpressure, allowing work at higher flow rates, while a longer column size 
should provide higher retention and a better separation of the free drug fraction from 
other sample components.
37,47
  
 The HSA microcolumns that were used in this chapter for ultrafast affinity 
extraction had sizes of 1-10 mm × 2.1 mm i.d.  These microcolumns were used at flow 
rates up to 3.5 mL/min, giving column backpressures of 1.9-3.2 MPa or less under these 
conditions.  The ultrafast affinity extractions that were conducted with gliclazide, which 
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has relatively weak binding to HSA,
33,47
 used 10 mm × 2.1 mm i.d. microcolumns.  The 
other drugs that were considered, which have stronger binding to HSA,
30-34
 were 
examined by using 5 mm × 2.1 mm i.d. microcolumns (e.g., for acetohexamide and 
tolbutamide) or even 1 mm × 2.1 mm i.d. microcolumns (for glibenclamide).   
 The flow rate that was used for ultrafast affinity extraction was also adjusted to 
control the sample residence time in the affinity microcolumns (e.g., see Figure 5.3).  
Low-to-moderate injection flow rates can result in some dissociation of a drug from its 
complexes with proteins in the sample, giving an apparent free fraction that is higher than 
what was present in the original sample.
37-39,46,47
  However, this effect can be minimized 
or made negligible when the flow rate is raised above a certain threshold level, which 
typically occurs when the sample residence time in the column is on the order of a few 
hundred milliseconds (ms).
37-39,47
 The size of this effect will vary from one drug to the 
next, as is shown in Figure 5.3, and depends on such factors as the rate of dissociation of 
the drug from the soluble proteins and the degree of drug-protein binding that was present 
in the original sample.
47
 
 Experiments were conducted early in this work to identify the flow rate conditions 
that could be used during ultrafast affinity extraction to measure the free fractions of 
sulfonylurea drugs in the presence of soluble HSA.  These initial studies were carried out 
by injecting 1.0 L samples that contained 5-10 M of the desired drug or a mixture 
containing 5-10 M of this drug and 5-20 M of normal HSA.  Some typical results are 
given in Figure 5.3.  It was found for tolbutamide that a consistent free drug fraction was 
obtained when using a minimum flow rate of 2.0 mL/min for sample injections on a 5 
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Figure 5.3  Effect of injection flow rate on ultrafast affinity extraction of the free 
fractions for various sulfonylurea drugs.  The results were obtained at pH 
7.4 and 37 oC for 1.0 μL injections of (a) 10 µM tolbutamide in the 
presence of 20 µM HSA and injected onto a 5 mm × 2.1 mm i.d. HSA 
microcolumn, (b) 10 µM acetohexamide in the presence of 20 µM HSA 
and injected onto a 5 mm × 2.1 mm i.d. HSA microcolumn, (c) 10 µM 
gliclazide in the presence of 20 µM HSA and injected onto a 10 mm × 2.1 
mm i.d. HSA microcolumn, or (d) 5 µM glibenclamide in the presence of 
5 µM HSA and injected onto a 1 mm × 2.1 mm i.d. HSA microcolumn.  
The values shown for the free fraction on the y-axis have no units, because 
they represent the ratio of the free drug concentration vs. the total 
concentration of the same drug in each sample. Reproduced with 
permission from X. Zheng, R. Matsuda, D.S. Hage, J. Chromatogr. A 
1371 (2014) 82-89. 
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mm × 2.1 mm i.d. HSA microcolumn (i.e., a column residence time of 415 ms or less).  
Similar experiments with the other sulfonylurea drugs provided the following conditions 
for their ultrafast affinity extraction: acetohexamide, 2.5 mL/min or greater when using a 
5 mm × 2.1 mm i.d. HSA microcolumn; gliclazide, 2.5 mL/min or greater when using a 
10 mm × 2.1 mm i.d. HSA microcolumn; and glibenclamide, 0.30 mL/min or greater 
when using a 1 mm × 2.1 mm i.d. HSA microcolumn.  These conditions for 
acetohexamide, gliclazide and glibenclamide corresponded to maximum column 
residence times during the extraction process of 333 ms, 665 ms and 554 ms, respectively.  
This range of residence times was in good agreement with previous kinetic studies or 
extraction experiments that have used some of the same analytes or drugs with similar 
affinities for HSA.
37-39,47
 
Figure 5.4(a) shows some typical chromatograms that were obtained when using a 
HSA microcolumn for the ultrafast affinity extraction of tolbutamide.  These results were 
generated by using samples containing a therapeutic level of tolbutamide, in the absence 
or presence of a physiological concentration of HSA, and which were injected onto a 5 
mm × 2.1 mm i.d. HSA microcolumn at 2.25 mL/min.  In this example, the non-retained 
peak for the soluble protein and drug-protein complex appeared within 30-40 sec (s) of 
injection (Note: injections of only HSA or glycated HSA produced similar non-retained 
peaks).  The peak for the retained, free fraction of tolbutamide had a maximum that 
appeared at 50-55 s and eluted within 2 min from the HSA microcolumn.  Similar 
chromatograms were generated for gliclazide, acetohexamide, and glibenclamide at 
therapeutically-relevant concentrations.  The non-retained peaks for these other drugs 
occurred within 0.3-0.6 min (at 2.5 mL/min) or within 3.0 min (at 0.35 mL/min), 
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respectively.  The retained peaks for these other drugs had maxima occurring at 40-45 s, 
65-70 s, or 8.0-8.3 min and eluted within 1.5-2.0 min, 3.5-4.0 min or 13-15 min under the 
final conditions that were employed for ultrafast affinity extraction.   
 
Optimization of conditions for multi-dimensional affinity system 
Baseline resolution was not obtained between the non-retained and retained peaks 
for most of the sulfonylurea drugs when using only a single HSA microcolumn.  This 
issue was overcome by using a multi-dimensional system with a second HSA column that 
was placed on-line after the free drug fraction had begun to elute from the first column.  
Figure 5.4(b) shows some chromatograms that were generated during the second part of 
this separation.  The additional column helped to improve resolution of the retained free 
drug fraction from other sample components, including any drug that had been released 
from drug-protein complexes in the sample during passage through the first column.  
 The results in Figure 5.4(b) were obtained for samples containing 185 µM 
tolbutamide/526 µM HSA and using various times for switching the second column on-
line with the first HSA microcolumn.  A single retained peak was recovered and observed 
for tolbutamide on this multi-dimensional affinity system.  This peak had a maximum 
that appeared at 7.8-8.4 min after sample injection, as acquired at a flow rate of 0.50 
ml/min when the second HSA column was placed on-line and this column that had a size 
of 10 mm × 2.1 mm i.d.  Similar chromatograms were observed for acetohexamide, 
gliclazide and glibenclamide, which gave peaks with maxima at 10.0-10.5 min (final flow 
rate, 0.75 mL/min; second HSA column size, 10 mm × 2.1 mm i.d.), 8.4-8.6 min (0.50 
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Figure 5.4. Typical chromatograms obtained at pH 7.4 and 37 oC on (a) a 5 mm × 2.1 
mm i.d. HSA microcolumn at 2.25 mL/min for 1 μL injections of 185 µM 
tolbutamide in the absence or presence of 526 µM HSA, or (b) the 
retained peak obtained on a 10 mm× 2.1 mm i.d. HSA column at 0.5 
mL/min and that was put in line with the first 5 mm × 2.1 mm i.d. HSA 
microcolumn after various times following injection of a 1 μL sample 185 
µM tolbutamide/526 µM HSA onto the first column at 2.25 mL/min.  The 
change in signal at 5-10 s for the chromatogram in (a) for only 
tolbutamide was due to a temporary change in pressure that occurred when 
the sample was injected onto the system. Reproduced with permission 
from X. Zheng, R. Matsuda, D.S. Hage, J. Chromatogr. A 1371 (2014) 82-
89. 
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mL/min; 25 mm × 2.1 mm i.d.), and 27.2-27.7 min (0.25 mL/min; 5 mm × 2.1 mm i.d.), 
respectively.  The flow rate and column conditions that were utilized for the second part 
of this multi-dimensional system were again selected based on the retention of each drug 
on the HSA columns, the backpressures of these columns, and the overall time of 
analysis. 
 The time at which the second column was placed on-line with the first column 
after sample injection was an important factor to consider when measuring small free 
drug fractions on the multi-dimensional affinity system.  Figure 5.5 shows how the peak 
area and apparent free drug fraction changed for acetohexamide as the time of this switch 
was varied.  Similar trends were noted for the other drugs that were examined in this 
chapter.  The time of this switching event occurred within the time frame that the free 
drug peak eluted from the first column.  As this switching time was increased, the total 
peak area (i.e., a measure of the recovery) seen for the drug on the second column 
decreased, as demonstrated in Figure 5.5(a).  This effect occurred because less of the 
retained peak from the first column was passed onto the second column at longer 
switching times.  A correction for this effect was made by comparing the peak areas for 
the free drugs that were captured from samples to the peak areas that were obtained on 
the same system for standards with known concentrations of these drugs.   
 Less contamination due to other sample components, including drugs that had 
dissociated from proteins in the sample during ultrafast affinity extraction, also occurred 
as the switching time was increased.  This effect resulted in the apparent free fraction 
dropping and approaching a constant value as the switching time was increased.  In 
Figure 5.5(b), the measured free fraction became a consistent value when a switching  
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Figure 5.5 Effect of valve switching time on (a) the area of the final peak observed 
for a 138 µM acetohexamide sample that was applied to the multi-
dimensional affinity system, and (b) the apparent free fractions that were 
measured by this system for a sample that contained 138 µM 
acetohexamide and 640 µM HSA.  These measurements were all made at 
pH 7.4 and 37 oC using a 5 mm × 2.1 mm i.d. HSA column operated at 2.5 
mL/min, followed by the on-line addition of a 10 mm × 2.1 mm i.d. HSA 
column and the use of a flow rate of 0.75 mL/min at the given switching 
times.  The error bars represent a range of ± 1 standard error of the mean 
(n = 4).  The times shown for the valve switching event represent the time 
that has elapsed since sample injection, and were selected to be beyond the 
elution time for the non-retained sample components leaving the first, 
affinity microcolumn in this system. Reproduced with permission from X. 
Zheng, R. Matsuda, D.S. Hage, J. Chromatogr. A 1371 (2014) 82-89. 
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time of 2.2 min or longer was used for acetohexamide.  However, there was also a loss of 
precision in the measured free fraction if the switching time was too long because only a 
small amount of the free drug was then being passed onto the second column.  This latter 
effect occurred in Figure 5.5(b) at switching times longer than 2.3 min.  The combination 
of these effects meant that there was a relatively well-defined window of times for the 
switching event that could be used to provide both reasonable accuracy and precision for 
free fraction measurements in the multi-dimensional affinity system.  Based on these 
criteria and similar plots to those Figure 5.5(b) for the other drugs that were examined, 
the switching times that were used in all later parts of this chapter were 2.2 min for 
acetohexamide, 1.5 min for tolbutamide, 0.85 min for gliclazide, and 5.0 min for 
glibenclamide.  
 
Measurement of free fractions for sulfonylurea drugs 
The next part of this project examined the use of ultrafast affinity extraction and 
the multi-dimensional system to measure the free fractions of various sulfonylurea drugs 
in the presence of normal HSA or glycated HSA at typical therapeutic or physiological 
levels for these agents.  Table 5.1 summarizes the results of these measurements.  This 
approach was found to be useful in reliably measuring small free drug fractions (e.g., 
values as small as 0.09% to 2.58%).  This method had a good absolute precision for these 
values (± 0.02-0.5%) and a reasonable relative precision (± 3.6-30%).  These free drug 
fractions also agreed with predicted values based on previously-measured binding 
constants for the same drugs with similar protein preparations (see Table 5.2).
30-34
  In 
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Table 5.1  Free drug fractions measured for various sulfonylurea drugs in the 
presence of normal HSA or glycated HSA (gHSA) 
   Drug and sample Measured free fraction
a
 
 Normal HSA      gHSA1      gHSA2 
Tolbutamide (275 μM) 
+ HSA (640 μM) 
2.58 (± 0.31)% 2.20 (± 0.08)%
b
 1.58 (± 0.09)%
c 
Acetohexamide (138 μM)  
+ HSA (640 μM) 
1.18 (± 0.35)%  1.53 (± 0.27)%
 
  1.41 (± 0.16)%
 
  
Gliclazide (23 μM)  
+ HSA (640 μM) 
2.17 (± 0.29)% 2.48 (± 0.51)%
 
 1.27 (± 0.31)%
c
 
Glibenclamide (0.4 μM)        0.09 (± 0.02)%      0.11 (± 0.03)%       0.14 (± 0.02)%d  
 + HSA (526 μM) 
 
a
These free drug fraction values were determined at pH 7.4 and 37 
o
C by using ultrafast affinity 
extraction and a multi-dimensional affinity system.  The values in parentheses represent a range 
of ± 1 S.D. (n = 4), as determined by error propagation. 
b
This value was significantly different from the result for normal HSA at the 90% confidence 
level but not the 95% confidence level. 
c
This value was significantly different from the results for normal HSA and gHSA1 at the 95% 
confidence level. 
d
This value was significantly different from the results for normal HSA at the 95% confidence 
level and from gHSA1 at the 90% but not the 95% confidence level. 
Reproduced with permission from X. Zheng, R. Matsuda, D.S. Hage, J. Chromatogr. A 1371 
(2014) 82-89. 
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addition, these results gave good correlation with free fractions that were determined for 
some of the same samples when using ultrafiltration as a reference. 
The sulfonylurea drugs that were used in this study are known to have strong 
binding to HSA and to have only small free fractions in serum.
7,8
 The free fractions in 
Table 5.1 show how this biologically-active fraction can be only a few percent of the total 
drug content in serum at therapeutic concentrations.  These results further show how the 
size of this fraction can vary with the type of sulfonylurea drug that is being administered.  
These differences are directly related to the affinities of these drugs for HSA (see Table 
5.2) and their total therapeutic concentrations.        
The results in Table 5.1 made it further possible to compare the free fractions that 
were seen for each drug in the presence of normal HSA or HSA with glycation levels 
similar to those seen in prediabetes (gHSA1) or diabetes (gHSA2).  It was found that the 
level of this glycation and the type of drug that was being examined both affected the 
change that was noted in the free fraction.  For example, going from normal HSA to 
gHSA1 (which had only a modest level of glycation) produced a possible 0.85- to 1.30-
fold change in the free fractions for these sulfonylurea drugs.  This level of variation was 
not significant at the 95% confidence level and was only significant at the 90% 
confidence level for tolbutamide.  However, going from normal HSA to gHSA2 gave 
changes of 0.59- to 1.56-fold for tolbutamide, glibenclamide, and gliclazide, which were 
all significant at the 95% confidence level.  Acetohexamide was the only exception, 
which gave only a 1.19-fold change between normal HSA and gHSA2 that was not 
significant.  Similar trends were seen when comparing the free fractions measured in the 
presence of gHSA1 versus gHSA2.   
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These variations agree with a previous estimate that HSA glycation may lead to a 
0.6- to 1.7-fold change in the free drug fractions for these sulfonylurea drugs (i.e., as 
based on prior binding studies using both in vitro and in vivo glycated HSA).
7,26
 Such 
changes in binding have been attributed to variations in the amount and types of 
glycation-related modifications that are formed at or near specific regions on HSA (e.g., 
Sudlow sites I and II) as the overall level of glycation for this protein is increased.
22-25
 
These variations in the free fractions of sulfonylurea drugs are of concern in that they 
represent a large difference in the actual versus expected dosage of such drugs, with the 
possible result being either inadequate control of elevated glucose levels (i.e., 
hyperglycemia) or the production of low glucose levels (hypoglycemia) in patients
7
 
 
Estimation of affinity for sulfonylurea drugs with normal HSA or glycated HSA 
The free fraction results that were obtained by ultrafast affinity extraction and the 
multi-dimensional affinity system were also used to estimate overall affinities of the 
sulfonylurea drugs with normal HSA or glycated HSA.  It is known that these drugs each 
have at least two major binding regions on HSA,
7,27,30-34
 so in this case the free fractions 
were used to calculate a global affinity constant (nKa’) for these interactions.  These 
global affinity constants were determined by using Equation 5.1, which can provide 
either the association equilibrium constant (Ka) for a system with single-site binding or 
the global affinity constant for a system involving multiple and independent binding 
regions.
37,38,47
 
  
221 
221 
𝐾a =
1− 0
 0([P]−[ ]+[ ] 0)
             (5.1) 
In this equation, [D] and [P] are the total concentrations of the drug and soluble protein in 
the original sample, while F0 is the free fraction measured for the drug in this sample.   
Table 5.2 shows the values of nKa’ that were found by using Equation 5.1 and the 
free fractions from Table 5.1 for the sulfonylurea drugs with normal HSA or glycated 
HSA.  No significant changes in these values were noted when varying the drug or 
protein concentration within the therapeutic or physiological range of these agents.  As an 
example, the use of samples that contained 185 µM tolbutamide and 526 µM HSA, 185 
µM tolbutamide and 752 µM HSA, 370 µM tolbutamide and 526 µM HSA, or 370 µM 
tolbutamide and 752 µM HSA all gave estimates for nKa’ that were in the range of 0.95-
1.08 × 10
5
 M
-1
.  This indicated there was a negligible effect of sample concentration on 
the global affinity constants that were estimated through ultrafast affinity extraction.  A 
similar conclusion has been reached in the use of this approach with other drug/protein 
systems at non-therapeutic concentrations.
47
  
The values in Table 5.2 agreed well with global affinity constants that were 
determined through previous binding data acquired for the same drugs and using 
comparable preparations of glycated HSA.
30-34
 The values estimated by ultrafast affinity 
extraction and the multi-dimensional affinity system had a relative precision of ± 6-29% 
and differed from these literature results by only 0-22% (average difference, 7%).  These 
global affinity constants also agreed with values that were determined for some of the 
same samples by using ultrafiltration. For instance, the nKa’ values obtained by 
ultrafiltration for acetohexamide with the same preparations of HSA and glycated HSA 
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Table 5.2  Global equilibrium constants estimated for sulfonylurea drugs with normal HSA or glycated HSA (gHSA)
a
 
 
Drug & Sample 
Global affinity constant, nKa (× 10
5
 
M
-1
) 
Normal HSA Literature value
b
 gHSA1
c 
Literature value
b
 gHSA2
d 
Literature value
b
 
Tolbutamide (275 μM) + HSA (640 μM) 1.0 (± 0.1) 1.1 (± 0.1) 1.2 (± 0.1) 1.3 (± 0.1) 1.7 (± 0.1) 1.4 (± 0.1) 
 Acetohexamide (138 μM) + HSA (640 μM) 1.7 (± 0.5) 1.7 (± 0.1) 1.3 (± 0.2) 1.4 (± 0.1) 1.4 (± 0.1) 1.5 (± 0.1) 
Gliclazide (23 μM) + HSA (640 μM) 0.73 (± 0.10) 0.79 (± 0.05) 0.64 (± 0.13) 0.64 (± 0.05) 1.26 (± 0.31) 1.12 (± 0.07) 
Glibenclamide  (0.4 μM) + HSA (526 μM) 21.1 (± 4.7) 21.6 (± 8.0) 17.3 (± 4.7) 18.9 (± 8.0) 13.6 (± 1.9) 13.7 (± 4.0) 
a
The global affinity constants from this study are based on the free drug fractions listed in Table 5.1.  All of the values in this table are for drug-protein binding 
that occurs at pH 7.4 and 37 
o
C.  The values in parentheses represent a range of ± 1 S.D. (n = 4), as determined by error propagation.   
b
The global affinity constants from the literature were calculated by using the association equilibrium constants and binding stoichiometries that had been 
measured for these drugs at Sudlow sites I and II,
30-34
 as well as at the digitoxin site in the case of glibenclamide.
34
  A similar range of values has been reported in 
Ref. 28.  
c
The level of glycation for gHSA1 was similar to that of an in vitro glycated HSA sample that was used in the previous binding studies and that contained 1.31 (± 
0.05) mol hexose/mol HSA).
29,31-34
 
d
The glycation level for gHSA2 was between the glycation levels for two in vitro glycated HSA samples that were used in previous binding studies and that 
contained 2.34 (± 0.13) or 3.34 (± 0.14) mol hexose/mol HSA.
29,31-34
 
Reproduced with permission from X. Zheng, R. Matsuda, D.S. Hage, J. Chromatogr. A 1371 (2014) 82-89. 
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differed by only 0-7.7% (average difference, 4.5%) from the results shown in Table 5.2 
based on ultrafast affinity extraction. 
 
Conclusions 
This study examined the use and development of ultrafast affinity extraction and a 
multi-dimensional affinity system for measuring free drug fractions at therapeutic levels. 
This approach was then used to compare the free fractions and global affinity constants of 
several sulfonylurea drugs in the presence of normal HSA or glycated HSA.  Factors that 
were considered in the optimization of this approach included the column size, flow rate 
and column residence times that could be used with sulfonylurea drugs during ultrafast 
affinity extraction with an HSA microcolumn.  The flow rate and column size used for 
the second affinity column in the system were also considered, as well as the time at 
which this second column was placed on-line with the HSA microcolumn.  This system 
was a general one that could also be adapted for use in coupling an HSA microcolumn 
with other types of analytical columns, such as those containing reversed-phase, ion-
exchange or size-exclusion supports.  These latter types of columns will be considered in 
future work as this approach is further optimized or extended to more complex mixtures 
of free solutes (e.g., mixtures of drugs or drugs and their metabolites).     
This approach holds several advantages.  First, the use of affinity microcolumns 
containing HSA, which has both fast and relatively strong binding to sulfonlyurea drugs, 
made it possible to isolate the free fractions of these drugs under time conditions that 
minimized dissociation of the protein-bound fractions of the same drugs as the samples 
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passed through the microcolumns.
37-40,45-47
 Given the relatively fast rate of these 
dissociation processes, such a separation would be difficult to obtain by using a more 
conventional reversed-phase or size-exclusion column.
36,37,40,46,47,52
 Another advantage of 
using an HSA microcolumn for these free drug measurements is that the same 
immobilized agent, which binds to many pharmaceuticals, could be used for all of the 
drugs of interest in this study.  In addition, the mobile phase for this column was an 
aqueous buffer with a physiological pH, which should not have significantly affected the 
drug-protein interactions in the original samples.  Finally, the use of these microcolumns 
for free drug measurements required only 1.0 µL of sample per injection and was able to 
measure free drug fractions as small as 0.09-2.58% with an absolute precision of ± 0.02-
0.5%.   
The free drug fractions and global affinity constants that were determined by this 
approach showed good agreement with those predicted from previous binding studies or 
determined through a reference method.  This technique was used to examine the possible 
effects of glycation on the binding of sulfonylurea drugs to HSA.  It was found that 
glycation could affect the free fractions of sulfonylurea drugs at typical therapeutic levels 
and that the size of this effect varied with the level of HSA glycation.  The same multi-
dimensional approach could be utilized to examine other drug-protein systems.  Possible 
future applications include the clinical analysis of free drug or hormone levels for disease 
diagnosis or treatment 
38-40,45,46
 and the high-throughput screening of drug-protein 
interactions.
36-38,47
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CHAPTER 6 
The Use of Ultrafast Affinity Extraction for Free Fraction Measurements of Various 
Drugs in Clinical Samples  
Portion of this chapter appear in X. Zheng, M. Podariu, D.S. Hage “Analysis of Free Drug Fractions in 
Human Serum by Ultrafast Affinity Extraction” Analytical and Bioanalytical Chemistry 2015, submitted. 
 
Introduction 
 Human serum albumin (HSA) is the most abundant transport protein in blood, 
with a normal concentration of 35-50 g/L (or 526-752 μM).1,2  This protein can bind to 
and transport many drugs through reversible interactions.  These interactions, in turn, can 
affect such processes as drug metabolism, absorption, distribution and excretion.
3,4
  For 
instance, this binding leads to the creation of both a protein-bound fraction of the drug 
and a free (or non-bound) fraction.  The free fraction for many drugs is generally 
considered to be the active form because it is this form that can cross cell membranes or 
bind to receptors.
2,3,5
   
 These features make the measurement of free drug fractions and the study of 
drug-protein interactions in serum of interest when characterizing both existing drugs and 
new drug candidates.
5-8
  However, the isolation and measurement of free drug fractions in 
serum can be difficult due to the many chemicals that are present in such a sample.
5,9-11
  
In addition, the free fraction may be only a small part of the total amount of drug that is 
present.  This means it must be possible to measure a relatively small concentration for 
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this fraction in the presence of a much larger concentration for the corresponding protein 
and protein-bound fraction.
5-11
   
 Two common methods that are used to measure free drug fractions are 
ultrafiltration and equilibrium dialysis.
7,8,12,13  
Unfortunately, these methods typically 
require relatively long separation or analysis times and need moderate-to-large amounts 
of sample.  The adsorption of drugs to the membranes or other system components that 
are used in these methods also must be considered to avoid introducing errors into the 
final free fraction values.
7,8,12,13  
Many other analytical methods have also been employed 
to study drug-protein interactions.
14-16
  Examples are surface plasmon resonance, 
capillary electrophoresis, and nuclear magnetic resonance spectroscopy, as well as 
equilibrium dialysis and ultrafiltration.
1,7,8,11-14,17-27
  However, many of these techniques 
employ simple aqueous samples for drug-protein interaction studies and can be difficult 
to use directly with a complex sample such as serum.
18-20,24
   
 Alternative techniques based on ultrafast affinity extraction have recently been 
developed to measure free drug fractions and to estimate binding parameters for drug-
protein interactions in solution.
3,7,8,10,11,24,28,29
  In this approach, the free drug fraction is 
rapidly extracted from a sample by using a small affinity column that contains a binding 
agent for the drug of interest.  This free fraction is then measured directly as it elutes 
form the affinity microcolumn
3,10,24
 or indirectly through the use of a method such as an 
on-line displacement immunoassay.
7,28,29
  Ultrafast affinity extraction has been used in 
combination with a chiral separation to simultaneous analyze the free fractions for both 
warfarin enantiomers (i.e., a drug with strong binding to HSA).
10
 Affinity microcolumns 
for ultrafast affinity extraction have also recently been combined with longer affinity 
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columns to measure the free forms of various drugs in aqueous protein solutions.
11  
In this 
latter method, an affinity microcolumn is first used to extract the free drug fraction from a 
sample, while the second column is used to further separate this free fraction from 
possible contaminants (e.g., drug that has dissociated from proteins in the sample) prior 
to measurement of the free fraction.
11
 
 In this chapter, ultrafast affinity extraction and a multi-dimensional system will be 
adapted and used to directly measure the free fractions for various drugs and to study 
drug-protein interactions in human serum. Several factors will be considered in 
modifying technique for use with serum. These factors will include the flow rate and 
column size that are used to isolate the free drug fraction, as well as the conditions that 
are employed to couple ultrafast affinity extraction with a second affinity column for 
further separation and measurement of the free fraction.
3,11
 The ability of this method to 
estimate the overall affinity of drug-protein binding in serum will also be explored. The 
results should provide important information on the relative advantages or potential 
limitations of using ultrafast affinity extraction for examining free drug fractions and 
drug-protein binding directly in biological samples. This information, in turn, should 
allow the future adaptation of this technique for work with other drugs, proteins or 
samples of interest in clinical chemistry, pharmaceutical science or biomedical research. 
1-6
 
 
Experimental 
Materials and reagents  
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 The HSA (Cohn fraction V, essentially fatty acid free, ≥ 96% pure), human serum 
(from male AB plasma, H4522, lot 039K0728; sterile filtered and tested negative for 
HIV-1/2 and hepatitis B/C), tolbutamide, acetohexamide, gliclazide, diazepam and 
quinidine were from Sigma Aldrich (St. Louis, MO, USA).  The reagents for the 
bicinchoninic acid (BCA) protein assay were purchased from Pierce (Rockford, IL, USA).  
The Nucleosil Si-300 silica (300 Å pore size, 7 μm particle diameter) was from Macherey 
Nagel (Dűren, Germany).  All buffers and aqueous solutions were prepared using water 
from a Milli-Q Advantage A 10 system (EDM Millipore Corporation, Billerica, MA, 
USA) and were passed through Osmonics 0.22 μm nylon filters from Fisher (Pittsburgh, 
PA, USA). 
 
Apparatus 
A Prep 24 pump from ChromTech (Apple Valley, MN, USA) was used to pack 
the columns that were used in this chapter.  The chromatographic system included a PU-
2080 Plus pump, an AS-2057 autosampler, and a UV-2075 absorbance detector from 
Jasco (Easton, MD, USA), plus a six-port LabPro valve from Rheodyne (Cotati, CA, 
USA).  This system was controlled by ChromNAV v1.18.04 software and LCNet from 
Jasco.  A CHM column heater and a TCM column heater controller from Waters (Milford, 
MA, USA) were used to maintain a temperature of 37.0 (± 0.1) 
°
C for the columns during 
all experiments.  Chromatograms were analyzed by utilizing PeakFit v4.12 software 
(Jandel Scientific, San Rafael, CA, USA). A temperature-controlled 5702RH centrifuge 
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from Fisher was used in the ultrafiltration studies, along with Ultracel YM-T cellulose 
membranes (30 kDa, cut-off) that were purchased from EDM Millipore. 
 
Column preparation 
The support and stationary phase used in this chapter consisted of Nucleosil Si-
300 silica that had been converted into a diol-bonded form and used to immobilize HSA 
by the Schiff base method, as described in Ref. 30.  A control support, in which no HSA 
was added during the immobilization step, was prepared by the same process.  The 
protein content of the final HSA support was determined in quadruplicate through a BCA 
assay by using HSA as the standard and the control support as the blank.
31-35
  This assay 
gave a content of 59 (± 1) mg HSA/g silica.  
Affinity columns with sizes of 5 × 2.1 mm i.d., 10 × 2.1 mm i.d., 20 mm × 2.1 
mm i.d., and 25 mm × 2.1 mm i.d. were packed into standard stainless steel housings 
using pH 7.4, 0.067 M potassium phosphate buffer as the packing solution.  Guard 
columns with a size of 1 mm × 2.1 mm i.d. were packed in a similar manner with the 
control support but using a frit-in-column design, as described in Ref. 35.  The packing 
pressure was 3000 psi (20 MPa) for the 1 mm and 5 mm long columns and 4000 psi (28 
MPa) for the 10 mm, 20 mm and 25 mm long columns.  Each of these columns was 
stored at 4 
o
C in pH 7.4, 0.067 M phosphate buffer when not in use. The affinity 
microcolumns that were used for free drug extractions were stable for at least 150 
injections. The longer analytical affinity columns could be used for at least 250 injections. 
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Chromatographic studies 
The multi-dimensional affinity system that was used in this study is illustrated in 
Figure 6.1.  A 1 mm × 2.1 mm i.d. guard column was used to protect the HSA 
microcolumn from particulate matter in the serum samples.  The HSA microcolumn was 
used to extract the free drug fractions.  The second, longer HSA column was later placed 
on-line with the HSA microcolumn to further separate the extracted free drug fraction 
from other sample components, such as any drug that had dissociated from proteins in the 
sample during passage through the HSA microcolumn.
11
  The following wavelengths 
were employed for detection: 227 nm, tolbutamide; 248 nm, acetohexamide; 230 nm, 
diazepam; 226 nm, gliclazide; and 331 nm, quinidine. 
The mobile phase used for all of these columns was pH 7.4, 0.067 M phosphate 
buffer.  Most of the drugs were dissolved in this buffer to give working stock solutions 
which contained approximately 8070 μM tolbutamide, 730 μM gliclazide, 123 μM 
diazepam or 480 μM quinidine.  These solutions were spiked into a commercial sample 
of human serum that contained 42 g/L (632 μM) HSA.  These spiked samples were 
prepared by dissolving approximately 10 μL of each drug solution into 300 μL of serum.  
Samples containing only the drug and no protein were prepared in the same manner but 
by combining the stock solution of the drug with pH 7.4, 0.067 M phosphate buffer 
instead of serum.  The final samples that were made in this manner contained 275 μM 
tolbutamide, 23 μM gliclazide, 3.5 μM diazepam or 10 μM quinidine, which were within 
the typical therapeutic ranges for these agents (i.e., 184-370 μM tolbutamide, 15-31 μM  
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Figure 6.1 General scheme used for the isolation of a free drug fraction from the 
drug’s protein-bound form and other components in serum through the use 
of ultrafast affinity extraction and a multi-dimensional HPAC system. 
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gliclazide, 0.7-7.0 μM diazepam, or 3-15 μM quinidine).36,37  The HSA concentration in 
these drug/serum mixtures was 610-618 μM, which was representative of the normal 
physiological levels for this protein.
36
   
An alternative approach was used to make the serum samples that contained 
acetohexamide.  In this case, 1 mg of acetohexamide was dissolved directly in 14.28 mL 
of human serum, with 268 μL of this mixture then being mixed with 150 μL serum.  The 
concentration of acetohexamide in this final spiked serum sample was 138 μM, which 
was within the normal therapeutic range for this drug (i.e., 61-216 μM).37  The 
concentration of HSA in the final spiked serum sample was the same as the original 
content of the serum (i.e., 42 g/L or 632 μM HSA).  Samples containing acetohexamide 
alone were prepared in the same manner but with this drug being dissolved in and diluted 
with pH 7.4, 0.067 M phosphate buffer instead of serum. 
Optimization of the flow rates, column sizes and valve switching times that were 
used to study the interactions of diazepam or quinidine with HSA will be described in the 
“Results and Discussion”.  The HSA microcolumns that were used in the final system to 
extract the free drug fractions had the following dimensions: 5 mm × 2.1 mm i.d. for 
tolbutamide, acetohexamide and diazepam; and 10 mm × 2.1 mm i.d. for gliclazide and 
quinidine.  The flow rates that were employed to inject samples onto these HSA 
microcolumns were as follows: 2.25 mL/min, tolbutamide; 2.5 mL/min, acetohexamide 
or gliclazide; and 3.0 mL/min, diazepam or quinidine.  The injection volume was 1 µL 
for tolbutamide, acetohexamide and gliclazide, and 5 µL for quinidine and diazepam.   
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The size of the second HSA column in the final system was 10 mm × 2.1 mm i.d. 
for tolbutamide, acetohexamide and diazepam, and 25 mm × 2.1 mm i.d. for gliclazide 
and quinidine.  A six-port valve was used to control the time at which this second column 
was placed on-line with the first HSA microcolumn.  The times for this switching event 
were 1.2 min after injection for tolbutamide, 1.5 min for acetohexamide, 0.6 min for 
diazepam, 0.7 min for gliclazide and 0.4 min for quinidine.  The flow rate was changed at 
this same time to 0.50 mL/min for tolbutamide, gliclazide and quinidine, and 0.75 
mL/min for acetohexamide and diazepam during the second portion of the separation.  
The free drug concentration was determined by comparing the resulting peak area to that 
which was obtained for standards containing only the drug.
10
  The free fraction was 
calculated by dividing the free drug concentration by the total concentration of the drug 
in the sample.
3,10,24
 
 
Ultrafiltration studies 
Each ultrafiltration tube was washed three times with 1 mL of water, followed by 
three similar washing steps with pH 7.4, 0.067 M potassium phosphate buffer.  The 
spinning speed and time used in these washing steps were 1500 × g and 5 min.  After the 
last washing step, the buffer in the tube was decanted.  The remaining buffer was 
removed by spinning the ultrafiltration device at 1500 × g for 15 min.  One mL of a drug 
or drug/protein sample in pH 7.4, 0.067 M phosphate buffer or in serum, and at the same 
concentrations as used in the chromatographic studies, was placed into a washed 
ultrafiltration tube and spun at 1500 × g and 37 
°
C.  The spinning time for a solution of 
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the drug alone or a drug in serum was 1.5 min or 10.0 min, respectively, based on data 
from previous ultrafiltration studies.
10,11 
The filtrates were injected onto a chromatographic system for measurement of the 
free drug fraction.  The injection volume was 20 L for the filtrates containing gliclazide, 
quinidine or diazepam, and 2 L for the filtrates containing tolbutamide or 
acetohexamide.  The columns used in these measurements contained the same 
immobilized HSA support as used in the affinity microcolumns but had the following 
dimensions: gliclazide, 10 mm × 2.1 mm i.d.; quinidine, 20 mm × 2.1 mm i.d.; and 
diazepam, tolbutamide or acetohexamide, 5 mm × 2.1 mm i.d.  Standards containing 
these drugs in pH 7.4, 0.067 M phosphate buffer were injected under the same conditions.  
The mobile phase was pH 7.4, 0.067 M phosphate buffer, which was applied at flow rates 
of 0.5 mL/min for gliclazide, quinidine, and tolbutamide; 0.25 mL/min for diazepam; and 
0.75 mL/min for acetohexamide.  The detection wavelengths and system temperature 
were the same as described earlier for ultrafast affinity extraction.  The concentration of 
the drug in each filtrate was found by comparing the peak areas obtained for both the 
filtrate samples and standard solutions.  The free drug fraction was calculated in the same 
manner as described for ultrafast affinity extraction. 
 
Results and Discussion 
Optimization of conditions for ultrafast affinity extraction 
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The residence time for the sample as it passes through an affinity extraction 
column is an important factor to consider during the isolation of a free drug fraction from 
its corresponding drug-protein complex.  This time can be adjusted by changing the size 
of the affinity extraction column or by altering the flow rate.
3,7,8
  For drugs such as 
tolbutamide and acetohexamide, which have relatively strong binding to serum proteins 
(i.e., association equilibrium constants or global affinities of ~10
5
-10
6
 M
-1 
for soluble 
HSA), it is known that an HSA microcolumn with a size of 5 mm × 2.1 mm i.d. can be 
used to extract and isolate their free fractions in aqueous samples.
3,11
  Diazepam has a 
similar affinity for soluble HSA, with a binding strength of roughly 2-12 × 10
5
 M
-1
,
20,38
 
so the free fraction of this drug was also isolated by using a 5 mm × 2.1 mm i.d. HSA 
microcolumn.  Gliclazide, which has moderately strong binding to soluble HSA (~10
4
-
10
5
 M
-1
), was analyzed by using a longer 10 mm × 2.1 mm i.d. HSA microcolumn.  The 
same type of longer microcolumn was used with quinidine, which has an affinity for 
soluble HSA in the range of 0.1-5 × 10
4
 M
-1
.
1,39
  
The effect of the injection flow rate on the measured free drug fractions was also 
considered.  Figure 6.2 illustrates this effect.  The data in this figure were obtained for 
injections of diazepam and quinidine, or mixtures of these drugs with soluble HSA, as 
made onto 5 mm or 10 mm × 2.1 mm i.d. HSA microcolumns.  It was found that low-to-
moderate injection flow rates (i.e., 0.5-2.0 mL/min for diazepam and 0.25-2.50 mL/min 
for quinidine) resulted in high values for the apparent free drug fractions.  However, 
when the flow rate was raised above 2.5 mL/min for diazepam or 3.0 mL/min for 
quinidine, a consistent free drug fraction was obtained.  The high values seen at low-to-
moderate flow rates were caused by dissociation of these drugs from their complexes  
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Figure 6.2  Measurement of free drug fractions at various injection flow rates.  These 
plots were obtained for 1.0 μL injections of (a) 10 µM diazepam or a 10 
µM diazepam/20 µM HSA mixture onto a 5 mm × 2.1 mm i.d. HSA 
microcolumn, and (b) 10 µM quinidine or a 10 µM quinidine/20 µM HSA 
mixture onto a 10 mm × 2.1 mm i.d. HSA microcolumn.  These results 
were measured at 37 °C in pH 7.4, 0.067 M phosphate buffer. 
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with soluble HSA while the samples were passing through the affinity extraction 
microcolumns.
3,7,10,24,29
  However, this dissociation was minimized at higher flow rates as 
the sample residence time in the column was decreased.  This latter situation occurred 
when the sample residence time was less than 333 millisecond (ms) for diazepam and 554 
ms for quinidine.  Based on the same type of experiment, the maximum sample residence 
times that gave similar behavior for the other drugs in this study were 415 ms for 
tolbutamide, 333 ms for acetohexamide, and 665 ms for gliclazide.
11
 
These flow rate and residence time data were also used to estimate the 
dissociation rate constant (kd) for each drug with soluble HSA.  This was done by using 
Equation 6.1 and the apparent free drug fractions that were measured at low-to-moderate 
flow rates.
3
 
      
(1− 0)
(1−  )
= 𝑘                        (6.1) 
In Equation 6.1, F0 is the original free fraction of the drug in the sample, as is measured 
at or above a flow rate that provides minimal dissociation of this drug from soluble 
proteins in the sample during passage through the affinity extraction column.  The term Ft 
is the apparent free drug fraction that is measured at a given column residence time t.  
The value of t is also equal to the column void time, which can be calculated by using the 
flow rate and column void volume.
3
   
 As is indicated by Equation 6.1, a drug-protein system that undergoes essentially 
first-order dissociation as it passes through the affinity extraction column should provide 
a linear relationship with an intercept of zero when ln[(1 - F0)/(1 - Ft)] is plotted against t.  
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Figure 6.3 shows examples of such linear relationships, as were obtained from the 
affinity extraction experiments that were conducted with quinidine or diazepam in the 
presence of soluble HSA.  These particular plots gave correlation coefficients of 0.990-
0.999 (n = 5-6) and intercepts that were equivalent to zero at the 95% confidence level.  
Similar behavior has been noted for the other drugs that were considered in this study.3  
The dissociation rate constants for these systems were then determined from the slopes of 
the best-fit lines for these plots. 
 Table 6.1 shows the dissociation rate constants that were estimated by using 
Equation 6.1 and the ultrafast affinity extraction data.  The kd values for quinidine and 
diazepam with HSA were 0.58 (± 0.02) and 0.63 (± 0.05) s
-1
, respectively, which had 
absolute differences of only 0.05-0.19 s
-1
 from values in the literatre.
22,40
  The relative 
precisions of these kd values were ± 3.4 to 7.9%.  The same approach, with similar 
relative precisions and agreement with the literature, has previously provided dissociation 
rate constant estimates of 0.59 (± 0.03) s
-1
 for tolbutamide, 0.67 (± 0.03) s
-1 
for 
acetohexamide, and 0.61 (± 0.02) s
-1
 for gliclazide.
3 
 
 
Optimization of conditions for multi-dimensional affinity system 
When working with a complex matrix such as serum, the large amount of proteins 
or other sample components that are present may make it difficult to obtain good 
resolution between the non-retained and retained peaks on an HSA microcolumn.  To 
avoid this problem, ultrafast affinity extraction was carried out as part of a multi-
dimensional affinity system.
10,11
  This was achieved by placing a second and longer HSA  
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Figure 6.3  Determination of the dissociation rate constants for (a) quinidine and (b) 
diazepam with soluble HSA by using ultrafast affinity extraction and 
Equation 6.1.  The chromatographic conditions were the same as in Figure 
6.2.  The equation for the best-fit lines were (a) y = 0.58 (± 0.02) x + 0.01 
(± 0.03) and (b) y = 0.63 (± 0.05) x + 0.02 (± 0.05).  The correlation 
coefficients for these plots were 0.990 (n = 5) and 0.999 (n = 6), 
respectively.  The error bars represent a range of ± 1 S.D. (n = 4). 
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Table 6.1   Dissociation rate constants measured for various drugs with soluble HSA 
by using ultrafast affinity extraction on HSA microcolumns
a 
 
         Dissociation rate constant, kd (s
-1
) 
Drug Ultrafast affinity 
extraction 
Literature  
[Ref.]  
Diazepam 0.63 (± 0.05) 0.44 [22] 
Quinidine 0.58 (± 0.02) 0.53 [40] 
Tolbutamide
b
 0.59 (± 0.03) 0.49 (± 0.15) [22] 
Acetohexamide
b
 0.67 (± 0.03) 0.58 (± 0.02) [22] 
Gliclazide
b
 0.61 (± 0.02) Not reported  
 
a
These kd values were measured at pH 7.4 and at 37 
°
C.  The injected samples contained 
10 μM of a given drug and 20 μM HSA.  The values in the parentheses represent a range 
of ± 1 S.D., as determined through error propagation from the slopes of the best-fit lines 
that were obtained according to Equation 6.1. 
b
These kd values, as measured by ultrafast affinity extractions were previously reported in 
Ref. 3. 
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column on-line after samples had passed through the microcolumn that was used for 
ultrafast affinity extraction.  In this system, part of the free drug fraction that was retained 
by and later eluted from the affinity microcolumn was delivered to the second column for 
further separation and analysis.  This technique has been shown in prior work to improve 
the separation of the retained free drug fraction from other sample components, including 
serum proteins or any protein-bound drug in the sample that had undergone dissociation 
during its passage through the affinity extraction column.
10
 
 In this multi-dimensional method, the time for switching the valve to place the 
second column on-line with the first is an important factor to consider, as it determines 
the amount of a drug and its free drug fraction that are transferred to the second 
column.
10,11
  This time was optimized by using samples that contained only the drug or a 
mixture of this drug plus soluble proteins that were each present at typical therapeutic or 
physiological concentrations.  In the case of quinidine, a sample containing 10 µM 
quinidine in the presence or absence of 600 µM soluble HSA was injected onto a 10 mm 
× 2.1 mm i.d. HSA column at an initial flow rate of 3.0 mL/min for ultrafast affinity 
extraction, as optimized in the previous section.  The retained drug was then delivered to 
a 25 mm × 2.1 mm i.d. HSA column at various times after sample injection.  Figure 6.4(a) 
provides examples of the retained drug peaks that were transferred to this second column 
for quinidine when the switching event occurred at 0.30, 0.35, 0.40, or 0.50 min after 
injection.  The flow rate was also decreased to 0.50 mL/min as the second column was 
placed on-line.  It was found in this multi-dimensional system that the retained drug gave 
a peak maximum that occurred at 4.3-5.2 min after sample injection.  Diazepam, 
tolbutamide, acetohexamide, and gliclazide provided similar chromatograms, in which  
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Figure 6.4 Effect of valve switching time on (a) the recovery of quinidine at 0.5 
mL/min on a 25 mm × 2.1 mm i.d. HSA column that was put on-line with 
a 10 mm × 2.1 mm i.d. HSA microcolumn after various times following 
the injection of a 5 μL sample of 10 µM quinidine onto the first column at 
3.0 mL/min, and (b) the apparent free drug fractions that were measured 
by using the same multi-dimensional system and chromatographic 
conditions as in (a) with a sample that contained 10 µM quinidine and 600 
µM HSA.  All of the times shown are the elapsed interval after sample 
injection.  The error bars represent a range of ± 1 standard error of the 
mean (n = 4).  All of these measurements were made at pH 7.4 and 37 °C.  
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peak maxima were observed at 7.5-7.9 min, 7.6-8.2 min, 9.6-10.0 min, or 7.6-7.8 min, 
respectively, under the final conditions that are given in the Experimental section.  
 The timing of the switching event also created some changes in the apparent free 
drug fractions that were measured.  This effect is illustrated in Figure 6.4(b) for injections 
that were made onto the multi-dimensional system of 10 µM quinidine or a mixture of 
this drug with 600 µM soluble HSA.  It was found that a time for the switching event that 
was too short caused an overestimation in the free drug fraction, due to contamination of 
this fraction by dissociation of the original drug-protein complex in the sample.  When 
the time for the switching event was made longer (e.g., at least 0.40 min in Figure 6.4), a 
consistent value in the measured free fraction was obtained.  However, this increase in 
time also eventually produced a loss in precision for the measured free fraction as the 
overall area for the transferred drug peak was decreased.  These combined effects led to 
the use of intermediate times for the switching event that provided both good accuracy 
and reasonable precisions for the measured free fractions.  For quinidine, the final 
switching time that was employed was 0.40 min.  The switching times that were 
optimized and selected for the other drugs were 0.6 min for diazepam, 1.5 min for 
acetohexamide, 1.2 min for tolbutamide, and 0.7 min for gliclazide.  
 
Measurement of free fractions and binding of drugs to HSA in serum 
The use of ultrafast affinity extraction with the multi-dimensional system was 
next used to measure the free fractions for various drugs that were present at typical 
therapeutic concentrations in serum.  The results are summarized in Table 6.2.  These  
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Table 6.2 Free drug fractions measured for various drugs in human serum
a
 
 
Serum content  
 
 
Ultrafast affinity 
extraction 
 
Ultrafiltration  
Diazepam (3.5 μM) 0.69 (± 0.10)% Not determinedb 
Quinidine (10 μM) 7.40 (± 0.53)% 7.71 (± 0.25)% 
Tolbutamide (275 μM) 2.44 (± 0.68)% 2.37 (± 0.07)% 
Acetohexamide (138 μM) 1.12 (± 0.07)% 1.41 (± 0.04)% 
Gliclazide (23 μM) 2.06 (± 0.16)% 2.01 (± 0.02)% 
 
a
These values were determined at 37 
°
C.  The values in parentheses were determined by 
error propagation and represent a range of ± 1 S.D. (n = 4). 
b
The free fraction of diazepam in this sample was too small to be detected by 
ultrafiltration but could be detected by ultrafast affinity extraction on the multi-
dimensional system. 
 
 
  
  
 
253 
free fractions were in the general range of 0.7-7.4% for all of the drugs and serum 
samples that were tested.  These results showed good agreement with those that were 
obtained by ultrafiltration for the same samples, with absolute differences of only 0.05%-
0.41%.  The results from the multi-dimensional affinity method also gave good absolute 
precisions for its measured free fractions (± 0.10-0.68%), as well as reasonable relative 
precisions (± 6.2–28%).  
The free drug fractions that were measured with the multi-dimensional affinity 
system were further used to estimate the binding constants for each drug with HSA in the 
serum samples.  These binding constants were calculated by using Equation 6.2, which 
can be used to provide the association equilibrium constant (Ka) for a system with single-
site binding or the global affinity constant (nKa
’
) for a system with multiple but 
independent binding sites.
3,10,24
   
𝐾a (    𝐾𝑎
 ) =
1− 0
 0([P]−[ ]+[ ] 0)
                     (6.2) 
In this equation, F0 is the free fraction for the drug that is measured in the absence of any 
appreciable drug-protein dissociation in the sample, while [D] and [P] are the 
concentrations of the drug and soluble protein in the original sample, respectively.  For 
drugs such as diazepam and quinidine, each having a single major binding site on 
HSA,
1,22,41
 Equation 6.2 can be used to provide the value of Ka for these interactions.  For 
tolbutamide, acetohexamide and gliclazide, which each have two major binding sites on 
HSA,
31-34
 Equation 6.2 would instead provide an estimate of the global affinity constant 
for these drug-protein interactions. 
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 Table 6.3 summarizes the values of Ka or nKa’ that were determined from the free 
drug fraction measurements.  The relative precisions for these binding constants ranged 
from ± 6.9-29%.  The values for tolbutamide, acetohexamide, gliclazide and quinidine 
were all consistent with previous binding constants that have been reported for the same 
drugs with HSA and at the same temperature and pH.
1,31-34,39
  For instance, the results in 
Table 6.3 differed from the literature values by only 8.3-15.7% (average difference, 8.9%) 
or fell within the range of previously-reported values (e.g., in the case of quinidine).  The 
binding constant determined for diazepam with HSA also fell within the range of 
previous values that have been obtained at the same pH but at room temperature.
20,38
  In 
addition, all of the binding constants that were measured by ultrafast affinity extraction 
and the multi-dimensional system agreed with the results that were obtained for the same 
samples when using ultrafiltration (i.e., Ka or nKa’ values that differed by only 2.4-24%).   
 
Conclusions 
This study used ultrafast affinity extraction and a multi-dimensional affinity 
system to measure free drug fractions and to study drug-protein interactions in serum.  
Several drugs were used to test and illustrate this approach (i.e., quinidine, diazepam, 
gliclazide, tolbutamide and acetohexamide, with previously-reported affinities for HSA 
that ranged from 10
3
-10
6
 M
-1
).
1,20,31-34,38,39
 Various factors were considered when 
optimizing this system to measure free drug fractions in serum at typical therapeutic 
concentrations.  These factors included the flow rates and column sizes that were used for 
extraction of the free drug fraction and the times at which the affinity extraction column  
  
 
255 
Table 6.3  Association equilibrium constants (Ka) or global affinity constants (nKa’) 
estimated for various drugs with HSA in serum based on free drug 
fractions  
 
 
Serum content 
 
Ka or nKa’ (× 10
4
 M
-1
)
a  
 
Ultrafast affinity 
extraction 
Ultrafiltration  Literature 
[Ref.] 
 
Diazepam (3.5 μM) 24 (± 4) 
 
Not determinedb 
 
22-125 [20,38]c 
 
Quinidine (10 μM) 2.0 (± 0.2) 
 
2.0 (± 0.1) 
 
0.16-4.78 [1,39] 
 
Tolbutamide (275 μM) 12 (± 3) 12 (± 1) 
10.8 (± 0.3)d [31,33] 
 
Acetohexamide (138 μM) 14 (± 1) 11 (± 1) 
17.2 (± 1.1)d [31,32] 
 
Gliclazide (23 μM) 8.1 (± 0.7) 
 
8.3 (± 0.1) 
 
7.9 (± 0.5)d [34] 
 
a
The ultrafast affinity extraction and ultrafiltration results were measured at 37 
°
C.  The values in 
parentheses were determined by error propagation and represent a range of ± 1 S.D. (n = 4). 
b
The free fraction of diazepam in this sample was too small to be detected by ultrafiltration but 
could be detected by ultrafast affinity extraction on the multi-dimensional system. 
c
These literature values were determined at pH 7.4 and room temperature. 
d
These literature values were obtained by using the binding stoichiometries and association 
equilibrium constants that have been estimated at pH 7.4 and 37 
°
C for the given drugs at Sudlow 
sites I and II. 
31-34
  A similar range of values has been reported in Refs. 3 and11.  
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was placed on-line with a larger affinity column for use in further isolating and 
measuring the retained free fraction.   
The free drug fractions that were estimated for each drug by this approach were in 
good agreement with the results that were obtained by ultrafiltration.  The binding 
constants that were estimated from the same data also agreed with those obtained by 
ultrafiltration and with literature values.  However, the approach based on ultrafast 
affinity extraction had several advantages over traditional methods for free drug 
measurements and drug-protein binding studies.  For instance, ultrafast affinity extraction 
required much smaller sample volumes per analysis than ultrafiltration (i.e., 1-5 µL 
versus 1 mL or more).
3,10,11,24
  The ultrafast affinity extraction and multi-dimensional 
affinity system also provided results within a relatively short period of time (i.e., 5-10 
min per sample) and could be used to measure free drug fractions as small as 0.69% in 
serum with an absolute precision of ± 0.07-0.68%.  The same type of system could be 
employed in future work to examine alternative drugs and drug-protein interactions in 
serum.  This method should also be adaptable for use in examining the binding of other 
small solutes (e.g., low mass hormones and fatty acids)
1,16,21
 with serum proteins or other 
binding agents. 
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CHAPTER 7 
The Use of Ultrafast Affinity Extraction to Study the Interactions of Steroid 
Hormone with Human Serum Albumin and Sex Hormone Binding Globulin  
Portion of this chapter appear in X. Zheng, M. Brooks, D.S. Hage “Analysis of Hormone-Protein Binding 
in Solution by Ultrafast Affinity Extraction:  Interactions of Testosterone with Human Serum Albumin and 
Sex Hormone Binding Globulin” Analytical Chemistry 2015, submitted. 
 
Introduction 
A number of low mass hormones are present in the bloodstream in both a free, or 
non-bound, form and a protein-bound form.
1-3
  One example is testosterone, which is a 
steroid hormone that has a normal plasma concentration of 10-42 nM in adult males.
1,4
  
Two important binding proteins for testosterone in blood are human serum albumin (HSA) 
and sex hormone binding globulin (SHBG).
2  
HSA is the most abundant serum protein, 
accounting for 60% of the total serum protein content and having a normal concentration 
of 35-50 g/L (526-752 μM).1,3  Testosterone has been reported to bind to HSA with a 
low-to-moderate affinity (i.e., 2.0-4.1 ×10
4
 M
-1 
at 37 ºC 
2,5-7
) and at a single site on 
domain IIA.4,8  SHBG is a homodimeric glycoprotein that acts as a transport protein for 
steroid hormones such as testosterone, dihydrotestosterone and estradiol.  The 
concentration of SHBG in adult males is 10-60 nM.
1,9
  Testosterone has an affinity for 
SHBG that has been reported to be as high as 10
9
 M
-1
, with binding that occurs at one or 
two sites per homodimeric unit.
2,6,10-13
  Only about 2% of testosterone is normally present 
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in its free form in serum, with approximately 53-55% of this hormone being bound to 
HSA and 43-45% being bound to SHBG.
2,4
  
The free form of testosterone is generally considered to play an important role in 
the tissue uptake and biological activity of this hormone.
2,14
 However, some studies have 
shown that the form of testosterone that is bound to HSA in plasma may also be available 
to tissues.
14
  To better understand how each fraction of testosterone affects the biological 
response of this hormone, it is important to have information regarding the interactions of 
testosterone with proteins such as HSA or SHBG, and the resulting free fraction of this 
hormone in blood.  The overall binding and rates of these interactions have been of 
particular interest.
15
 
Various methods have been used to investigate the interactions between steroid 
hormones and HSA or SHBG.  These methods have included rapid filtration,
15-17
 
equilibrium dialysis,
5,17-19
 solvent partitioning,
2,14,20,21
 affinity capillary electrophoresis,
22
 
and electron spin resonance spectroscopy.
23
  However, some of these methods require 
relatively large sample volumes or amounts of protein, or may have long analysis times 
(e.g., equilibrium dialysis, gel filtration and the equilibrium partition method).
5,7,14,18
  In 
addition, prior binding studies with testosterone in many of these methods have used 
highly diluted serum or samples that were not prepared at typical physiological 
concentrations.
2,15,16
  It would be also be desirable in such studies to use a single method 
that can provide both thermodynamic and kinetic parameters, but previous work 
examined the interactions between steroid hormones and plasma proteins in separate 
approaches or experimental conditions to obtain such information.
15-23
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Recently, a method based on ultrafast affinity extraction was developed for 
simultaneously estimating both the equilibrium constants and rate constants for drugs 
with HSA in solution.
24
  In this method, an affinity microcolumn that contained an 
immobilized binding agent with relatively fast and strong binding for the target of interest 
was used to extract the free form of drugs from their protein-bound form in drug/protein 
samples.  It was found that by varying the flow rate and column size, which altered the 
time for passage of the sample through the microcolumn, it was possible to obtain 
information on both the dissociation rate of a drug-protein complex and its binding 
constant.
24-26
  Advantages noted for this approach have included its ability to be used as a 
label-free method and to directly examine drug-protein interactions in solution.  Other 
potential advantages are its speed, ease of automation, ability to be used with various 
HPLC detectors, good correlation with reference methods, and need for only a small 
amount of the drug and protein.
24-26  
It has further been shown that this method can be 
modified to measure the free fractions of many drugs at clinically-relevant 
concentrations.
25,26
 
In this study, ultrafast affinity extraction will be adapted and tested for use in 
examining the interactions of testosterone with HSA and SHBG in solution.  The 
conditions needed for this type of analysis will be considered to make it allow for both 
the dissociation rate constants and association equilibrium constants to be obtained for 
these systems.  The results of this study should provide valuable information that can be 
used to extend ultrafast affinity extraction to the study of other hormone-protein 
interactions and should provide a more complete picture of these binding processes 
within the body.    
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Experimental  
Materials and reagents 
 The HSA (Cohn fraction V, essentially fatty acid free, ≥ 96% pure), testosterone 
and hexane (≥ 98.5% pure) were from Sigma (St. Louis, MO, USA).  The purified human 
SHBG was obtained from AbD Serotec (≥ 90% pure, 1 mg/mL in ammonium bicarbonate; 
batch number 060613; Raleigh, NC, USA).  The reagents for the bicinchoninic acid 
(BCA) protein assay were obtained from Pierce (Rockford, IL, USA).   The Nucleosil Si-
300 silica (7 μm particle diameter, 300 Å pore size) was from Macherey Nagel (Dűren, 
Germany).  All buffers and aqueous solutions were prepared using water from a 
NANOpure system (Barnstead, Dubuque, IA, USA) and were passed through Osmonics 
0.22 μm nylon filters from Fisher Scientific (Pittsburgh, PA, USA).   
   
Apparatus 
The microcolumns used in this study were packed using a Prep 24 pump from 
ChromTech (Apple Valley, MN, USA).  A V-630 UV-Vis spectrophotometer from Jasco 
(Easton, MD, USA) was used to determine the testosterone concentration during the 
sample preparation.  The HPLC system consisted of a PU-2080 Plus pump, an AS-2057 
autosampler, and a UV-2075 absorbance detector from Jasco, plus a six-port Lab Pro 
valve (Rheodyne, Cotati, CA, USA).  A CHM column heater and a TCM column heater 
controller from Waters (Milford, MA, USA) were used to maintain a temperature of 37.0 
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(± 0.1) °C for the columns during all experiments in this chapter.  ChromNAV v1.8.04 
software and LCNet from Jasco were used to control the HPLC system.  The 
chromatograms were analyzed through the use of PeakFit v4.12 software (Jandel 
Scientific, San Rafael, CA, USA).   
 
Column preparation 
HSA immobilized to Nucleosil Si-300 silica was used as the stationary phase for 
ultrafast affinity extraction and in the multi-dimensional affinity system.  This stationary 
phase was prepared by immobilizing HSA onto aldehyde-activated silica by using the 
Schiff base method, as described previously.
27,28
 The same material, but with no HSA 
being added during the immobilization step, was used as a control support.  A BCA assay 
was used to determine the protein content of the final support in triplicate by using HSA 
as the standard and the control support as the blank.
27,28
  This assay gave a protein 
content of 66 (± 1) mg HSA/g silica, where the value in parentheses represents a range of 
± 1 S.D.   
The HSA support and control support were packed into standard stainless steel 
columns with 2.1 mm i.d. and lengths of 5-25 mm by using pH 7.4, 0.067 M potassium 
phosphate buffer as the packing solution.  The packing pressure was 4000 psi (28 MPa) 
for 10, 20, or 25 mm long columns and 3000 psi (20 MPa) for the 5 × 2.1 i.d. mm long 
columns.  These columns were stored in pH 7.4, 0.067 M potassium phosphate buffer at 4 
o
C when not in use.  These affinity microcolumns were each used for up to 40-100 
injections, over a period of six months, to provide optimum retention and peak resolution; 
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however, these types of columns have been previously been found to be stable for at least 
300-400 injections.
24,25
 
 
Preparation of Testosterone Solutions 
Due to the low solubility and slow dissolution of testosterone in aqueous solutions, 
testosterone was dissolved indirectly into pH 7.4, 0.067 M potassium phosphate buffer.  
This was carried out by first using 2.5 mL hexane to dissolve testosterone at 
concentrations ranging from 1 to 100 μg/mL.  A 1.2 mL portion from each of these 
standard solutions was placed into a series of vials for later use as standard in absorbance 
measurements.  Another 1.2 mL portion of a testosterone/hexane solution was mixed with 
3.0 mL of pH 7.4, 0.067 M potassium phosphate buffer.  These mixtures were carefully 
shaken for more than 15 h at room temperature to allow partitioning of the testosterone to 
occur between the hexane and phosphate buffer.
14
  After this mixing step, the hexane and 
buffer phases were allowed to settle for 30 min to produce two distinct layers.  The upper 
hexane layer and the lower phosphate buffer layer in each vial were then removed and 
placed into separate vials.   
The concentration of testosterone in each hexane solution after the partitioning 
step was determined by diluting both these solutions and the testosterone/hexane 
standards ten-fold with pure hexane.  The absorbance due to testosterone in each hexane 
sample or standard was then measured at 231 nm and was used to determine the amount 
of testosterone that had entered the phosphate buffer layers.  The final measured 
concentrations of testosterone in the pH 7.4 phosphate buffer ranged from 0 to 51.5 μM 
by this approach.  The corresponding solutions of testosterone in pH 7.4, 0.067 M were 
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then diluted further with the pH 7.4 buffer, as needed, to prepare the working solutions of 
testosterone for the chromatographic studies. 
 
Chromatographic studies 
The mobile phase used for sample preparation and the chromatographic studies 
was pH 7.4, 0.067 M potassium phosphate buffer.  All mobile phases were degassed for 
30 min prior to use.  The aqueous solutions of testosterone were prepared as described in 
the previous section.  All testosterone/protein mixtures that were used in this work were 
incubated for at least 30 min at 37 ºC prior to injection to allow equilibrium to be 
established between the free and protein-bound fractions of the hormone in the sample.
24-
27
 Replicate injections (n = 4) were made for all samples and standards.  Components 
eluting from the chromatographic system were monitored at 249 nm.   
In the measurements of association equilibrium constants and dissociation rate 
constants for testosterone with HSA, the testosterone samples were prepared by diluting 
the stock solutions of testosterone, which were prepared as described previously, to a 
concentration of 20 μM.  The mixtures of testosterone with HSA were prepared by 
dissolving HSA in the testosterone sample to give a solution containing 20 μM 
testosterone and 40 μM soluble HSA.  Samples that contained only testosterone or a 
mixture of testosterone and HSA were injected onto a 10 mm × 2.1 mm i.d. HSA 
microcolumn by using an injection volume of 1 μL.  The flow rate for sample application 
ranged from 0.1 to 5.0 mL/min.  To confirm the results obtained on the 10 mm × 2.1 mm 
i.d. HSA microcolumn, a similar experiment was performed by making injections of 
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samples containing 10 μM testosterone or a mixture of 10 μM testosterone and 20 μM 
HSA onto a 5 mm × 2.1 mm i.d. HSA microcolumn.  The flow rate for sample 
application in this case ranged from 0.5 to 2.5 mL/min. 
In the measurement of association equilibrium constants or global affinities, a 
relatively fast flow rate and short column residence time were used for the sample 
injection, which minimized the time that was allowed for any dissociation of testosterone 
from its complexes with a protein such as HSA (or SHBG).
24 
Under these conditions, the 
measured free fraction should represent the original amount of the free hormone that was 
present in the sample before its injection, as illustrated in Figure 7.1(a).  To determine the 
dissociation rate constant for testosterone from HSA interaction, low-to-medium flow 
rates were used to provide longer residence times as the sample passed through the 
column, as shown in Figure 7.1(a).  The apparent free fraction of testosterone in a 
testosterone/protein mixture that was obtained at a given flow rate was found by dividing 
the peak area for the free testosterone by the total peak area for the same hormone in a 
solution that contained the same total amount of testosterone but no soluble protein.   
The interactions between testosterone and SHBG were examined in a similar 
manner.  In these experiments, the testosterone/SHBG mixture was prepared by diluting a 
commercial solution of SHBG (at a concentration of 1 mg/mL in ammonium bicarbonate 
buffer) with an aqueous solution of testosterone at a concentration of 42.4 nM in pH 7.4, 
0.067 M phosphate buffer (i.e., a 0.0018:2 (v/v) mixture).  The final mixture contained 42 
nM of testosterone and 20 nM of SHBG, which was representative of the physiological 
concentrations of these agents.  Samples containing only testosterone were prepared in  
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Figure 7.1   General scheme for examining hormone-protein binding by ultrafast 
affinity extraction.  In this approach, a hormone/protein mixture is injected 
onto an affinity microcolumn that contains an immobilized binding agent 
for the hormone, such as HSA.  A separation of the free and protein-bound 
forms of the hormone can be obtained on this column and provide 
apparent free hormone fractions that can be used to estimate the 
dissociation rate constant for the system (kd) at low-to-moderate injection 
flow rates or the association equilibrium constant (Ka) or global affinity 
(nKa’) for the same system at higher flow rates.  If further resolution of the 
retained free fraction is needed for other sample components, a portion of 
this fraction can be passed to a second affinity column for further 
separation prior to the final measurement of the free drug fraction.   
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the same manner but using pH 7.4, 0.067 M phosphate buffer instead of the SHBG stock 
solution.  The measurements of association equilibrium constants, dissociation rate 
constant and free fraction were made by injecting 50 L samples that contained 
testosterone or a testosterone/SHBG mixture onto a 20 mm × 2.1 mm i.d. HSA 
microcolumn at 0.25-2.0 mL/min.  
Measurements of the free fraction and Ka for testosterone with HSA at 
physiological concentrations were carried out by using ultrafast affinity extraction in a 
multi-dimensional affinity system (see right portion of Figure 7.7.1).  This was needed 
because of the large excess of HSA that was present versus testosterone (i.e., over a 10
4–
fold mol excess),1,3 which made it more difficult to measure the free fraction of 
testosterone when using only a single column.  Work with the multi-dimensional system 
was carried out using 50 L injections of samples that contained 25 nM testosterone or 
25 nM testosterone and 600 μM HSA in pH 7.4, 0.067 M phosphate buffer.  A 5 mm × 
2.1 mm i.d. HSA microcolumn was used to extract the free fraction of testosterone at 2.0 
mL/min.  A second HSA column with a size of 25 mm × 2.1 mm i.d. was then placed on-
line with the first column to further separate the extracted fraction from other sample 
components (e.g., HSA or testosterone that had dissociated from soluble HSA).  This 
second column was placed on-line with the first column at 0.35-0.40 min after the sample 
injection, with the flow rate being changed at the same time to 0.50 mL/min.  The free 
testosterone concentration was determined by comparing the peak areas obtained on the 
second column to those obtained on the same system for testosterone standards.
25,26 
 The 
free fraction was found by dividing the measured free testosterone concentration by the 
total concentration of the hormone in the sample.
 
  
271 
    
Results and Discussion 
Optimization of ultrafast affinity extraction for testosterone-protein binding studies 
The flow rate and column size are two important factors to consider in ultrafast 
affinity extraction, as they determine the time allowed for the dissociation of the protein-
bound form of a solute as the sample passes through the column.
24-28
 For instance, a 
shorter column or a higher flow rate can provide a shorter time for samples to pass 
through the column, which would help minimize dissociation of the solute from its 
complex with soluble protein.  This effect is illustrated in Figure 7.2 when using various 
flow rates for the injection of mixtures of testosterone with HSA or SHBG onto 5 mm or 
20 mm × 2.1 mm i.d. HSA microcolumns.   
At low-to-medium flow rates, the apparent free fraction for testosterone increased 
with a decrease in flow rate.  This effect occurred up to a flow rate of 2.0 mL/min for the 
testosterone/HSA data in Figure 7.2 and up to a flow rate of 1.25 mL/min for the 
testosterone/SHBG samples.  This was caused by an increase in dissociation of the 
hormone from its complex with soluble HSA or SHBG as the samples passed through the 
affinity extraction column over longer periods of time.  In addition, the use of a larger 
affinity extraction column also provided a higher apparent free testosterone fraction when 
compared to a smaller column that was used at the same flow rate.  This difference was 
also a result of the longer time that was allowed for solute-protein dissociation as the 
sample passed through the larger column at the given flow rate.
24,25
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Figure 7.2   Effect of the injection flow rate on the measurement of the apparent free 
fraction of testosterone in the presence of soluble HSA or SHBG.  These 
results were acquired at pH 7.4 and 37 C for 1 µL injections of 10 µM 
testosterone/20 µM HSA made onto a 5 mm × 2.1 mm i.d. HSA 
microcolumn (top), or 50 µL injections of 42 nM testosterone/20 nM 
SHBG made onto a 20 mm × 2.1 mm i.d. HSA microcolumn (bottom).  
Other conditions are given in the text. 
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Figure 7.3 shows some typical chromatograms that were obtained from injections 
of testosterone and HSA onto a 5 mm × 2.1 mm i.d. HSA microcolumn.  The non-
retained peak, which was due to HSA and testosterone’s complex with the soluble HSA 
in the sample, eluted in approximately 1 min or less from this column, depending on the 
application flow rate.  The observed elution time for the peak due to the retained free 
fraction of testosterone occurred at 0.3 min (at 2.5 mL/min) to 1.5 min (at 0.5 mL/min), 
and showed a separation from the protein-bound fraction of testosterone fraction in the 
sample.  Similar separations were obtained on 10 mm × 2.1 mm i.d. HSA microcolumns, 
in which the non-retained peak and retained peak eluted within 8 s to 4 min and 25 s to 
10 min, respectively, at flow rates ranging from 0.10 to 5.0 mL/min. 
The apparent free hormone fractions that were measured in the low-to-moderate 
flow rate range were used to estimate the dissociation rate constant for the complex of 
testosterone with soluble HSA (or later SHBG).  This was accomplished by using the 
apparent free fractions that were measured at each flow, or column residence time, and 
plotting these results according to a first-order integrated rate expression, such as given 
by Equation 7.1 or 7.2.
24
 
       
(1 −  0)
(1 −   )
= 𝑘                                (7.1) 
      
1
(1 −   )
= 𝑘d −    (1 −   )                     (7.2) 
In these two equivalent equations, Ft is the apparent free fraction that was measured at a 
given column residence time t, and F0 is the original free fraction of the same solute in 
the original sample.  The term t is also equal to the column void time and can be  
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Figure 7.3   Chromatograms obtained at various flow rates for 1 μL injections of 10 
μM testosterone and 20 μM HSA onto a 5 mm × 2.1 mm i.d. HSA 
microcolumn at pH 7.4 and 37 
o
C. 
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calculated by employing the flow rate and column void volume or by measuring the 
elution time of a non-retained solute.
24
   
Equations 7.1 and 7.2 predict that a solute-protein system that follows first-order 
dissociation should provide a plot for either ln[(1 - F0)/(1 - Ft)] or ln [1/(1 - Ft)] against t 
that gives a linear relationship.  Examples of such plots are given in Figure 7.4 for 
experiments examining the interaction of testosterone with soluble HSA by using a 10 
mm × 2.1 mm i.d. HSA column.  In each case, the dissociation rate constant kd can be 
determined from the slope of the best-fit line.  When using Equation 7.1, a measurement 
or estimate for F0 is also required and the intercept of the resulting fit should be 
essentially equal to zero.  A plot constructed according to Equation 7.2 does not require 
this information and instead gives a positive intercept that can be used to obtain the value 
of F0. 
It can be seen in Figure 7.2 that the measured free fraction for testosterone 
approached a constant value once the column residence time reached a certain minimum 
value.  In the example for the injection of a testosterone/HSA mixture onto a 5 mm × 2.1 
mm i.d. HSA microcolumn, this occurred when the flow rate was greater than or equal to 
2.0 mL/min, or a column residence time of around 416 milliseconds (ms) or less.  At or 
above this flow rate, dissociation of testosterone from its protein-bound form was 
minimal due to the short column residence that was present.  The free fraction of 
testosterone that was measured at or about this optimum flow rate was then employed to 
determine the free fraction of testosterone in the original sample (F0).  If it was known or 
assumed that the sample prior to injection was at equilibrium, the association equilibrium  
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Figure 7.4   Measurement of the dissociation rate constant for testosterone from HSA 
at pH 7.4 and 37 C by using ultrafast affinity extraction.  The sample 
contained 20 µM testosterone/40 µM HSA, which was injected onto a 10 
mm × 2.1 mm i.d. HSA microcolumn.  These results were analyzed by 
using Equation 7.2 (top) or Equation 7.1 (bottom), where the latter 
included a point at the origin.  The equations for the best-fit lines were y = 
2.17 (± 0.08) x + 0.71 (± 0.06) and y = 2.20 (± 0.03) x + 0.01 (± 0.03), 
respectively.  The correlation coefficients for these plots ranged from 
0.998 to 0.999 (n = 5-6).  The error bars represent a range of ± 1 S.D. (n = 
4). 
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constant (Ka) for testosterone with the soluble protein could then also be calculated from 
the value of (F0) and the known contents of the sample.  For a solute and soluble protein 
with a 1:1 interaction, this can be accomplished by using Equation 7.3,   
       𝐾a =
1 −  0     
 0([P]0 − [A]0 + [A]0  0 )
                       (7.3) 
where [A]0 and [P]0 are the original concentrations of the analyte and soluble protein in 
the injected sample, respectively.
24-28
  If multiple but independent binding sites are 
present for the solute with the protein, the value that is obtained by Equation 7.3 is 
instead the global affinity constant, nKa’, where n represents the number of sites that are 
involved in the interaction.
24-27   
 
   
Determination of binding strength for testosterone with HSA 
The binding parameters for testosterone with HSA were examined by using a 10 
mm × 2.1 mm i.d. HSA microcolumn for ultrafast affinity extraction.  This type of 
microcolumn and column size have previously been shown to be useful in this method for 
studying the interactions of HSA with drugs that have low-to-moderate strength 
interactions (e.g., affinities in the range of 10
4
-10
5
 M
-1
), which are comparable to the 
affinities that have been reported for testosterone with HSA.
2,5-7,24,25
 The experiments 
with this particular microcolumn were carried out by injecting 1.0 μL samples that 
contained 20 μM testosterone and 40 μM HSA at flow rates ranging from 0.1 to 5.0 
mL/min.  A consistent free hormone fraction was obtained when the flow rate was at or 
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above 4.5 mL/min of this particular column, or when the column residence time for the 
sample was less than or equal to about 370 ms.   
Figure 7.4 shows the results that were obtained when these data were plotted 
according to Equations 7.1 and 7.2.  Linear responses were obtained for both types of 
plots, with correlation coefficients that ranged from 0.998 to 0.999 (n = 5-6).  The value 
of Ka for testosterone with HSA values were determined by either utilizing the 
extrapolation method based on Equations 7.2 and 7.3 or by only using Equation 7.3 but 
with a known F0 value that was measured at the optimum flow rate.  As shown in Table 
7.1, the value of Ka that was obtained through these methods was 3.2-3.5 × 10
4
 M
-1
 at pH 
7.4 and 37 ºC, which gave excellent agreement with values of 2.0-4.1 × 104 M-1 that have 
been previously determined for the same system by using other methods.
2,5,7
 
To verify these parameters, the ultrafast affinity experiment was repeated by using 
two-fold lower concentrations of both testosterone and HSA and a shorter HSA 
microcolumn (i.e., 5 mm × 2.1 mm i.d.).  This shorter column made it possible to still 
obtain good retention for the free fraction of testosterone but also had half of the column 
residence time of the 10 mm × 2.1 mm i.d. column when used at the same flow rate.  In 
this second set of experiments, 1.0 μL samples that contained 10 μM testosterone and 20 
μM HSA were applied at 0.5 to 2.5 mL/min.  As shown in Figure 7.2, a minimum flow 
rate of only 2 mL/min was now required to obtain a consistent free hormone fraction on 
this shorter column but the column residence time obtained at this flow rate (416 ms) was 
comparable to the maximum allowable residence time that was observed when using the 
longer 10 mm × 2.1 mm i.d. HSA microcolumn.   
  
2
8
2 
Table 7.1  Equilibrium constants and rate constants for the interactions of testosterone with HSA
a 
 Association equilibrium constant, 
Ka (× 10
4 
M
-1
) 
Dissociation rate constant, 
kd (s
-1
) 
Association rate constant, 
ka (× 10
4
 M
-1
s
-1
)
b
 
Samples
c
 Equation 7.3 
only 
Equations 
7.2-7.3 
Equation 7.1 Equation 7.2 Equations 7.2-7.3 
10 μM Testosterone/20 μM HSA 3.2 (± 0.2) 3.3 (± 0.6) 2.07 (± 0.03) 2.08 (± 0.12) 6.7 (± 0.6) 
20 μM Testosterone/40 μM HSA 3.5 (± 0.3) 3.2 (± 0.5) 2.20 (± 0.04) 2.17 (± 0.08) 7.6 (± 0.7) 
Literature values [Refs.] 2.02-4.06 [3,5,7] 3.5 (± 0.4) [16]  
 
a
All of these values were measured at pH 7.4 and 37 
o
C.  The values in parentheses represent a range of ± 1 S.D. (n = 4).   
 
b
The ka values were calculated by using the formula ka = kd Ka,  where Ka was determined by using experimentally measured free 
fraction values and Equation 7.3, and kd was found by using Equation 7.2. 
cThe samples containing 10 μM testosterone/20 μM HSA were analyzed using a 5 mm × 2.1 mm i.d. HSA microcolumn, and the samples 
containing 20 μM testosterone/40 μM HSA were analyzed using a 10 mm × 2.1 mm i.d. HSA microcolumn. 
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The data that were obtained when using the 5 mm × 2.1 mm i.d. HSA 
microcolumn again gave linear relationships when they were plotted according to either 
Equations 7.1 or 7.2.  The correlation coefficients for these plots ranged from 0.998 to 
0.999 (n = 3-4).  The values of Ka that were determined from this plots were 3.2-3.3 × 10
4
 
M
-1
, as shown in Table 7.1.  These values were within 3.1-8.6% of those measured on the 
10 mm × 2.1 mm i.d. column and fell within the range of values that have been reported 
in the literature.
 2,5,7
  The relative precisions of the Ka values that were measured by 
ultrafast affinity extraction ranged from ± 6.3 to 18.2% when using both sizes of HSA 
microcolumns and samples that contained 10-20 μM testosterone plus 20-40 μM HSA.  
Further experiments were carried out using the 5 mm × 2.1 mm i.d. HSA microcolumn as 
part of a multi-dimensional affinity system and with samples containing physiological 
levels of both testosterone and HSA (i.e., 25 nM testosterone and 600 μM HSA).  The 
free fraction of testosterone measured in this condition was 4.94-4.99%, with precisions 
of ± 0.23-1.05%. These data gave a value for Ka of 3.2 (± 0.1) × 10
4
 M
-1
, which agreed 
with these other experimental results and reference values.  The consistency of these 
values also confirmed that the ultrafast extraction results and measured association 
equilibrium constants for testosterone with HSA were independent of concentration, as 
would be expected for a system involving one or more saturable sites.   
 
Determination of rate constants for interactions of testosterone with HSA 
The dissociation rate constants for testosterone and HSA were estimated by fitting 
the data in Figure 7.4 (which were obtained on a 10 mm × 2.1 mm i.d. HSA microcolumn) 
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directly to Equation 7.2 or to Equation 7.1 with a point included at the origin.  Plots gave 
a value for kd of 2.17-2.20 s
-1
 at pH 7.4 and 37 ºC.  This set of values was consistent with 
a kd of 3.5 (± 0.4) s
-1 that has been previously determined by rapid filtration assay at the 
same temperature and pH using radiolabeled testosterone and a Krebs-tricine buffer.16   
A shorter HSA microcolumn (5 mm × 2.1 mm i.d.) was also used to measure the 
dissociation rate constant for testosterone with HSA.  The kd values that were obtained 
are also given in Table 7.1.  These dissociation rate constants differed by only 4.2 to 5.9% 
from those obtained on the 10 mm × 2.1 mm i.d. HSA microcolumn.  The relative 
precisions of the kd values that were determined by using both types of HSA 
microcolumns were in the range of ± 1.4 to 5.8%. 
The Ka and kd values that were determined in this study were also utilized to 
calculate the second-order association rate constant (ka) for testosterone with soluble 
HSA, based on the relationship ka = kd Ka.  Table 7.1 summarizes the values that were 
used in these calculations and the estimates of ka that were obtained.  The ka values of 
6.7-7.6 × 104 M-1s-1 that were found gave good agreement with the range of association 
rate constants that have been reported for HSA with other solutes (e.g., gliclazide and 
chlorpromazine) that have similar association equilibrium constants and/or dissociation 
rate constants for this protein to those seen here for testosterone.
24 
  
 
Determination of the binding strength for testosterone with SHBG 
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The binding affinity for testosterone-SHBG interaction followed a similar 
procedure as for testosterone with HSA.  The samples in this case were prepared at 
therapeutic-relevant concentrations: 42 nM testosterone and 20 nM SHBG.  The injection 
volume also increased to 50 μL for a better detection of testosterone at low 
concentrations.  A single HSA affinity microcolumn that has a size of 20 mm × 2.1 mm 
i.d. were used in this study to measure the free fraction of testosterone in the sample 
containing this hormone and SHBG.   
Figure 7.2 shows the apparent free hormone fractions that were measured at flow 
rates ranging from 0.25 to 2.0 mL/min.  The effect of flow rate on hormone-protein 
dissociation occurred in the column was minimized as the flow rate was raised.  A 
constant free fraction was obtained when the flow rate was above 1.25 mL/min, or when 
the column residence time was at least 2.66 s.  At or above the optimum flow rate, the 
original free fractions of testosterone that was present at equilibrium in the samples were 
estimated, giving a value of 54.4 (± 1.7)% at 1.25 mL/min, 54.1 (± 1.3)% at 1.5 mL/min, 
and 54.3 (± 1.6)% at 2.0 mL/min.  This information can be used to determine the global 
affinity constant for testosterone with SHBG according to Equation 7.3.  As summarized 
in Table 7.2, the estimated value for nKa’ was 1.1 (± 0.1) × 10
9
 M
-1
 at pH 7.4 and 37 ºC 
when taking an average of the values that were measured at the optimum flow rates (i.e., 
1.25, 1.5 and 2 mL/min).  
The apparent free fraction values that were measured at various low-to-moderate 
flow rates were also used to estimate the global association equilibrium constant based on 
Equations 7.2 and 7.3.  As shown in Table 7.2, the value of nKa’ that was obtained was 
1.0 (± 0.6) × 10
9
 M
-1
, which differed by only 9.1% from the results determined based on  
  
2
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Table 7.2  Equilibrium constants and rate constants for the interactions of testosterone with SHBG
a 
 Global affinity constant,  
nKa’ (× 10
9 
M
-1
) 
 
 
Overall dissociation rate 
constant, kd (s
-1
) 
 
 
Overall association rate 
constant, ka (× 10
7
 M
-1
s
-1
)
b
 
Samples Equation 7.3
c Equations 
7.2-7.3 
 Equation 7.1 Equation 7.2  Equations 7.2-7.3 
42 nM Testosterone/20 nM SHBG 1.1 (± 0.1) 1.0 (± 0.6) 
 
0.058 (± 0.002) 0.057 (± 0.004) 
 
6.3 (± 0.7) 
Literature values [Refs.] 0.3-1.9 [3, 5,7,29]  0.032-0.059 [15,30,31]
d   
 
a
All of these values were measured at pH 7.4 and 37 
o
C, except where otherwise indicated.  The values from ultrafast affinity 
extraction were obtained on a 20 mm × 2.1 mm i.d. HSA microcolumn.  The values in parentheses represent a range of ± 1 S.D. (n = 
4), except where otherwise indicated.   
b
These ka values were calculated by using the formula ka = kd (nKa’),  where nKa’ was determined by using experimentally measured 
free fraction values and Equation 7.3, and kd was found by using Equation 7.2. 
c
These nKa
’
 values were obtained by taking the average of the values that were measured at  1.25, 1.50 and 2.00 mL/min.  
d
The value of kd was measured at 37 
o
C and pH 7.4  in Ref. 15, at 37
o
C and pH 7.2  in Ref. 30 and at 37.5 
o
C and pH 8 in Ref. 31. 
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experimentally measured free fraction values and Equation 7.3.  Both of these two values 
fit within the range of the affinity constants that were determined through other methods 
for the same binding system.
2,5,7,29
 
 
Determination of rate constants for the interactions of testosterone with SHBG 
The rate constants for testosterone with SHBG were determined by using 
Equations 7.1 and 7.2 and the apparent free fraction values that were measured for this 
system at various flow rates.  Figure 7.5 shows some typical plots that were obtained, 
which gave linear responses with correlation coefficients that ranged from 0.991 to 0.997 
(n = 5-6).  The overall dissociation rate constants that were determined from these plots 
were 0.057-0.058 s
-1
, which agreed well with reference values (see Table 7.2).
15,30,31
 The 
relative precision for the measured kd values was ± 3.4-7.0%.   
 The overall second-order association rate constant for testosterone with soluble 
SHBG was calculated from the measured values for kd and nKa
’
 shown in Table 7.2.  The 
estimated ka was 6.3 (± 0.7) × 10
7
 M
-1
s
-1
.  This value was larger than a value of 1.75 × 
10
6
 M
-1
s
-1 
that has been reported for the same binding system at 4 
o
C,
31
 but was 
comparable to the result obtained for a system with a similar affinity for the interaction of 
testosterone with progesterone-binding globulin (guinea pig, 4 
o
C; nKa’, 2.4 × 10
9
 M
-1
; kd, 
9.5 × 10-3 s-1; ka, 2.2 × 10
7
 M
-1
s
-1
).
32 
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Figure 7.5  Measurement of the overall dissociation rate constant for testosterone 
from SHBG at pH 7.4 and 37 C by using ultrafast affinity extraction.  
The sample contained 42 nM testosterone/20 nM SHBG, which was 
injected onto a 20 mm × 2.1 mm i.d. HSA microcolumn.  These results 
were analyzed by using Equation 7.2 (top) or Equation 7.1 (bottom), 
where the latter included a point at the origin.  The equations for the best-
fit lines were y = 0.057 (± 0.004) x + 0.785 (± 0.027) and y = 0.058 (± 
0.002) x + 0.002 (± 0.012), respectively. The correlation coefficients for 
these plots ranged from 0.991 to 0.997 (n = 5-6).  The error bars represent 
a range of ± 1 S.D. (n = 4). 
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Conclusions  
This work used ultrafast affinity extraction and a multi-dimensional affinity 
system to examine the hormone-protein interaction and to measure the free hormone 
fractions at therapeutic levels.  The information obtained included the dissociation rate 
constants and association equilibrium constants for the testosterone-HSA and 
testosterone-SHBG interactions.  The obtained results gave good agreement with 
previous values that have been reported for the same binding systems based on other 
analytical approaches.  However, the ultrafast affinity extraction based HPAC method 
has various advantages.  This method is able to provide the both the binding constant and 
rate constant in a single experiment.  This allows the measurements to be accomplished 
with small consumptions of samples and time.  The ultrafast extraction can also be 
coupled with a multi-dimensional system to estimate the free fraction of hormone in 
samples prepared at therapeutic and physiological concentrations.  In addition, the 
amount of samples required for each sample injection is very small, which significantly 
decreases the cost for this method.   
The results obtained in this work demonstrates that the ultrafast affinity extraction 
method can be a general approach that could not only be used on drug-protein binding 
studies, as has been reported previously,
25-27
 but also be adapted for use with other 
binding studies such as the interactions between hormone and plasma proteins.  Another 
important finding is that this method can be used to study the analyte-protein interaction 
with very strong binding (testosterone/SHBG; affinities, ~10
9
 M
-1
) by the use of an 
affinity column, which has weaker binding to this analyte (testosterone/HSA; affinities, 
~10
4
 M
-1
).  Therefore, it is possible to extend the ultrafast affinity extraction method to 
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study broad types of biological interactions with small limitations of the binding strength 
among the analyte.   
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CHAPTER 8 
Development of High Capacity Affinity Microcolumns Based on Hybrid Cross-
Linking and Protein Immobilization Methods 
Portion of this chapter appear in X. Zheng, M. Podariu, D.S. Hage, “Development of Enhanced Capacity 
Affinity Microcolumns by using a Hybrid of Protein Cross-linking/Modification and Immobilization” 
Journal of Chromatography A 2015, submitted. 
 
Introduction 
High-performance affinity chromatography (HPAC) is a type of high-
performance liquid chromatography that uses biologically-related binding agents such as 
proteins or antibodies as the stationary phase.
1-3
 This method has been widely used for 
chiral separations and the purification or analysis of biological agents, as well as for 
characterization of the biological interactions.
1-4
 The retention and selectivity of this 
technique depend on the specific binding of the target analyte to the immobilized binding 
agent, and the amount of binding sites that are available in the column.
4
  This latter factor 
is related to, in turn, the total amount of binding agent that is present in the column and 
its relative activity.
2,4
   
Covalent immobilization is often used in affinity chromatography to couple a 
binding agent such as protein to a support.  For example, this process might involve the 
use of amine, sulfhydryl, carboxyl, or carbonyl groups on a protein or glycoprotein.
1,4-9
 
This general approach can produce affinity columns that have high stabilities and that can 
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be reused for many sample applications or experiments.  However, the amount of protein 
that can be immobilized is generally limited by the size of protein and the surface area of 
the support.  In addition, effects such as improper orientation of the binding agent or 
steric hindrance may lead to a decrease in this agent’s apparent activity.6,9  As a result, it 
would be useful to have alternative strategies that could avoid such limitations and be 
used to increase the binding capacity and/or activity of columns that contain proteins as 
their stationary phases.  A specific area in which this is of interest is in work with 
miniaturized affinity devices and affinity microcolumns, in which an increase in activity 
helps to provide higher retention and resolution for such devices.
10-13
 
This chapter will include the examinations of some possible routes for creating 
affinity microcolumns with increased binding capacities and activities by using a 
combination of covalent immobilization and protein cross-linking or modification (see 
Figure 8.1).  Human serum albumin (HSA), which is the most abundant protein in human 
serum 
2,4,8
, will be used as a model protein and binding agent for these experiments.  HSA 
has been of interest for use in affinity chromatography as a chiral stationary phase 
8
 and 
in studies of the binding by this protein with drugs, long-chain fatty acids, and some 
hormones.
8,14-15
  This protein is a single chain polypeptide consisting of 585 amino acid 
residues and has a mass of 66.5 kDa.
8,14-15
  It has two major drug binding sites (i.e., 
Sudlow sites I and II) but only one free sulfhydryl group (Cys34), which is not located 
near either of these two sites.
4,8,14-15
  Various methods have previously been developed to 
immobilize this protein to chromatographic supports, including both amine-based 
coupling methods
 9,16-21
 and the coupling of this protein through Cys34 to maleimide-
activated supports.
5,9
  However, these techniques are all inherently limited by the  
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Figure 8.1  General schemes considered for the preparation of high capacity HSA 
supports, such as (a) immobilization of HSA followed by 
modification/cross-linking of the immobilized protein with soluble protein 
or (b) modifying/cross-linking of soluble HSA, followed by 
immobilization of the resulting protein products. 
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available surface area of the support and may be subject to at least some steric hindrance 
or other immobilization effects.
6,9
 
An alternative approach that will be considered in this chapter is to use the cross-
linking or modification of a protein such as HSA, either before or after covalent 
immobilization, to provide an increase in the amount of active protein that can be placed 
into small affinity columns.   Bismaleimidohexane (BMH), a homobifunctional cross-
linker that reacts specifically with sulfhydryl groups 
22-27
, will be the reagent employed 
for this approach.  The protein content and relative activity of HSA columns that are 
modified with BMH will be compared to those obtained by using only covalent 
immobilization.  Affinity microcolumns that are made by this hybrid approach will then 
be examined for use in drug-binding studies and ultrafast affinity extraction, among other 
applications.  The results will be used to determine the advantages or possible limitations 
of this hybrid modification/immobilization strategy, as well as its potential uses in areas 
such as high-throughput studies of drug-protein binding, new methods for biointeraction 
studies, and microscale affinity-based separations.            
 
Experimental 
Materials and reagents 
 The HSA (Cohn fraction V, essentially fatty acid free, ≥96% pure), 
carbamazepine, racemic verapamil, racemic warfarin, dimethyl sulfoxide (DMSO), 
sodium nitrate, sodium borohydride and sodium cyanoborohydride were obtained from 
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Sigma (St. Louis, MO, USA).  The ethacrynic acid was purchased from Fisher Scientific 
(Atlanta, GA, USA).  The Zeba spin desalting columns (5 mL, 7 kDa cutoff), BMH, and 
reagents for the bicinchoninic acid (BCA) protein assay were from Thermo Scientific 
(Rockford, IL, USA).  The Nucleosil Si 300 silica (7 μm particle diameter, 300 Å pore 
size) was purchased from Macherey Nagel (Dűren, Germany).  All buffers and aqueous 
solutions were prepared using water from a Milli-Q Advantage A 10 system (EDM 
Millipore Corporation, Billerica, MA, USA) and were passed through Osmonics 0.22 μm 
nylon filters from Fisher (Pittsburgh, PA, USA). 
 
Apparatus 
The HSA solutions or silica slurries were mixed and allowed to react with added 
reagents by using a Labquake Shaker from Barnstead Thermolyne (Dubuque, IA, USA).  
The affinity microcolumns were packed using a Prep 24 pump from ChromTech (Apple 
Valley, MN, USA).  The HPLC system consisted of a PU-2080 Plus pump, an AS-2057 
autosampler, and a UV-2075 absorbance detector from Jasco (Easton, MD, USA).  An 
Alltech water jacket (Deerfield, IL, USA) and an Isotemp 3013D circulating water bath 
from Fisher were used to maintain a temperature of 37.0 (± 0.1) °C for the columns 
during all experiments described in this chapter.  ChromNAV v1.18.04 software and 
LCNet from Jasco were used to control the HPLC system.  Chromatograms were 
analyzed through the use of PeakFit v4.12 software (Jandel Scientific, San Rafael, CA, 
USA). 
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Preparation of affinity supports 
The reference HSA supports were prepared by immobilizing HSA onto silica that 
had initially been prepared in a diol-bonded form and then converted into an aldehyde-
activated form for use in the Schiff base immobilization method.
28
  Sodium 
cyanoborohydride was also placed in the HSA/aldehyde-silica slurry during 
immobilization to reduce each Schiff base upon its formation, to create a more stable 
secondary amine linkage. After the Schiff base immobilization reaction had been allowed 
to occur, the remaining aldehyde groups on the support were reduced by adding sodium 
borohydride.  A control support was prepared in the same manner but with no HSA being 
added during the immobilization step.
28
   
The BMH-treated HSA silica that was used in the chromatographic studies was 
prepared according to the strategy shown in Figure 8.1(b).  This method involved 
dissolving 70 mg HSA in 1.0 mL of pH 7.0, 1.5 M potassium phosphate buffer and 
combining this solution with 30 μL of 0.072 M BMH in DMSO, giving a mixture with a 
final concentration of 2 mM BMH and 1 mM HSA (i.e., a 2:1 mol/mol ratio for BMH vs. 
HSA).  This mixture was incubated for 8 h at room temperature, followed by additional 
mixing for 24 h at 4 
o
C.  A desalting column (5.0 mL volume, 7 kDa cutoff) was used to 
remove excess reagents from the cross-linked or modified HSA.  The pH of this protein 
solution was slowly adjusted to pH 6.0 by adding a small amount of 50% (v/v) 
hydrochloric acid, giving a final total volume of approximately 1 mL.  This protein 
solution was then combined with 0.15 g Nucleosil Si-300, which had been already 
converted into an aldehyde-activated form and washed with pH 6.0, 0.10 M phosphate 
buffer for use in the Schiff base immobilization method.
28
  Sodium cyanoborohydride 
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was also added to this mixture to reduce the Schiff bases upon their formation, and 
sodium borohydride was again added later to reduce and remove any aldehyde groups 
that remained after the immobilization process.
28
  A control support was prepared by the 
same procedure but with no HSA being placed into the reaction buffer during the cross-
linking/modification reaction.  All of HSA supports and control supports that are 
discussed in this chapter were stored in pH 7.4, 0.067 M potassium phosphate buffer and 
at 4 
o
C when not in use. 
A portion of each HSA support or BMH-treated HSA support was analyzed for its 
protein content by using a BCA protein assay.  This assay was carried out in triplicate 
using normal HSA as the standard and the control support as the blank.  The same assay 
was also carried out using samples that contained 0.5 μM soluble BMH or a control 
support that was prepared from the reference HSA silica after treating this material with a 
two-fold mol excess BMH, following protein immobilization.  The soluble BMH did not 
have any noticeable effect on the results of the BCA assay, but the BMH-treated HSA 
control support gave a result that was 37.7% (± 2.1%) lower than that obtained for the 
same support before treatment with BMH.  All of the protein assay results reported in this 
study and that involved BMH-treated HSA have been corrected for this BMH-induced 
decrease in response, based on the results of these control experiments.   
 
Chromatographic studies 
The supports that were used in the chromatographic studies were downward 
slurry packed into separate 10 mm × 2.1 mm i.d. microcolumns at 4000 psi (28 MPa) or 
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into 5 mm × 2.1 mm i.d. microcolumns at 3000 psi (20 MPa).  The packing solution was 
pH 7.4, 0.067 M potassium phosphate buffer. The microcolumns were stored in the same 
buffer at 4 °C when not in use.  The column-to-column variation in overall support 
content, as determined by making replicate injections of the tested drugs onto several new 
columns of the same size and packed with the same HSA support, was ± 0.4 to 6.8%.  
The mobile phase used in the chromatographic experiments was pH 7.4, 0.067 M 
potassium phosphate buffer, except where otherwise indicated.  The following 
wavelengths were employed for absorbance detection: warfarin, 308 nm; verapamil, 229 
nm; carbamazepine, 284 nm; ethacrynic acid, 280 nm; and sodium nitrate, 205 nm.   
The measurements of retention factors were made by injecting 5 μL samples that 
contained 10 μM of racemic warfarin, racemic verapamil, or carbamazepine dissolved in 
the mobile phase.  All samples were injected in quadruplicate on 5 mm or 10 mm × 2.1 
mm i.d. HSA microcolumns and control columns at 0.1-1.5 mL/min.  Sodium nitrate, 
which has no retention on the HSA reference columns or control columns 
6,29
, was used 
as a void marker; this compound was injected onto each microcolumn under the same 
conditions as used for each drug.  The extra-column void time was measured by injecting 
sodium nitrate onto the HPLC system with a zero dead volume connector being used in 
place of the column.   
The retention due to interactions with BMH was measured by injecting each drug 
in quadruplicate onto a reference 10 mm × 2.1mm i.d. HSA microcolumn before and 
after the microcolumn had been treated with BMH.  The BMH solution that was used for 
this treatment contained 1.25 mM of BMH in pH 7.0, 1.5 M potassium phosphate buffer 
plus 3.5% DMSO.  A syringe pump was used to apply this solution to the HSA 
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microcolumn at 3 μL/min for 15 h at room temperature.  The estimated ratio for BMH 
versus HSA was 20:1 mol/mol while the BMH solution was passing through the column.  
This column was then washed with pH 7.4, 0.067 M potassium phosphate buffer for 8 h 
at 0.25 mL/min and room temperature prior to its used in further retention studies. 
The chiral separation of R/S-warfarin was obtained by injecting 10 μL of 10 μM 
racemic warfarin at 1.5 mL/min onto a 10 mm × 2.1 mm i.d. BMH-treated HSA 
microcolumn and using a mobile phase that consisted of pH 7.4, 0.067 M potassium 
phosphate buffer with 1.5% (v/v) 1-propanol.  The reversible binding of ethacrynic acid 
with HSA was examined by injecting 20 μL of 10 μM ethacrynic acid onto 10 mm × 2.1 
mm i.d. BMH-treated HSA or reference HSA microcolumns at 1.5 mL/min.   
In the ultrafast affinity extraction experiments, racemic warfarin, racemic 
verapamil, carbamazepine and HSA were injected onto a 10 mm × 2.1 mm i.d. BMH-
treated HSA microcolumn or reference HSA microcolumn.  This was carried out by 
injecting 1 μL samples that contained 10 μM of each drug or a mixture containing of 10 
μM of the drug plus 20 μM soluble HSA.  These samples were incubated for at least 30 
min prior to injection, with both the sample and mobile phase being preheated to 37 
o
C 
before passage through the affinity microcolumn.  The flow rates used for ultrafast 
affinity extraction ranged from 0.25 to 2.5 mL/min for verapamil, 0.25 to 6.0 mL/min for 
warfarin and 0.05 to 1.0 mL/min for carbamazepine.  Each free fraction was calculated 
by dividing the peak area for the free drug by the peak area for the total drug in the 
sample.
16-18
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Results and Discussion 
Optimization of HSA modification 
Two possible cross-linking and modification strategies were explored for 
increasing the HSA content of affinity supports that contain this immobilized protein.  
This modification and cross-linking could be performed either after protein 
immobilization, as shown in Figure 8.1(a), or before immobilization, as illustrated in 
Figure 8.1(b).   
In the approach represented by Figure 8.1(a), HSA was first immobilized onto 
silica, as achieved in this particular study by using the Schiff base method.  Soluble HSA 
and BMH were then incubated with this immobilized HSA silica for cross-linking and 
modification of the soluble and immobilized forms of this protein.  Initial studies of this 
strategy looked at the amount of soluble HSA that was needed for the cross-linking and 
modification reaction.  A support prepared by using only the Schiff base immobilization 
method had a protein content of 61.4 (± 0.7) mg HSA/g silica.  A 0.25 mL slurry 
containing roughly 40 mg of this support (or 2.4 mg immobilized HSA) was incubated 
with 10 mg/mL of soluble HSA and 0.60 mM BMH in pH 7.0, 0.10 M phosphate buffer 
that contained 0.15 M NaCl.  These conditions gave only a 15.3 (± 2.2)% increase in the 
final protein content of the support.  When the concentration of the soluble protein in the 
slurry was increased to 40 mg/mL, no further increase in the amount of immobilized 
protein was noted compared to the original protein content of the support.  The same 
amount of soluble HSA and BMH were also added in three portions to the HSA silica in 
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5 h intervals.  This method gave only a small and essentially negligible increase in 
protein content, or a 3.7 (± 2.0)% change, when compared to the original support. 
These small or negligible changes in the immobilized protein content when using 
the strategy in Figure 8.1(a) were probably the result of steric hindrance that prevented 
the soluble HSA from reaching the immobilized HSA and/or orientation effects that made 
it difficult for the immobilized and soluble HSA to align properly for cross-linking 
through their modified or free sulfhydryl groups.
9
  It is also likely that the BMH had 
cross-linked some of the soluble HSA with other molecules of soluble HSA, which would 
then not have been available for reacting with the free sulfhydryl groups on the 
immobilized HSA. 
In the second approach, as illustrated in Figure 8.1(b), the HSA was first 
dissolved in the reaction buffer and then incubated with BMH for cross-linking and 
modification.  After removing the excess BMH, the cross-linked or modified proteins 
were immobilized by the Schiff base method.  This method was performed by dissolving 
5 mg or 20 mg of HSA in 1.0 mL of the BMH reaction buffer.  This mixture initially 
contained 0.00, 0.15 mM or 0.75 mM BMH for a 5 mg HSA sample; or 0.00, 0.60 or 3.01 
mM BMH for a 20 mg HSA sample, providing a 0:1, 2:1, or 10:1 mol/mol ratio for BMH 
versus HSA.  When the concentration of BMH was 10-fold higher than that of the soluble 
HSA, the protein content of the final support was increased by 64 (± 4)% or 65 (± 3)% 
for the solutions containing 5.0 mg/mL or 20.0 mg/mL of HSA and when compared to an 
immobilization scheme in which no BMH had been added.  When the concentration of 
BMH was only 2-fold higher than the concentration of soluble HSA, the protein content 
of the final support increased by 75 (± 4)% when using 20.0 mg/mL of soluble HSA.  
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However, decreasing the BMH content further (e.g., down to a 1:2 mol/mol ratio of BMH 
versus HSA) did not provide any further increase in the protein content.   
The concentration of the reaction buffer that was used in both of the strategies that 
are shown in Figure 8.1 was also considered.  This was done by increasing the 
concentration of the pH 7.0 potassium phosphate buffer to 1.5 M.
5,29,30
  It has been 
suggested that increasing the ionic strength of the buffer for this reaction can inhibit 
charge repulsion of adjacent proteins and increase the rate of nucleophilic addition of a 
sulfhydryl group to maleimide.
30
  For the immobilization/modification strategy in Figure 
8.1(a), no apparent increase in protein content was found when a higher ionic strength for 
the buffer was used during the modification reaction.  However, an increase as high as 
113 (± 2)% was observed when this same buffer was used for the 
modification/immobilization strategy in Figure 8.1(b).  This modification/immobilization 
strategy and set of conditions were later employed in the following sections of this study.  
 
Effects of protein modification on retention 
The next set of studies sought to characterize the effects of combining protein 
modification and immobilization on the retention that was observed for various drugs on 
HSA columns.  One drug that was used in these experiments was warfarin, which is an 
anticoagulant known to bind to HSA at Sudlow site I.
19-21,28
  Two other drugs that were 
tested were verapamil, a calcium channel blocking agent that has a primary binding site 
at Sudlow site I 
31
, and carbamazepine, an anticonvulsant that binds to Sudlow site II.
32
  
These drugs represented binding strengths that spanned roughly a 100-fold range in 
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affinities for HSA, with reported association equilibrium constants (Ka) at 37 
o
C and pH 
7.4 of  2.0-5.7 × 10
5
 M
-1 
for racemic warfarin, 1.4 (± 0.1)× 10
4
 M
-1
 for racemic verapamil, 
and 5.2-5.5 × 10
3
 M
-1
 for carbamazepine.
19-21,28,31-33
  
Figure 8.2 shows some typical chromatograms that were obtained for these drugs 
on BMH-treated HSA microcolumns and reference HSA microcolumns.  As is suggested 
by these results, the BMH-treated HSA columns gave a significant increase in retention 
for each of the tested drugs.  In the case of verapamil, a partial chiral separation with a 
resolution (Rs) of 0.61 (± 0.06) could be achieved by the BMH-treated HSA 
microcolumns in the presence of only pH 7.4 phosphate buffer at some of the flow rates 
that were used; however, no chiral separation was observed at the same flow rates when 
using the reference HSA microcolumn, as indicated in Figure 8.2(a).  Both types of 
columns gave at least a partial separation for racemic warfarin in the presence of only pH 
7.4, 0.067 M phosphate buffer, with Rs = 0.59 (± 0.02) on the reference HSA 
microcolumn and 0.74 (± 0.02) on the BMH-treated HSA microcolumn, as shown in 
Figure 8.2(b).  It was possible to increase the extent of the chiral separation for warfarin 
to nearly baseline resolution (Rs = 1.32 (± 0.05)) for the BMH-treated HSA microcolumn 
by including a small amount of 1.5% 1-propanol in the mobile phase, as shown in Figure 
8.2(c), while prior work under similar conditions with a reference HSA microcolumn 
gave a resolution of 1.12 (± 0.03).
17
 
 Table 8.1 lists the average retention factors that were obtained at 37 ºC and pH 7.4 
for each drug on 10 mm × 2.1 mm i.d. microcolumns containing BMH-treated HSA or a 
reference sample of HSA.  For each drug and at each sample flow rate, there was a  
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Figure 8.2 Chromatograms obtained for the injection of (a) 5 µL of 10 µM racemic 
verapamil onto a 10 mm × 2.1 mm i.d. BMH-treated HSA microcolumn or 
a reference HSA microcolumn at 0.25 mL/min and in the presence of pH 
7.4, 0.067 M phosphate buffer; (b) 5 µL of 10 µM racemic warfarin onto 
the same columns at 0.5 mL/min and in the presence of pH 7.4, 0.067 M 
phosphate buffer; or (c) 10 µL of 10 µM racemic warfarin onto a 10 mm × 
2.1 mm i.d. BMH-treated HSA microcolumn at 1.5 mL/min and in the 
presence of pH 7.4, 0.067 M phosphate buffer containing 1.5% (v/v) 1-
propanol.  All of these separations were carried out at 37 C and using 
BMH-treated HSA columns that were prepared with the 
modification/immobilization scheme described in Section of Optimization 
of HSA modification 
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.  
  
 
3
11
 
Table 8.1 Retention factors (k) measured on BMH-treated HSA supports and standard HSA supports
a
 
 
Drug 
Flow rate 
(mL/min) 
k, Reference 
HSA support 
k, BMH-treated 
HSA support 
Total change  
in k (%) 
Specific change  
in k due to HSA (%) 
Warfarin
b
    1.50 116 (± 7) 218 (± 3) 88 (± 7) 70 (± 9) 
   0.50 124 (± 3) 233 (± 5) 88 (± 5) 70 (± 8) 
Verapamil
b
    1.00 13.3 (± 2.2) 35.7 (± 1.5) 168 (± 20) 95 (± 29) 
   0.50 14.4 (± 1.2) 37.3 (± 1.5) 159 (± 13) 86 (± 24) 
   0.25 13.7 (± 1.6) 35.2 (± 2.2) 157 (± 20) 84 (± 29) 
Carbamazepine    0.50 2.3 (± 0.1) 4.6 (± 0.3) 100 (± 14) 96 (± 15) 
   0.25 2.1 (± 0.1) 4.2 (± 0.2) 100 (± 11) 96 (± 13) 
   0.10 2.1 (± 0.2) 4.3 (± 0.1) 105 (± 11) 100 (± 12) 
a
The retention factors were determined at pH 7.4 and at 37
o
C for 10 mm × 2.1 mm i.d. columns.  The values in parentheses represent a 
range of ± 1 S.D., as determined by error propagation.  The estimated retention due to interactions with BMH were 18.1 (± 6.3)% for 
warfarin, 73 (± 21)% for verapamil, and 4.3 (± 6.1)% for carbamazepine.   
b
The results provided for warfarin and verapamil were based on the average retention factors for R- and S-enantiomers. 
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consistent and significant increase in the total retention factor that was measured on the 
BMH-treated HSA microcolumns compared to the reference HSA microcolumns.  This 
overall increase ranged from 88% for warfarin to 100-105% for carbamazepine and 157-
168% for verapamil.  Part of this increase was found to be the result of non-specific 
interactions by some of the drugs with BHM residues, as determined through control 
studies that compared retention on a reference HSA column vs. the same column after 
treatment with BMH, but with no cross-linking to soluble HSA.  The increase in retention 
due to these non-specific interactions was found to be only 4.3 (± 6.1)% for 
carbamazepine and 18.1 (± 6.3)% for warfarin; however, this effect lead to 73 (± 21)% of 
the increase in retention that was noted for verapamil.  This trend agrees with previous 
reports in which verapamil has been noted to have much higher non-specific interactions 
on other types of affinity microcolumns than warfarin, carbamazepine or other drugs.
18,31
  
The retention increase due to the immobilized HSA was determined by correcting 
the overall change in retention for the increase due to the non-specific interactions with 
BMH.  These corrected values are also included in Table 8.1.  The size of this corrected 
increase in retention was now in the general range of 70-100% for all of the tested drugs, 
regardless of whether these drugs were known to bind at Sudlow site I (i.e., warfarin and 
verapamil) or at Sudlow site II (carbamazepine).
19-21,28,31,32
  This increase in protein-based 
retention was in the same general range as the 75-113% increase in overall protein 
content that had been noted in the previous section for the BMH-treated HSA supports.  
The similarity in these values indicates that this increase in retention was directly related 
to the higher protein content of the BMH-treated HSA supports.  This increase was 
probably also aided by the site-selective nature of the modification process that was used 
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in this study and the fact that Cys34, the modification site, is distant from both Sudlow 
sites I and II of HSA.
4,8,14-15
   
 
Use of BMH-treated HSA microcolumns with a sulfhydryl-reactive drug 
One unique application that was explored for the BMH-treated HSA 
microcolumns was their use in studying the reversible binding of a drug that can also 
undergo a covalent linkage with HSA at Cys34.  Ethacrynic acid was used as the model 
drug for this work.  Ethacrynic acid is a diuretic drug that can rapidly form a covalent 
bond with Cys34 at a neutral pH (see Figure 8.3).
34-37
  In prior work, this drug has been 
used to modify HSA columns to distinguish between reversible and covalent interactions 
by other solutes with this protein.
35-37
  However, this drug is also known to be able to 
reversibly bind at major two sites on HSA (i.e., Sudlow sites I and II).
34-38
  Isothermal 
titration microcalorimetry and circular dichroism spectroscopy have previously been used 
to study these latter processes, resulting in estimated binding constants on the order of 
10
5
-10
6
 M
-1
 for these reversible interactions.
34,36,39,40
   
Figure 8.3(b) shows some chromatograms that were obtained when ethacrynic 
acid was injected at 1.5 mL/min onto a 10 mm × 2.1 mm i.d. reference HSA 
microcolumn or a BMH-treated HSA microcolumn.  On the BMH-treated HSA column, a 
peak for ethacrynic acid was observed with a retention time of about 12 min.  This value 
corresponded to a retention factor of 502 (± 2) at 37 ºC and pH 7.4 and is the type of 
behavior that would be expected for a strong but reversible drug-protein interaction.  
However, no peak was seen when the same drug sample was injected onto the reference  
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Figure 8.3  (a) The reaction between ethacrynic acid and Cys34 on HSA and (b) 
chromatograms obtained for 20 µL injections of 10 µM ethacrynic acid 
onto a 10 mm × 2.1 mm i.d. BMH-treated HSA microcolumn or a 
reference HSA microcolumn.  These results were obtained at 1.5 mL/min 
and 37 C using pH 7.4, 0.067 M phosphate buffer as the mobile phase. 
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HSA microcolumn, as would occur if this drug were quickly and covalently binding to 
HSA.  Injections of ethacrynic acid onto an inert control column with no protein present 
gave a peak area for ethacrynic acid that differed by only 3.0% from that observed on the 
BMH-treated HSA microcolumn, indicating that all the injected ethacrynic acid was 
being eluted and recovered from this microcolumn.  Neither the area or position of this 
peak was affected by including up to 100 µM BMH as a competing agent in the injected 
sample, confirming that this retention was due to the interaction of ethacrynic acid with 
HSA rather than with the groups added by BMH to HSA. 
The retention factor that was measured for ethacrynic acid on the BMH-treated 
HSA microcolumn was used to estimate the global affinity constant (nK’a) for this drug at 
its reversible binding sites on HSA.  This value was determined by using the relationships 
given in Equations 8.1-8.2.
4,13,14
 
𝑘 =
(𝑛1𝐾a1+ 𝑛2𝐾a2+   + 𝑛n𝐾an)𝑚L
𝑉M
                                    (8.1) 
𝑘 =
(𝑛𝐾 a)𝑚L
𝑉M
                                      (8.2) 
In these equations, the terms Ka1 through Kan represent the association equilibrium 
constants for the ethacrynic acid at each of its reversible binding sites with HSA, and n1 
through nn are the mole fractions for each type of site in the column, where nK’a is the 
sum of n1Ka1 through nnKan.  The term mL is the total moles of all binding sites for 
ethacrynic acid in the column, and VM is the void volume of the column.  
The interactions of ethacrynic acid at its two major and reversible binding sites on 
HSA (i.e., Sudlow sites I and II) are known to have binding constants that are roughly 
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two orders of magnitude higher than those for any weak binding sites that are present for 
this drug.
34,36,38-40
  Under these conditions, Equation 8.1 can be simplified to the two-site 
form given in Equation 8.3,  
   𝑘 =
(𝑛1𝐾a1+ 𝑛2𝐾a2)𝑚L
𝑉M
=
𝑛𝐾a (𝑚L1+𝑚L2)
𝑉M
                   (8.3) 
where n1 and n2 are the relative number of sites 1 and 2 (e.g., Sudlow sites I and II) on the 
binding agent in the column.  Equation 8.3 was next combined with the corrected 
retention factors that had been measured earlier in this chapter on BMH-treated HSA 
microcolumns for warfarin and carbamazepine (i.e., probes for Sudlow sites I and II) and 
with the known or measured association equilibrium constants of these drugs with HSA 
(see next Section).  By placing this information and the measured retention factor for 
ethacrynic acid into Equation 8.3, the global affinity constant for the reversible 
interactions of ethacrynic acid with HSA was found to be 3.2 (± 0.1) × 10
5
 M
-1
 at 37 ºC 
and pH 7.4.  This value was in good agreement with previous literature values of 1.65 × 
10
5
 M
-1
 to 1.2 × 10
6
 M
-1
 that have been obtained under similar conditions and by using 
techniques such as circular dichroism or isothermal titration microcalorimetry.
34,38-40
  
 
Use of BMH-treated HSA microcolumns in ultrafast affinity extraction 
Another application that was considered was the use of the BMH-treated HSA 
microcolumns in ultrafast affinity extraction and free drug fraction measurements.  These 
experiments were carried out by using samples that contained a drug in the presence or 
absence of soluble HSA, with small amounts of these samples being injected onto a 
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BMH-treated HSA microcolumn or a reference HSA microcolumn.
16-18
 These injections 
were made under column size and flow rate conditions that allowed part or all of the non-
bound (or free) drug fraction in the sample to be extracted by the immobilized HSA 
without allowing sufficient time for dissociation of a significant portion of the protein-
bound form of the drug in the sample.  As shown in Figure 8.4(b), the excess protein and 
original drug-protein complex eluted as a non-retained peak in this experiment, while the 
extracted free form of the drug was retained and eluted later from the column.  By 
comparing the retained peak area for the free drug and the total peak area for the same 
drug in the absence of any soluble HSA, the free drug fraction was then determined for 
the original sample.
16-18
  
The residence time of the drug/protein sample in the affinity extraction column is 
an important factor to consider in this type of free fraction analysis.  The use of a 
relatively long sample residence time may cause dissociation of the protein-bound form 
of a drug, resulting in a high value for the apparent free fraction.  This effect can be 
minimized by using a short column and/or by increasing the flow rate that is used for 
sample injection.
16-18
  It is also necessary to use a column size and flow rate conditions 
that allow sufficient resolution to be obtained between the non-retained and retained drug 
fractions to avoid having high free fraction measurements.
16-18
   
Figure 8.4(a) shows the results of free fraction measurements for verapamil/HSA 
mixtures that were injected onto both a BMH-treated HSA microcolumn and a reference 
HSA microcolumn at various flow rates.  The apparent free fraction decreased as the flow 
rate was increased until a consistent free fraction was obtained when the flow rate was at  
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Figure 8.4  (a) Effect of flow rate on the apparent free drug fractions measured for 1 
μL samples of 10 μM verapamil or 10 μM verapamil plus 20 μM soluble 
HSA injected onto a 10 mm × 2.1 mm i.d. BMH-treated HSA 
microcolumn (modification/immobilization strategy; black line, ) or a 10 
mm × 2.1 mm i.d. reference HSA microcolumn (gray, ▲), and (b) 
chromatograms obtained for 1 μL injections of 10 μM racemic verapamil 
plus 20 μM HSA onto the same columns at 1.25 mL/min on the BMH-
treated HSA microcolumn (black) or at 1.75 mL/min on the reference 
HSA microcolumn (gray).  These results were all acquired at 37 C and 
using pH 7.4, 0.067 M phosphate buffer as the mobile phase. 
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or above 1.25 mL/min on the BMH-treated HSA column.  However, the same 
measurements on the reference HSA microcolumn required a flow rate of at least 1.75 
mL/min for consistent free fractions to be obtained (Note: typical chromatograms for 
verapamil at these flow rates are provided in Figure 8.4(b)).  The differences in these 
flow rate requirements probably reflect the higher retention and better resolution that was 
between the free and bound drug peaks on the BMH-treated HSA microcolumns, which 
also helped minimize positive errors in the apparent free drug fraction.
3,5
  The same 
overall trend, in which lower or equivalent flow rates could be used in the free fraction 
measurements on the BHM-treated columns, was observed for warfarin and 
carbamazepine.   
The free drug fractions that were measured at or above these optimum flow rates 
were used to estimate the association equilibrium constants for each drug with soluble 
HSA.  These values were calculated by using Equation 8.4.
16,17
  
𝐾a =
1 −  0     
 0([P]    −  [ ]    + [ ]    0)
                     (8.4) 
In Equation 8.4, F0 is the free drug fraction that is measured at equilibrium (i.e., at or 
above a flow rate that minimizes drug-protein dissociation in the sample), while [D]tot 
and [P]tot are the total concentrations of the drug and soluble protein in the original 
sample.  The value of 𝐾a in this equation is the association equilibrium constant for a 
drug and protein with a single-site interaction, or the global affinity constant for a drug 
that has multiple but independent binding sites on the protein.
16,17
   
Table 8.2 shows the Ka values that were obtained by using Equation 8.2 and free 
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Table 8.2 Association equilibrium constants measured for various drugs with soluble HSA by using free fraction analysis on a 
BMH-treated HSA microcolumn or reference HSA microcolumn
a
 
 
Drug Reference HSA 
microcolumn 
BMH-treated HSA 
microcolumn  
Literature value  
[Ref.] 
Warfarin 2.5 (± 0.2) × 10
5
 M
-1
 2.6 (± 0.2) × 10
5
 M
-1
 2.0-5.7 × 10
5
 M
-1  
[19-21,28] 
Verapamil 1.5 (± 0.4) × 10
4
 M
-1
 1.4 (± 0.1) × 10
4
 M
-1
  1.4 (± 0.1) × 10
4 
M
-1  
[31] 
Carbamazepine 5.3 (± 0.4) × 10
3
 M
-1
 5.3 (± 0.4) × 10
3
 M
-1
  5.2-5.5 × 10
3
 M
-1  
[32,33] 
a
These results obtained in this study were measured at pH 7.4 and at 37
o
C.  The values in parentheses represent a range of ± 1 S.D., as 
determined by error propagation.  The results given for warfarin and verapamil are the ranges or average association equilibrium 
constants for the R- and S-enantiomers; the value given for verapamil is for the high affinity site of verapamil on HSA. 
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drug fractions that were measured on the BMH-treated HSA microcolumns or reference 
HSA microcolumns.  The values that were obtained in this chapter had relative precisions 
in the range of ± 7-8% and were based on peak area measurements that could be made 
within 1 to 6.5 min of sample injection. In each case, there was good agreement between 
the Ka values that were measured on these columns and with reference values that have 
been determined under the same pH and temperature conditions.  These results confirmed 
that the BMH-treated HSA microcolumns could be successfully used to quickly estimate 
Ka values for drug-protein binding based on free drug fraction measurements.  
 
Conclusions 
This study developed a new hybrid method to produce enhanced capacity affinity 
microcolumns containing HSA by combining BMH as a reagent for protein modification 
or cross-linking with a covalent immobilization method.  Various factors were considered 
in determining the optimum conditions for this method, including the use of BMH 
modification before or after protein immobilization and the reaction conditions involved 
in this process.  The supports that were obtained in the optimized method had up to a 75-
113% increase in protein content when compared to supports that were prepared using 
only covalent immobilization.  These BMH-modified HSA supports also gave a large 
increase in protein-based retention (i.e., 70-100%) versus a reference support when both 
types of materials were used in microcolumns to bind various drugs that are known to 
interact at Sudlow sites I or II of HSA.   
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The BMH-treated HSA microcolumns were tested for use in estimating free drug 
fractions and association equilibrium constants for drug-protein interactions.  These 
columns gave results comparable with those determined by reference HSA microcolumns 
or those reported in literature.  In addition, the BMH-treated HSA microcolumns were 
used to investigate the reversible interactions between HSA and ethacyrnic acid, a drug 
which can also covalently bind to the HSA through its free sulfhydryl group.  This type 
of hybrid modification/immobilization scheme is not limited to HSA but should also be 
useful in work with other proteins and in the study of alternative drug-protein systems.  
Possible applications for such columns include the high-throughput analysis of drug-
protein binding, protein-based chiral separations, the analysis of free drug fractions in 
clinical or pharmaceutical samples, and the screening of drug candidates for their protein 
interactions.
16-18
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CHAPTER 9 
Summary and Future Work 
 
Summary of Work 
The work in this dissertation mainly involved studies of the interactions between 
drugs or hormones and proteins by using high-performance affinity chromatography 
(HPAC) and affinity microcolumns. Human serum albumin (HSA) was used as a model 
protein for binding studies in this work. Chapter 1 introduced the general background for 
the work that is presented in this dissertation. This chapter included a discussion of the 
types of microcolumns that can be used for the study of biomolecular interactions, as well 
as the potential advantages of each type. This chapter also examined how affinity 
microcolumns have been used to examine biomolecular interactions with HPAC methods 
such as zonal elution and frontal analysis methods. A specific technique used throughout 
this dissertation, ultrafast affinity extraction, was also described in this chapter. 
Chapter 2 reviewed several analytical methods that have been to study the kinetics 
of biological interactions. These techniques included common or traditional methods 
such as stopped-flow analysis and surface plasmon resonance spectroscopy, as well as 
alternative methods based on affinity chromatography and capillary electrophoresis. This 
chapter described the general principles and theory behind these approaches, and showed 
how each technique can be utilized to provide information on the kinetics of biological 
interactions. Examples of applications, relative advantages or potential limitations were 
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also given for each method regarding its use in kinetic studies. 
Chapter 3 described the development of a method based on ultrafast affinity 
extraction and HPAC to determine both the dissociation rate constants and equilibrium 
constants for drug-protein interactions in solution. Several drugs that are known to bind 
to human serum albumin (HSA) were examined. The dissociation rate constants (kd) 
obtained for soluble HSA with each drug gave good agreement with previous rate 
constants that have been reported for the same drugs or other solutes with comparable 
affinities for HSA. The association equilibrium constants (Ka) that were determined 
simultaneously with the kd values also showed good agreement with the literature.  
Chapter 4 described a multi-dimensional system that was based on affinity 
microcolumns, ultrafast affinity extraction and chiral separations to measure the free 
fractions of drug enantiomers and to study their binding with serum transport proteins.  
R/S-Warfarin and the HSA were used as models to test this approach.  The free fractions 
of R- and S-warfarin that were determined by this method gave good agreement with 
those measured by ultrafiltration.  It was also found that this approach could provide a 
fast estimate of the association equilibrium constants for drug-protein interactions, giving 
results consistent with the literature and reference methods.  This method could also be 
utilized with clinically-relevant concentrations of warfarin and HSA and could be 
extended to other chiral drugs and serum proteins or used for the high-throughput 
screening of drug-protein interactions.  
Chapter 5 showed how ultrafast affinity extraction and a multi-dimensional 
affinity system could be used to investigate the effects of protein modification on drug 
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binding at therapeutic levels.  This approach was used to compare the free fractions and 
global affinity constants of several sulfonylurea drugs in the presence of normal HSA or 
glycated forms of this protein, as are produced during diabetes. Various factors were 
considered in optimizing the multi-dimensional HPAC system, including the flow rates 
and column sizes that were used to initially extract the free drug fractions and time at 
which this extracted fraction was passed onto the second column for further separation 
and analysis.  This method was able to measure free drug fractions as small as 0.09-
2.58% with an absolute precision of ± 0.02-0.5%.  The results that were obtained 
indicated that glycation can affect the free fractions of sulfonylurea drugs at typical 
therapeutic levels and that the size of this effect varies with the level of HSA glycation.  
Global affinity constants that were estimated from these free drug fractions gave good 
agreement with those predicted from previous binding studies or that were determined by 
using a reference method.   
Chapter 6 used ultrafast affinity extraction and a multi-dimensional affinity 
chromatographic system to measure the free fraction of drugs in serum and to examine 
the interactions of these drugs with HSA. These studies were conducted at typical 
therapeutic drug concentrations that were spiked into control human serum.  The drugs 
that were examined in this work included quinidine, diazepam, gliclazide, tolbutamide 
and acetohexamide. The dissociation rate constants for these drugs with HSA were 
measured during the process of system optimization, giving results in good agreement 
with previous literature values.  With the final multi-dimensional system, free drug 
fractions in serum were measured with values in the range of 0.69-7.40% and with 
absolute precisions of ± 0.1-0.7%.  The association equilibrium constants for each drug 
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with HSA were also estimated from these data and gave values that agreed well with 
those in the literature under comparable solution conditions.   
In Chapter 7, ultrafast affinity extraction was used to study hormone-protein 
interactions in solution, using the binding of testosterone with the transport proteins 
human serum albumin and sex hormone binding globulin (SHBG) as models.  In this 
method, an affinity microcolumn containing HSA was used to isolate and measure the 
free fraction of testosterone in a sample at equilibrium and after allowing various lengths 
of time for hormone-protein dissociation.  The resulting data were used to determine both 
the association equilibrium constants and dissociation rate constants for testosterone’s 
interactions with soluble HSA and SHBG.  The kd and Ka values that were obtained for 
testosterone with HSA were 2.07-2.20 s-1 and 3.2-3.5 × 104 M-1 at pH 7.4 and 37 oC.  The 
corresponding constants for the interactions of testosterone with SHBG were 0.057-0.058 
s-1 and 1.0-1.1 × 109 M-1.  All of these values gave good agreement with previous 
literature values.  This study indicated that ultrafast affinity extraction could provide 
information on both the rate constants and binding strengths for hormone-protein 
interactions in solution and at clinically-relevant concentrations for such agents.  
In last chapter, Chapter 8, a hybrid method was developed and examined for 
increasing the binding capacity and activity of protein-based affinity columns by using a 
combination of protein cross-linking/modification and covalent immobilization.  Various 
applications of this approach in the study of drug-protein interactions and in use with 
affinity microcolumns were considered.  HSA was utilized as a model protein for this 
work.  Bismaleimidohexane (BMH, a homobifunctional maleimide) was used to modify 
and/or cross-link HSA through the single free sulfhydryl group that is present on this 
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protein.  Up to a 75-113% increase in protein content was obtained when comparing 
affinity supports that were prepared with BMH versus reference supports that were made 
by using only covalent immobilization.  Several drugs that are known to bind HSA (e.g., 
warfarin, verapamil and carbamazepine) were also found to have a significant increase in 
retention on HSA microcolumns that were treated with BMH (i.e., a 70-100% increase in 
protein-based retention).  These BMH-treated HSA microcolumns were also used in 
ultrafast affinity extraction to measure free drug fractions in a drug/protein mixtures, 
giving association equilibrium constants that had good agreement with literature values.  
In addition, it was found that the reversible binding of HSA with ethacrynic acid, an 
agent that can also combine irreversibly with the free sulfhydryl group on this protein, 
could be examined by using the BMH-treated HSA microcolumns. The same hybrid 
immobilization method could be extended to other proteins or to alternative applications 
that may require protein-based affinity columns with enhanced binding capacities and 
activities. 
 
Future Work 
 The work presented in this dissertation has shown that ultrafast affinity extraction 
can be powerful tools for the examination of solute-protein interactions. It was found that 
this method could allow use of a single experimental system to provide information 
regarding the free fraction of solutes, their dissociation rate constants for proteins, and the 
equilibrium constant for the biomolecular reaction. In addition, this method could be used 
to the study of the samples that are more complex, such as those containing a racemic 
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mixture of two enantiomers of the solute, human serum or samples that are prepared at 
clinically-relevant concentrations. 
 To further improve this method, this system could also be used with other types of 
analytical columns, such as those containing reversed-phase, ion-exchange or size-
exclusion supports. These new combinations could be used to optimize and extend the 
ultrafast affinity extraction method to systems that have even weaker binding or faster 
dissociation of the immobilized ligand. This new approach could also be adapted for the 
study of more complex mixtures of free solutes, such as mixtures of drugs or drugs and 
their metabolites. 
 Studies could also be performed to examine the use of ultrafast affinity extraction 
on alternative types of affinity column to investigate the effects of changing the support 
or immobilization method on the ability to carry out a free fraction analysis. Examples of 
supports and immobilization methods that are of interested would include the use of 
entrapment-based immobilization, the use of covalent immobilization on silica particles 
versus organic monoliths, or the use of the hybrid immobilization method that was 
introduced in Chapter 8. This type of study should provide a better understanding of how 
ultrafast affinity extraction can be used with other types of affinity microcolumns in 
HPAC method. The optimum chromatographic conditions that are required for each 
column type could also be examined. 
 Another application of ultrafast affinity extraction is in the analysis of free drug 
fractions in sample that contain more than one binding protein. Even though HSA is the 
most abundant protein in plasma, the target of interest may have much stronger binding 
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strength to other proteins that are present in serum, but at a much lower concentration. 
This type of sample will make a consideration regarding the interactions for the target 
with both types of the binding proteins necessary. The measurement of free target 
fractions in such a situation will provide more precise information on solute-protein 
interactions in this type of situation under typical clinical conditions. 
Columns that are prepared based on the hybrid immobilization method could be 
further used to study solutes that have reversible binding plus covalent interactions with 
free sulfhydryl groups on an immobilized ligand. Other hybrid immobilization strategies 
can also be explored to improve the capacity and active content of proteins that are 
immobilized within microcolumns for use in ultrafast affinity extraction or related 
methods.  
